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Abstract 
Plant lectins and Ribosome inactivating proteins (RIPs) have been studied for well over a 
century.The first published work on the canonical RIP, Ricin, from Ricinis communis being 
characterised by Stillmark in his doctoral thesis in 1888. These proteins are characterised by 
the ability to selectively and reversibly bind to the carbohydrate groups of glycoconjugates, 
agglutinate erythrocytes and, in the case of RIPs, act as RNA glycosidases, depurinating a 
specific adenine residue within the highly conserved ricin/sarcin loop of the 28S ribosomal 
sub unit. Lectins and RIPs are used extensively in biotechnology and biomedical research. 
Winter Aconite Lectin (EHL) extracted from the corms of the Eranthis hyemalis plant was 
previously identified as having the characteristics of a Type II RIP, and therefore provided a 
novel target for functional characterisation studies.  Homologous proteins have shown 
potential as immunotoxins and diagnostic tools in cancer research, mainly due to the changes 
in glycosylation patterns of tumour cells such as, expression of the Tn antigen rarely found in 
healthy tissue. As EHL has a glycomic binding profile that has highest affinity for N-acetyl-D-
galactosamine, the defining carbohydrate unit of the Tn antigen, it therefore offers an 
interesting target for exploring the biological structure, function and effects on model 
organisms and cell lines.  
The first aim of the research reported within this thesis was to establish an extraction and 
purification protocol, which would provide a homogeneous, pure and consistent yield of EHL 
in sufficient quantity to allow further study of the characteristics and structure.  Once 
established, toxicity studies were carried out using Caenorhabditis elegans to examine the 
effect of EHL in a biological system. The data collected indicated that EHL binds to the 
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amphid neurons in C.elegans and causes a wide variety of concentration dependent effects 
including abnormal dauer formation.  
In order to elucidate the structure of the protein, crystallographic screening was 
undertaken. A number of large single crystals produced diffraction data.  A model structure 
was constructed using molecular replacement for phasing. The model is presented, as a 
work in progress with interesting observations as to potential glycosylation sites and active 
site residues.  
A preliminary investigation into the viability of a conjugation of EHL to gold nanoparticles 
was undertaken in collaboration with The Bioscope group (University of Lisbon) and the 
conjugate was also tested for biological activity. Initial results indicated that the 
nanoparticles caused a cessation of the toxic effect of EHL. 
In the final stages of the research presented herein, EHL was tested for antineoplastic 
activity against a number of cancer cell lines using a variety of methods to develop a viable 
protocol for future studies. Preliminary results indicate that EHL may act as a mitogenic 
agent on some cell lines, which also presents an opportunity for onwards research.  
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Chapter 1: Introduction 
1.1 Winter Aconite 
The Eranthis hyemalis plant or Winter Aconite is a late winter/early spring flowering perennial 
plant of the family Ranunculaceae.  Though heavily cultivated by commercial growers, in a 
natural setting E.hyemalis can be found in deciduous woodland across central Europe.  It is 
classified as an ephemeral plant due to the short life cycle which allows the plant to exploit 
higher light levels in winter when the overgrowing canopy has undergone autumnal 
abscission. The aerial parts of the plant emerge and a short period of growth culminates in a 
flowering period in late winter between January and March, when seeds are formed, foliage 
then dies back and the plant retreats below ground for the rest of the season (Royal 
Horticultural Society, 2016).  
E.hyemalis is native to Europe and was introduced and thrived in North America and Canada, 
naturally occurring in woodland and commonly cultivated in gardens.  A close relative Eranthis 
cilica extends the geographical range of the genus to Turkey and Afghanistan. E. hyemalis 
propagates easily by tuberous growth and seeding.  Within the horticultural community, it is 
observed that this plant appears to be free from particular pests and pathogens (Missouri 
Botanical Gardens, 2016).  Other members of this family include buttercups, marsh marigold 
and larkspur. As with many members of the buttercup family (Ranunculaceae), it is widely 
recognised as being a toxic plant if ingested and warnings of skin irritation are generally 
provided with any commercially available stock. Research first carried out in 1985 by 
Cammue, Peeters and Peuman (1985) indicated however that E.hyemalis also expresses a 
proteinaceous toxin of potentially more notable impact than causing skin irritation to various 
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substrates when isolated and purified.   This toxin was found to cause clumping (agglutination) 
of erythrocytes as well as impacting on the fitness of some formidable herbivorous 
agricultural pests and plant viruses in later work by Kumar et al., (1993). This toxin was named 
Eranthis hyemalis lectin or EHL. To date E.hyemalis is the sole representative of the 
Ranunculaceae to be reported to express lectin activity, and it is towards this activity that this 
research is focused.  
1.2 Lectins  
Lectins are a family of proteins found in plants, animals, bacteria and viruses which have the 
ability to selectively, specifically and reversibly bind to carbohydrate groups and can also be 
referred to as carbohydrate binding proteins (Sharon and Lis, 2007).   This study will focus 
discussion on lectins found only within the plant kingdom.  
Research into the biological properties of lectins began in the 19th century, mainly focusing 
on the observation that lectins agglutinate erythrocytes. This is widely believed to have been 
first reported in the doctoral thesis written by Peter Stillmark in 1888 (Stillmark, 1888; Sharon 
and Lis, 2004) on the highly toxic ricin, the hemagglutinin from the Castor bean plant (Ricinis 
communis) shortly followed by Abrin from Abrus precatorius.  These early candidates were 
plant derived and were termed phytohemagglutinins.  Karl Landsteiner built on the early work 
of Stillmark and made his subsequent own discovery that agglutination of blood cells from 
one individual by the sera of other groups of individuals could also be induced by the use of 
plant lectins, (Landsteiner, 1907) for which he won a Nobel Prize in 1930 (Schwarz and Dorner, 
2003). In the following years, blood types had been well defined (for the ABO system) and 
many lectins were identified as having specificity for a particular blood group (Renkonen, 
1948), however a new discovery published by Morgan and Watkins in 1953 identified  
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individual blood group determinants as being carbohydrate structures.  This work presented 
the finding that lectins differentially agglutinated various animal blood cells, and that by 
competitive (hapten) inhibition with mono or oligosaccharides, agglutination could be 
inhibited, thereby demonstrating the specific interaction between lectins and the varying 
surface carbohydrates of specific types of erythrocytes (Morgan and Watkins, 1953).  
Understanding the differences in blood types had far reaching implications in medical science 
including increasing the successful outcome of blood transfusions and eventually organ 
transplants. The schematic (Figure 1.1) below shows a basic representation of the differing 
erythrocyte surface epitopes made up from the core fucose ͚H͛ (O) antigenic determinant. 
The epitope is the region of a structure from where an antigenic response is elicited, so in the 
case of the A type the Anti-A antibody will respond to the GalNAc terminal residue. Lectins 
cause the agglutination of cells as a result of binding to the terminal glycans and as most 
lectins have more than one carbohydrate binding region (Berg et al., 2002), this results in 
cross linkage.  
Lectins which agglutinate human erythrocytes for groups A and O are readily found in nature, 
with blood group B specific lectins being rarer. This characteristic common to all lectins, is 
then the ability to bind to the carbohydrate moieties of cell surface glycoconjugates 
specifically and reversibly without introducing conformational changes to the mono- or 
oligosaccharides they to which they ligate (Sharon and Lis, 2004). 
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Figure 1.1 Schematic of the ABO surface antigen determinants. 
Lectins are involved in a wide range of processes including carbohydrate transport, cell 
signaling and defence, and in potentially mediating symbiotic relationships between 
leguminous plants and their associated rhizobium (Sharon and Lis, 2004). Plant lectins have 
been proposed as playing a key role as plant defence mechanisms (Peumans and Van Damme, 
1995), with many known to specifically bind to epithelial cells in herbivore and nematode guts 
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(Schubert et al., 2012; Delatorre et al., 2007). Insecticidal, antifungal and antiviral qualities 
have also been widely described (Edwards and Gatehouse, 2007; Peumans, Hao and Van 
Damme, 2001; Rao et al., 1998). The empirical observations made by horticulturists that 
E.hyemalis has no reported pests perhaps hints towards the presence within its tubers of a 
lectin with toxic properties.  
Some lectins have shown the capability of acting as a mitogenic stimuli to lymphocytes and 
other cells (Morgan, Ruscetti and Gallo, 1976). This results in a quiescent lymphocyte 
undergoing cell division and proliferation as a result of treatment by a mitogenic agent.  Many 
lectins possess this characteristic but may only demonstrate it under the optimal 
experimental conditions with the right cell type (Kilpatrick, 1998). This property was 
discovered serendipitously during an experiment using a lectin from Phaseulus vulgaris (PHA) 
to separate leucocytes from red blood cells by agglutination and subsequent division of the 
whole blood products.  The experiment indicated that the PHA was initiating mitosis among 
the leucocytes, a characteristic which was then exploited to maintain the lymphocyte culture 
(Nowell, 1960). With the finding that other lectins are also mitogenic, their use in biological 
applications was firmly rooted, and major advances such as the discovery of T Cell Growth 
Factor (interleukin-2) (Mier and Gallo, 1982) have resulted from their use both as serological 
and mitogenic tools. Commonly used lectins for mitogenesis are Concanavalin A, PHA and 
Pokeweed mitogen (Kilpatrick, 1998). 
This thesis focuses on the lectin found in the tubers of Winter Aconite, Eranthis hyemalis, 
(EHL) which should be more accurately described as a ribosome inactivating protein (RIP). 
Earlier work has alluded to this fact, and with the structural work completed here, it is 
unreservedly the case. To-date, EHL is the sole representative of the Ranunculaceae to be 
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identified as a RIP. EHL preferentially binds N-acetyl-galactosamine, but also binds Galactose, 
Galacto-pyransosyl, D-glucose, and to a lesser degree D-ribose (Cammue, Peeters and 
Peuman, 1985). EHL is indeed a lectin but this description tells only half the story, and EHL 
should indeed be fully classified as a Type II Ribosome Inactivating Protein (RIP) based on the 
previously published structural and toxicity studies conducted (Cammue, Peeters and 
Peuman, 1985; Kumar et al., 1993; George et al., 2011) and the work herein described. 
1.3 Ribosome Inactivating Proteins. 
Ribosomes are the complex cellular organelles responsible for protein synthesis, by 
translating messenger RNA (the product of gene transcription) into polypeptide chains (Ben-
Shem et al., 2011).  The eukaryotic ribosome is a complex of three or four ribonucleic acid 
molecules (dependent on taxonomy) and over 80 different proteins.  The structure actually 
consists of a large and small subunit (Lodish, 2008) designated 60S and 40S respectively. 
These combine upon initiation of translation to form the 80S assembled ribosomal complex 
which binds to and deciphers the mRNA template.  The S designation is a measure of the 
relative centrifugal sedimentation rate of each component measured in Svedberg units. This 
also applies to the rRNA molecules designated as 28S; 5S (also 5.8S in vertebrates) in the large 
60S subunit and 18S in the small subunit.  After the complex process of initiation has begun 
and the correct initiator methionine-charged tRNA (transfer RNA) has bound to the small 
subunit, addition of amino acids can proceed with the involvement of the elongation factors 
EF1 and EF2. When a stop codon is reached on the mRNA, release factors terminate 
translation and the mature peptide is released from the ribosome for processing (Lodish, 
2008). 
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Ribosome inactivating proteins are a class of enzymes (EC 3.2.2.22) with a mode of action 
which results in the breakage of a glycosidic bond in the 28S rRNA in the 60S subunit of the 
ribosome, resulting in halt of protein synthesis and subsequent cell death. This characteristic 
mechanism, common to all RIPs, is the ability to cleave a single adenosine from a specific site 
in the ribosomal rRNA, A4234. The Adenosine residue is situated in a highly conserved region 
known as the ricin-sarcin loop. The result of this glycosidic cleavage prevents EF1 from binding 
correctly. EF1 binding is essential for translation to proceed. Without EF1 binding 
appropriately, protein synthesis is terminated (Lodish, 2008). This N-glycosidase or 
glycosylase activity on rRNA is also reported to act on other deoxyribose nucleic acid 
substrates in vitro and therefore RIPs can be considered as polynucleotide deadenylating N-
glycosidases (Barbieri et al., 1997). RIPs are currently classified as Type I, Type II or Type III  
(see figure 1.2) based on the overall polypeptide chain composition and crucially, the 
presence or absence of lectin activity. Type I RIPs consist of a single RNA N-glycosidase domain 
which for ease of description will be termed an A chain.  Most Type I RIPs consist of a single 
polypeptide of circa 30 kDa but may also assemble into oligomeric conformations. In addition 
to these Type I RIPs, some controversy exists as to the nomenclature of an out-group of RIPs 
which appear to be formed from proteolysis of a zymogen form of the 30 kDa polypeptide.  
This has resulted in two shorter peptide chains bound by noncovalent interactions referred 
to as either two chain Type I RIPs or more rationally Type III RIPs (Van Damme et al., 2001). 
Type III RIPs continue to be classified due to their recent emergence in the research field, and 
will not be included in this discussion. 
Type II RIPs consist of either one or two heterodimers (tetrameric form) linked by disulphide 
bonds; an A and a B chain. By convention, the B subunit or chain is a sugar specific lectin 
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containing the highly conserved ricin B domain which facilitates binding to extracellular 
glyconjugates. The mode of action of type II RIPs shows that this binding then mediates entry 
to the intracellular environment for the attached cytotoxic A-chain with the N-glycosidase 
activity by endocytosis (Virgilio et al., 2010). The toxin is then subjected to retrograde 
transport via the Golgi complex, to the endoplasmic reticulum, where the disulphide bonds 
are reduced and the A chain is released in the cytosol to refold into an enzymatically active 
form (Hartley and Lord, 2004). 
As previously mentioned the A chain of a Type II RIP acts as an inhibitor of eukaryotic protein 
synthesis by enzymatically breaking the glycosidic bond of a single Adenosine molecule at 
position 4234 (A4234) of the 60S rRNA subunit (Hartley and Lord, 2004). The B chain of a Type 
II RIP is a sugar specific lectin and contains multiple carbohydrate binding domains known as 
ricin-b domains. It is this binding mechanism which makes Type II RIPs more highly toxic than 
Type 1, despite the conserved A chain tertiary structures and sequence homology. Entry into 
eukaryotic cells is mediated by the binding of the lectin to cell surface glycoconjugates and 
receptors expressing particular glycomic profiles mirrored by the leĐtiŶ͛s carbohydrate 
affinities. Type I RIPs exhibit extensive amino acid sequence conservation in the active site 
and overall similarity to the A chain of Type II RIPs. 
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Figure 1.2 Schematic diagram of the over simplified structure of RIPs
TǇpe I ‘IP: “iŶgle polǇpeptide 
ĐhaiŶ ǁith ĐǇtotoǆiĐ N-
glǇĐosidase aĐtiǀitǇ. No leĐtiŶ 
aĐtiǀitǇ. 
TǇpe III oƌ Ϯ ĐhaiŶ TǇpe I ‘IP: “iŶgle 
zǇŵogeŶ polǇpeptide ĐhaiŶ oƌ 
pƌoteolǇtiĐ pƌoduĐt ƌesultiŶg iŶ tǁo 
tƌuŶĐated ĐhaiŶs, ĐǇtotoǆiĐ. 
No leĐtiŶ aĐtiǀitǇ.  
TǇpe II ‘IP: CǇtotoǆiĐ A aŶd 
ĐaƌďohǇdƌate ďiŶdiŶg leĐtiŶ B ĐhaiŶ 
ǁith ďiŶdiŶg sites.  
GlǇĐaŶ 
ďiŶdiŶg sites 
 
Disulphide 
ďoŶd  
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In recent years the potential of lectins for use in cancer therapies has become a significant 
research focus due to their ability to preferentially bind to specific carbohydrates and 
differentiate between glycosylation patterns.  Moreover, a number of plant derived lectins 
have been shown to have potent in vitro and in vivo anti-cancer effects (Voss et al., 2006; 
Otsuka et al., 2014) inducing autophagous and apoptotic pathways in tumour cells, and 
some are already used therapeutically.  For instance, the recombinant mistletoe lectin 
rViscumin has been through phase 1 clinical trials and a number of other native mistletoe 
lectin preparations such as Lektinol and Iscador are prescribed widely throughout Europe 
as adjuvant therapies in chemotherapy, although their efficacy is not readily quantified 
(Horneber et al., 2008). 
Type II RIPs are specifically an area of increasing interest due to their antineoplastic 
properties, and their glycomic binding profile can be used to target specific glycans of 
biological molecules. For instance, the GalNAc specific RIP Ximenia americana (Riproximin) 
(Voss et al., 2006)), Sambucas sp (Ferreras et al., 2011)) and ML1 from Viscum album 
(Tonevitsky et al., 1996) show higher binding affinity for tumour cells than for healthy cells, 
due to the over expression of particular surface saccharide groups in the changing 
glycomics of malignant cells (Bayer et al., 2012). It is to this end that this thesis seeks to 
establish if EHL can demonstrate similar preferential binding to malignant cells.  
The evolution of RIPs has been extensively studied and currently two main hypothesis are 
considered to be plausible. The classic hypothesis is that RIP genes were acquired by an 
ancestor of the seed plants, from which the Type I RIPs evolved.  The acquisition of a lectin 
domain was then the subject of horizontal gene transfer from bacterial species and 
resulted in the Type II lineage. Subsequently a further deletion of the B-chain of these 
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divergent Type IIs giving rise to the Type III RIPs more recently (Peumans and Van Damme, 
2010). However, according to Lapadula, Puerta and Ayub (2013) an alternative more 
parsimonious hypothesis is proposed. The fact that RIP domains have been found in both 
gram positive, gram negative bacteria and fungi presents the notion that paralogs of the 
RIP gene were present in the last universal common ancestor (LUCA.), and, were lost in 
some species and duplicated in others. This created the wide diversity of RIPs found, and 
expression of more than one type in some species such as those found in the Iridaceae, 
Euphorbiaceae, and Cucurbitaceae (Van Damme et al., 2001). Lapadula, Peura and Ayab 
(2013) do however support the theory that the lectin domain was acquired and fused to 
the RIP domain in some species. This serves to illustrate the complexity of making a 
definitive phylogeny of the ribosome inactivating proteins. Furthermore, with the addition 
of newly identified RIPs to the databases and the discovery of the structure of novel 
divergent RIPs such as EHL providing more sequences on which to build a phylogeny, the 
discussion will continue into the future. The taxonomic lineage of Eranthis hyemalis can be 
seen in Table 1 and a characteristic example of a flowering E. hyemalis in figure 1.3. 
Despite more than 40% and in some cases 50% homology to other RIPs, EHL would appear 
to belong to an outgroup of N-glycosidases as can be seen in figure 1.4.  Using the NCBI 
BLASTp search for homologs shows that EHL is extremely divergent from Type I RIPs, and 
this is also reflected in the higher sequence divergence of the A-chain of homologous Type 
II RIPs.  In contrast, the B-chain of EHL shows a much higher sequence similarity to other 
Type II RIPs.  This is discussed in more detail in Chapter Three.
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1.4 Glycosylation 
One of the main forms of peptide post translational modification is glycosylation. The study 
of glycomics, and in particular altered glycomics as disease markers is key to the 
progression of lectin research. It has been previously reported that in tumorogenesis 
alterations to the normal glycosylation pattern of the diseased cell, such as incomplete or 
truncated O-linked glycosylation, are one of the primary events which occur as an outcome 
of underlying genetic changes in glycosyltransferases leading to pathogenicity (Ghazarian, 
Idoni and Oppenheimer, 2011; Gorelik, Galili and Raz, 2001).   
Table 1    
 Kingdom Plantae 
Sub kingdom Viridiplantae 
Infrakingdom Streptophyta  
Superdivision Embryophyta 
Division Tracheophya 
Class Magnoliopsida 
Superorder Ranunculanae 
Order Ranunculales 
Family Ranunculaceae 
Genus Eranthis 
Species hyemalis 
Table 1. Taxonomy of Eranthis hyemalis 
(TSN 18775) from the Integrated 
Taxonomic Information System on-line 
database. 
Figure 1.3. Cultivated Winter Aconite (E. Hyemalis) 
in flower. 
27 
 
 
Figure 1.4 Neighďouƌ JoiŶiŶg phǇlogeŶetiĐ tƌee of EHL aŶd otheƌ TǇpe II ‘iďosoŵe iŶaĐtiǀatiŶg pƌoteiŶs. EHL is the ͚uŶkŶoǁŶ͛ Ŷode. 
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Of particular interest for future work with EHL is the cancer associated antigen, the Tn Antigen 
(Madariago et al., 2014). N-linked and 0-linked glycosylation are the major pathways of 
interest in the biosynthesis pathways of glycoconjugates.  N-linked glycans are N-
acetylglucosamine units covalently bonded to an asparagine residue of a poly-peptide. O-
linked glycans consist of a primary GalNAc unit covalently bonded to either a serine or 
threonine residue. These form the core of many glycoconjugation events, with further 
saccharide units being added to form a complex and vast array of possible branched or 
unbranched oligosaccharides (Gorelik, Galili and Raz, 2001). These are formed in mammals 
from a set of ten core monosaccharides, all of which can be derived from cellularly produced 
glucose. These are Glucose (Glc); galactose (Gal); N-acetylglucosamine (GlcNAc); N-
acetylgalactosamine (GalNAc); Fusose (Fuc); Mannose (Man); Xylose (Xyl); glucuronic acid 
(GlcA), iduronic acid (IdoA), and 5-N-acetylneuraminic acid (Neu5Ac), more commonly known 
as sialic acid (Stowell, Ju and Cummings, 2015). 
Amino acids undergo glycosylation as a form of post translational modification which attaches 
specific glycans to the peptide as can be seen in the N-acetylglucosamine unit attached to 
residues Asn 11 and Asn 355 in the current model of EHL. Biosynthesis of glycoproteins begins 
in the secretory pathway which compromise the endoplasmic reticulum and Golgi apparatus, 
and, ultimately signals the destination of the proteins in membrane localization or secretion 
to the cytosol. Whilst glycosylation of this nature is part of the normal cellular function, when 
underlying genes are mutated this can result in incomplete or mutated glycan structures 
being constructed or completely absent.  As already mentioned, an example of this of 
particular interest is the Tn antigen which is recognised as an oncogenic marker (Ju, Otto and 
Cummings, 2011).  Normally cells express the T antigen which is an O-linked structure with a 
29 
 
terminal GlcNAc unit and a GalNAc core. In antineoplastic disease, many enzymes can be 
affected.  Specifically, the T synthase or N-acetylglucosamine transferase can be absent, 
caused by mutations in a gene such as cosmc (Hofmann et al., 2015). The outcome of this is 
that the repetitive GalNAc core is exposed and produces the GalNAc clustered Tn antigen. 
This has now been classified as a biomarker of metastatic potential in cancers, with a 
correlation found between Tn density and the aggressiveness of a particular cancer.  Lectins 
have been used to detect Tn antigen successfully in vitro and the hypothesis of increased 
binding to cancer cells by GalNAc specific lectins and RIPs is an area of current research 
(Madariago et al., 2014). 
1.5 Uses of lectins and ribosome inactivating proteins. 
Due to their ability to bind preferentially to specific carbohydrates, plant lectins are now used 
in many aspects of immunology, biotechnology and biomedical research in both diagnostic 
and therapeutic roles. Over recent years lectin research has evolved as a means of gaining 
further understanding of many aspects of cancer and metastatic development due to the 
glycobiology of the cellular transformations. Lectins are useful in tumor cell recognition due 
to their binding affinity to antineoplastic biomarkers (Heinrich et al., 2005). Furthermore, 
lectins are also used for their mitogenic and agglutinating properties in medical applications 
such as blood typing and cell culture (Mody, Joshi and Chaney, 1995). As previously 
mentioned, Mistletoe lectin extract is a widely used adjuvant therapy in Europe for patients 
undergoing chemotherapy, and a study conducted in 2002 with a group of breast cancer 
patients resulted in reduced primary treatment side effects and an increase in relapse-free 
time (Schumacher et al., 2002). 
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Lectins and RIPs including Ricin are commercially produced for use in applications such as 
affinity chromatography, whereby the sugar specific lectin of choice is bound to a matrix, such 
as agarose or sepharose, to which the target glycoprotein will then bind in a column and be 
separated.  Full lectin array kits are available in order to probe the expression of glycans on a 
substrate, and commercial mitogens are also in use. Fluorescent labelling of lectins has 
multiple applications in histochemistry and the relatively new concept of lectin 
immunoblotting can provide an economical alternative to traditional western blotting, and 
allow for the probing of specific sugar motifs on receptors (Dan, Liu and Ng, 2016). The 
symbiotic interaction between lectins and carbohydrates remains an area of research where 
potential applications are constantly emerging. Therefore, the contribution of this thesis in 
further characterizing the structure and activity of a lectin and ribosome inactivating protein 
with evolutionary divergence offers new possibilities.  
1.6 Biological assays with Caenorhabditis elegans (C.elegans). 
C. elegans is a free living nematode species used in laboratories worldwide for a variety of 
genetic and toxicology studies due to its well documented physiological and genetic 
characteristics which make it an ideal model organism.  Due to the conserved nature of 
disease pathways between C. elegans and other organisms, including humans, it is an ideal 
model to carry out in vivo research and has led to many important discoveries.  The culturing 
of C. elegans populations in the laboratory is an economical and accessible system and can 
yield extremely powerful statistical outputs due to the well-defined and annotated genotypes 
and phenotypes.  The worms develop from an egg laid by a self-fertilising hermaphrodite 
adult and will reach reproductive maturity within only three days.  An adult  reaches around 
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1.3mm long and  is capable of producing around 300 offspring, and is therefore ideal for 
studies involving reproductive fitness (Kaletta and Hengartner, 2006).  
With an average lifespan of around 2 weeks, studies into aging and lifespan effects can also 
be conducted, with experimental results again producing powerful statistical outputs due to 
the large numbers of replicates involved. An example which illustrates this well is that of the 
recent findings of Stastna et al. (2015), who tested the hypothesis that calorific restriction is 
widely believed to increase lifespan. However, using a complex genetic panel of nematodes, 
they were able to establish that this effect is actually genotype dependent, and in some 
unfavourable genetic interactions (which they were able to map) it has the opposite effect 
(Stastna et al., 2015). As such, C. elegans forms the system of choice for the toxicity assays 
carried out in this work, and indeed they were able to show a suite of complex effects 
(Chapter Five). 
During the normal life cycle of C. elegans, the nematode passes through four larval stages (L1-
L4), the first of which takes 16 hours and the second to fourth (L2-L4) stages taking 12 hours 
each under normal environmental conditions. Maturity is reached within 3 days as already 
mentioned.  There is also an alternative larval stage, the dauer larvae, which may present 
upon increasing population density or restricted food availability. The dauer stage of C. 
elegans is illicited when environmental conditions indicate that they are unfavourable for 
reproductive success (Riddle et al.,1997). 
The dauer larva is in a state of arrested development, sealed by a thick outer cuticle in order 
to survive harsh conditions, and it can only be entered into at L2 stage in response to 
chemosensory signals or pheromones detected in the L1 phase (Cassada and Russell, 1975). 
This dauer then has the ability to survive considerably longer than the normal two week life 
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cycle, and potentially up to eight times longer (Klass and Hirsh, 1976). Upon return of 
hospitable environmental conditions, the dauer larva can exit this state of arrested 
development by beginning to feed and will reach reproductive maturity as normal (Riddle and 
Albert, 1997). This mechanism is controlled by the amphid neurons of the worm which are 
responsible for chemosensation of dauer and other pheromones or the bacterial food source. 
The work presented in this thesis and the publication associated with it (McConnell et al., 
2015) explore a previously unreported dauer phenotype as a result of treatment with EHL.  
1.7 Nanoparticles 
Colloidal gold nanoparticles are not in themselves a new discovery and have long been 
exploited in both science and interestingly in art for their optical properties. Differing sizes 
absorb light of different wavelengths which produce a variety of coloured colloidal 
suspensions. Their applications in recent years have increased enormously and are used 
routinely in both material science and within biomedical sciences as therapeutic agents and 
drug delivery vehicles.  The optical and electronic properties of nanoparticles are able to be 
manipulated by the alteration of surface chemistry or the use of differing sizes of particles. 
Gold nanoparticles are of particular interest in biomedical research mainly due to their 
inherently low toxicity and compatibility in a variety of biological applications, but also due to 
the optical properties referred to earlier. These are conferred by their localised surface 
plasmon resonance and the ability to be conjugated to a variety of useful substrates such as 
peptides and therapeutic drugs (Hutter and Fendler, 2004). Whilst a detailed explanation of 
the physics behind nanoparticles is beyond the scope of this thesis, the basic concept of note 
is that the surface plasmon resonance of a particle can be excited at a specific frequency of 
light depending on the size, shape, and surface texture of a particle.  This results in strong and 
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characteristic light scattering and intense energy absorption. Localised surface plasmon 
resonance is the oscillation of charge density in metallic particles when subjected to excitation 
(Hutter and Fendler, 2004); a property used in tumour destruction through the technique of 
photothermal ablation (Hutter and Maysinger 2011). Gold nanoparticles have also shown 
extensive potential in conjugated drug deliver in cancer studies (Ahmad et al., 2013).  
Nanoparticles can be functionalised with ligands, with high affinity and specificity for target 
cells such as Tn+ which is where the ultimate interest in conjugating a RIP such as EHL presents 
an opportunity. With the ability to be functionalised with both therapeutic and imaging 
agents simultaneously, they are indeed a powerful tool in cellular studies (Ahmad et al., 
2013).  The work presented herein with nanoparticles is a preliminary investigation into the 
viability of the conjugate and set of initial assays to establish if the EHL biological effect is 
altered by it, providing insight for future research.  All of the synthesis, functionalisation and 
quality analysis work on the particles has been conducted by the Bioscope Group at the 
University of Lisbon with EHL supplied to them through this work.  All biological work was 
conducted by the author. 
 1.8 Aim and objectives of this thesis.  
The aim of this thesis was to conduct an in depth study of the structure and biological effects 
of the Winter Aconite (Eranthis Hyemalis) lectin (EHL). Other Lectins and RIPs have shown 
promise in biomedical research and have multiple biotechnological applications.  Due to the 
conserved nature of the RIP family of proteins, it is likely that EHL could also have potential in 
similar applications. In order for that potential to be fully explored, the underlying structure 
and biological activity of EHL needed to be elucidated. As a first step, the existing extraction 
and purification protocol was refined. This was to allow increased and consistent protein 
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yields for downstream applications and further study including the conjugation of gold 
nanoparticles.   
The investigation of the structure of the EHL protein was then carried out.  This structural 
work had two aspects.  Molecular biology techniques were employed in order to find the 
underlying gene sequence of the protein. Crystallisation screening was undertaken and the 
results of that were used to obtain diffraction data to establish the 3 dimensional structure 
of the protein.  
A set of biological assays were conducted to explore the potential toxicity of the protein in 
living organisms. The biological assays initially focused on the model organism Caenorhabditis 
elegans. This work included using wild type N2 strains of the nematodes and also an 
exploration of the effects EHL has on genetically mutated strains; the work was carried out 
with the natural protein and with EHL conjugated gold nanoparticles. Finally, preliminary 
studies of the potential cytotoxic effect of EHL on mammalian cancer cell lines were 
conducted in order to develop a viable method for future research. 
Specifically, the objectives of this thesis were:  
1. To establish improved methods for the extraction and purification of Eranthis hyemalis 
lectin, and to carry out analysis to validate the success of these such as SDS-PAGE and 
agglutination testing. This work will be reported in Chapter Two.  
2. To investigate the underlying gene sequence of EHL.  This part of the research is presented 
in Chapter Three. 
3. To investigate conditions that would allow crystallisation of Eranthis hyemalis to occur and 
use any resultant diffraction data to build the structure of the protein. Chapter Four contains 
the results of this investigation. 
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4. To investigate the effect of Eranthis hyemalis lectin on the model organism Caenorhabditis 
elegans and to characterise the effects in genetic mutants (Chapter five). 
5. To establish the viability of a functionalised EHL nanoparticle conjugate and its potential 
effect on the cytotoxicity of EHL (Chapters Three and Five). 
6. To develop a protocol for testing mammalian cancer cell lines with EHL (Chapter six). 
IŶ suŵŵaƌǇ, EraŶthis hyeŵalis oƌ WiŶteƌ AĐoŶite is a late ǁiŶteƌ floǁeƌiŶg peƌeŶŶial plaŶt of 
the faŵilǇ ‘aŶuŶĐulaĐeae. E.hyeŵalis eǆpƌesses leĐtiŶ aĐtiǀitǇ aŶd the leĐtiŶ fouŶd iŶ the 
tuďeƌs of the plaŶt is a sugaƌ speĐifiĐ ;N-aĐetǇl-D-galaĐtosaŵiŶeͿ TǇpe II ‘iďosoŵe IŶaĐtiǀatiŶg 
PƌoteiŶ. TǇpe II ‘IPs haǀe shoǁŶ aŶtiŶeoplastiĐ pƌopeƌties aŶd heŶĐe haǀe poteŶtial as 
theƌapeutiĐ ageŶts. A ŵodified pƌotoĐol foƌ the eǆtƌaĐtioŶ aŶd puƌifiĐatioŶ of the E. hyeŵalis 
leĐtiŶ ;EHLͿ usiŶg affiŶitǇ ĐhƌoŵatogƌaphǇ has ďeeŶ deǀeloped. The ďioĐidal pƌopeƌties of EHL 
haǀe ďeeŶ iŶǀestigated agaiŶst CaeŶorhaďditis elegaŶs. CƌǇstallisatioŶ tƌials haǀe Ǉielded 
ĐƌǇstals ǁhiĐh haǀe pƌoduĐed diffƌaĐtioŶ data at ϭ.ϲ aŶd ϭ.ϴ AŶgstƌoŵs ƌesolutioŶ iŶ tǁo 
ĐƌǇstal sǇsteŵs, ǁith spaĐe gƌoup PϮϭ aŶd PϮϭϮϭϮϭ ƌespeĐtiǀelǇ. MoleĐulaƌ ƌeplaĐeŵeŶt has 
ďeeŶ used to eǆtƌaĐt phases aŶd a stƌuĐtuƌe solutioŶ geŶeƌated foƌ EHL usiŶg a ‘IP ǁith ϰϬ% 
hoŵologǇ ǁhiĐh has ƌepoƌted aŶti-ĐaŶĐeƌ pƌopeƌties. 
The first aim of the research undertaken within this thesis was to establish an extraction and 
purification protocol as mentioned, which would provide a homogeneous, pure and 
consistent yield of EHL in sufficient quantity to allow further study of the characteristics and 
structure.  Once this was established, toxicity studies were carried out using Caenorhabditis 
elegans to examine the effect of EHL on lifespan and development, reproduction and the 
induction of abnormal dauer formation discovered in the first experiments conducted. The 
data collected indicated that EHL binds to the amphid neurons in C.elegans and causes a 
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wide variety of concentration dependent effects including the induction of a state of 
arrested development, the dauer state.  
In order to elucidate the structure of the protein, crystallographic screening was 
undertaken. A number of large single crystals produced diffraction data.  These data were 
used to construct a model structure using a molecular replacement solution. The model is 
presented, as a work in progress with interesting observations as to potential glycosylation 
sites and active site residues.  
A preliminary investigation into the viability of a conjugation of EHL to gold nanoparticles 
was undertaken in collaboration with The Bioscope group (University of Lisbon) and the 
conjugate was also tested for biological activity. Initial results indicated that the 
nanoparticles caused a cessation of the toxic effect of EHL. 
In the final stages of the research presented herein, EHL was tested for antineoplastic activity 
against a number of cancer cell lines using a variety of methods including the use of Resazurin, 
a redox reagent which is only reduced by metabolically active cells, to develop a viable 
protocol for future studies. Preliminary results indicate that EHL may act as a mitogenic agent 
on some cancer cell lines, causing proliferation, which also presents an opportunity for 
onwards research. Futuƌe ǁoƌk ǁill ĐoŶtiŶue ǁith a ǀieǁ to ĐoŵpletiŶg a suĐĐessful pƌotoĐol 
foƌ eǆaŵiŶiŶg the effeĐt of gold ŶaŶopaƌtiĐle ĐoŶjugatioŶ aŶd EHL oŶ ǀaƌious ŵaŵŵaliaŶ 
ĐaŶĐeƌ Đells. 
  
37 
 
Chapter 2: Extraction, isolation and purification of Eranthis hyemalis lectin 
(EHL) and the synthesis of EHL conjugated functionalised gold nanoparticles. 
 
The Extraction and purification of EHL as reported here has been published in:  
McConnell, M.T., Lisgarten, D.R., Byrne, L.J., Harvey, S.C. and Bertolo, E., 2015. Winter Aconite 
(Eranthis hyemalis) Lectin as a cytotoxic effector in the lifecycle of Caenorhabditis 
elegans. PeerJ, 3, p.e1206. 
 
The synthesis and characterization of the functionalised Gold nanoparticles was performed in 
the BIOSCOPE-PROTEOMASS Laboratory (FCT-UNL, Portugal) by Dr Javier Lodeiro and Ms 
Jamila Djafari. The BIOSCOPE group is headed by Prof. Carlos Lodeiro and Prof. Jose Luis 
Capelo.  The BIOSCOPE gƌoup͛s method of synthesis and results of the work are reported here. 
 
2.1 Introduction 
Winter Aconite Lectin or EHL has been the target of previous investigation and extraction 
protocols were published by Cammue, Peeters and Peuman (1985), Kumar et al. (1993) and 
George et al. (2011). All three methods showed various levels of success, with yields ranging 
from 380 ʅg/ŵl to a maximum of approximately 1mg/ml. The aim of this work was to develop 
a method which returned consistently high yields, which would facilitate downstream 
applications; additionally, the aim was to obtain a product of high purity in order to conduct 
crystallisation studies. The extraction process of EHL was originally based on previously 
published work which stated that the protein could be eluted from the chromatography 
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column using distilled H2O (Cammue, Peeters and Peumans, 1985). However protein yield was 
low and inconsistent, leading to the development of a new protocol which combined 
elements from all previously reported work to achieve the desired outcome. 
Column chromatography is a method for the separation of complex mixtures of molecules 
based on various sets of characteristics. This can be separation based on size, such as in gel 
filtration columns (size exclusion), charge (ion exchange), hydrophobic interaction and as in 
this work, affinity chromatography which exploits a particular binding affinity between the 
stationary and mobile phase of the chromatography reagents. The stationary phase or matrix 
of the affinity column used in this work was an agarose bound glycoprotein fetuin from fetal 
calf serum (Sigma Aldrich). Bovine fetuin is glycosylated with a high percentage (>70%) of N-
linked sialylated branched oligosaccharides with mostly GlcNac or Gal terminally sialylated 
residues (Green et al., 1988). This branching allows for a great many lectin interactions and 
makes it an ideal choice for purifying carbohydrate binding proteins such as Type II RIPs.  Work 
conducted in 1975 (Sela, Wang and Edelman, 1975) showed that a fetuin conjugated matrix 
could efficiently be used as a single affinity purification step for a variety of lectins with 
differing carbohydrate specificities, and thus was the matrix of choice in this research. In 
addition to the highly efficient binding affinity of fetuin-agarose, as the research progressed 
it became apparent that an additional purification step would be advantageous. The purpose 
of this additional purification step would aid in the maintenance and lifespan of the column 
matrix, and would help to achieve an even greater level of purity of protein for 
crystallographic studies. To this end an ammonium sulfate precipitation step was added. 
Ammonium sulfate ((NH4)2SO4) precipitation of globular proteins works on the principle of 
volume exclusion, whereby the high concentration of ammonium sulfate molecules increase 
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the surface tension of the solvent. This in turn increases the hydrophobic interactions 
between protein and water, encouraging folding and reducing the solubility of the protein. 
This causes precipitation and aggregation of the proteins (Wingfield, 2001). As differing 
protein structures all have varying degrees of exposed hydrophilic surface amino acid 
residues, they  will be ͚salted out͛ by the (NH4)2SO4 at different percentage saturations 
dependent on their solubility. This property can be exploited to fractionate crude protein 
mixtures. Ultimately, the reduction of interactions at the water/protein interface results in an 
increase in protein-protein interactions, resulting in precipitation. Exposing the combined 
(NH4)2SO4 - protein solution to centrifugal forces results in the formation of a protein pellet 
(from the aggregated proteins), which can then be resuspended in buffer. It was observed 
that, over time, contaminating residues were retained on the column in the manual system; 
the useful lifespan of the matrix was shortened and yields reduced. Hence the ammonium 
sulfate precipitation step was introduced to reduce contaminant proteins and effectively add 
in a further purification step. An initial (NH4)2SO4 saturation of 80% was successfully trialed, 
which subsequently facilitated the introduction of a graduated (NH4)2SO4 cut. This has the 
advantage of allowing proteins above or below a particular solubility threshold being 
discarded, and a purer crude extract being prepared for affinity chromatography. EHL activity 
was monitored by testing for haemagglutination of erythrocytes.  
The possibility of conjugating the purified EHL to gold nanoparticles was explored in 
collaboration with Bioscope group at the University of Lisbon (Portugal). Gold nanoparticles 
(AuNPs) have attributes which can be exploited for many aspects of cell biology research, such 
as their optical properties, which make them powerful imaging tools and they are also used 
as drug conjugated delivery systems (Ahmad et al., 2013). Despite the low inherent cellular 
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toxicity of AuNPs, cancer cells are more vulnerable to destruction by nanoparticles than are 
healthy cells, and when combined with a chemotherapeutic agent, can increase localised drug 
concentrations whilst lowering overall systemic toxicity (Kodiha et al., 2015). This makes them 
an interesting target to conjugate with a Type II RIP. One of the obstacles faced by cellular 
nanotechnology is initial cell specific surface binding. With EHL potentially having an affinity 
for the GalNAc repeating tumour specific Tn antigen (Ju, Otto and Cummings, 2011), the work 
here reports the successful conjugation of EHL to functionalised gold nanoparticles with a 
view to exploring the impact on the native protein and the biological effects of the conjugate. 
2.2 Material and Methods 
2.2.1 Preparation of affinity chromatography column 
Initial protocols used a manually operated gravity fed Biorad econo column with a ratio of 
1:20 width to height ratio (1.5 cm x 30 cm) which was packed at room temperature to prevent 
bed expansion with a custom chromatography medium. A bed volume of 8 ml was applied 
with 16 ml Fetuin-Agarose in solution with 0.5 M NaCl and immobilised on cross-linked 4 % 
beaded agarose (Sigma-Aldrich Company ltd, UK). The column matrix was allowed to settle 
with an additional head volume of 16 ml 0.5 M NaCl solution being applied to aid in bed 
compaction. The column was allowed to settle for 2 hours before being equilibrated with 200 
ml of phosphate buffered saline (PBS). This column was connected to a UV path monitor, 
peristaltic pump and chart recorder to monitor peak absorbance. The process was mainly 
carried out in a cold room at 4°C until failure of the chart recorder occurred due to the low 
operating temperature. The arrival of the AKTA Pure protein purification system in the 
research labs meant that a column with greater pressure tolerances was required and so 
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initially a Pharma LC column was poured with the same media for use in conjunction with the 
AKTA. Subsequently a GE column was purchased and used due to its superior packing and 
running characteristics in conjunction with the AKTA Pure system.  
2.2.2 Extraction of EHL 
Dry mass of tubers from E. hyemalis ranged from 20g to 100 g and were supplied by Eurobulbs 
Ltd (UK). A final mass of 60g appeared to give the most consistent yield, as higher amounts 
resulted in higher levels of lipids and contaminants as well as aggregation and precipitation 
of the protein. The tubers were finely sliced and chopped before being homogenised with 250 
ml of ice cold PBS and left to settle on ice for 30 minutes. The homogenate was removed and 
stored, and the remaining slurry was mixed with a further 250 ml of PBS. The two fractions 
were then combined and stirred at 4°C for 4 hours. The homogenised mixture was then 
centrifuged (Sorvall RC6 plus HSC) at 20,000 g for 30 minutes. The supernatant was retained 
and frozen at -80°C overnight in order to induce aggregation of any remaining lipid content in 
the sample. The sample was then defrosted and filtered through 3MM Whatman filter paper 
or muslin before undergoing a further centrifuge cycle of 20,000 g for 20 minutes. In the initial 
development of the protocol, the clarified supernatant was then applied to a Biorad 
chromatography column. Subsequently, as previously mentioned, the protocol was amended 
to include an ammonium sulfate precipitation step, in which solid ammonium sulfate 
((NH4)2SO4) was slowly dissolved in the crude filtered extract whilst under constant stirring at 
4°C.  The (NH4)2SO4 was added to the crude extract according to the published ammonium 
sulfate precipitation tables dependent on volume and temperature. Lectin activity was found 
to be retained in the 40% ammonium sulfate fraction pellet (as seen in figure 2.5). This 
fraction was subsequently centrifuged at 10,000 g for 35 minutes.  The resulting pellet was 
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suspended in a minimal volume of phosphate buffered saline and extensively dialysed (3 x 
200x volume) reservoir changes over 20-24 hours) using a semi permeable dialysis membrane 
(20 kDa molecular weight cut off (MWCO)) to remove the ammonium sulfate. This step is 
essential when affinity chromatography is the downstream purification step as the salt 
molecules will also interfere with column binding due to hydrophobic interactions with the 
chromatography media.  
2.2.3 Purification of EHL 
In the first instance the crude extract was applied to the gravity column using a Watson 
Marlow SciQ400 peristaltic pump and allowed a contact time of 30 minutes to increase 
adsorption of target protein. The sample was also reapplied to the column to maximise 
specific binding. Non target proteins were then eluted consecutively with PBS and 1 M NaCl 
until absorbance at ʄ280 fell below 0.01. The column was then equilibrated with PBS and 
subsequently EHL was eluted with the previously published elutant of distilled water 
(Cammue, Peeters and Peuman, 1985). The resultant protein yield was extremely low, 
between 100 and 400 ʅg/ŵl, and as the column became less efficient due to residual crude 
contaminants, levels dropped to zero. A novel purification protocol (figure 2) was developed 
initially by trialing new elutants, such as lactose and n-acetyl galactosamine; however, the 
protein was retained on the column. However, elution with 40 mM 1,3 diaminopropanol 
(DAP) produced a sharp peak (Figure 2.1) and a Bradford assay was performed using Bovine 
Serum Albumin (BSA) as a standard, in UV micro-cuvettes (Fisherbrand). This confirmed a 
relative increase in yield of up to 1.3 mg/ml. As the project proceeded, a move towards using 
the Qubit flourometric assay for quantification of protein was taken. With the introduction of 
DAP, the protein initially appeared inactive as no agglutination of erythrocytes was observed. 
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Once the eluant was neutralised with 2-Amino-2-hydroxymethyl-propane-1,3-diol 
hydrochloride (Tris-HCl) at pH 7.0, activity returned. The arrival of a GE healthcare AKTA Pure 
protein purification system, facilitated the introduction of control over additional paramaters 
such as column pressure, flow rate and undiluted application of the sample to the new GE 
column.  Elution of the target protein from the column was carried out and collected using 
the AKTA fraction collector in 0.5 ml aliquot. This allowed precision collection of defined peak 
fractions with no sample dilution from pre and post column washes. After neutralization as 
described with Tris HCl, samples were dialysed against PBS in 3 buffer changes. These each 
consisted of 200 x the sample volume, including a final overnight step. This became the 
foundation for the new and final protocol including ammonium sulfate precipitation and 
fractionation, dialysis, 0.45 and 0.22 ʅm filtration, use of the AKTA purification system with 
elution using 40 mM 1,3 diaminopropanol and subsequent neutralization with Tris HCl, buffer 
exchange with Pierce Slide-a-lyzer dialysis cassettes (20 kDA MWCO) and finally concentration 
as required using a Vivaspin PES device (30 kDa MWCO) A schematically represented overview 
of the process can be seen in Figure 2.  
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 Figure 2.1 Typical AKTA Pure run with EHL using manual commands in Unicorn. Note  the EHL peak at approximately 125 ml.  
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2.2.4 Analysis of EHL 
Purified EHL was tested for agglutination activity using defibrinated rabbit erythrocytes 
(TCS Bioscience), with 20 µl of post column eluant added to a 20 µl sample of erythrocytes 
in a welled microscope slide. The purified EHL was also analysed by SDS-PAGE, with both 
reduced and non-reduced samples electrophoresed on 12 % protogel quick cast gels and 
subsequently stained with Coomassie Brilliant Blue. Initially concentration was measured 
by monitoring absorbance at ʄ280 nm using a ThermoFisher Evolution 201 UV 
spectrophotometer. Typically, absorbance was found to be outside the linear range. 
Consequently 1/20 dilutions were carried out to produce an absorbance within the linear 
range. This method was found to be prone to inconsistencies due to natural variation 
within yields, and thus a move towards quantification using chemofluorometry was made. 
A Qubit 2 fluorometer was then routinely used to measure specific protein concentrations 
in post column purified fractions. The Qubit fluorometer utilises bovine serum albumin 
(BSA) at concentrations of ϬŶg/ʅl, 200 Ŷg/ʅl and 400 Ŷg/ʅl to establish a concentration 
curve. Typical EHL yields are in the range of 1.3mg/ml to 2.4mg/ml. Differences can be 
attributed to moisture content within plant tubers and natural seasonal variation. 
During attempts to concentrate the protein, it was discovered that Centricon Plus-70 
Centrifugal Filter Units appear to retain the protein on the regenerated cellulose 
membrane, possibly due to lectin binding. Therefore EHL was concentrated successfully for 
downstream applications using Sartorius Vivascience vivaspin 6 (30,000 MWCO) 
Polyethersulfone PES membrane. The Vivaspin tubes were also used for buffer exchange 
after purification to remove DAP where appropriate. A further preliminary investigation 
into the specificity of EHL for agglutinating blood type specific erythrocytes was carried 
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out.  The crude method which will undergo further development required the addition 
drop wise of four differing blood types to a 12 well plate, 50 ʅl of EHL was added to each 
and an incubation time of 5 minutes allowed prior to imaging (Figure 2.4). 
2.2.5 Synthesis of EHL conjugated Gold nanoparticles 
Gold nanoparticles functionalised with EHL (AuNPs+EHL) were synthesised by ligand 
exchange with citrate gold nanoparticles. The adsorption of protein onto gold 
nanoparticles to produce a bioconjugated nanosystem is presented as an excellent option 
to obtain a protein/nanoparticle hybrid system without any covalent modification to the 
protein which can result in modified activity. To minimize changes to the protein, citrate 
gold nanoparticles were used as the nanoparticle support. To this end Au+Citrate NPs were 
synthesised following a modified Frens synthesis (Frens, 1973; Shang et al., 2007). For this 
synthesis, an aqueous solution containing 1 mM of tetrachloroauric acid (125 mL of MilliQ 
water) was heated until boiling and then 12.5 ml of citrate trisodium 1% (p/v) on boiling 
was added. The reaction mixture was allowed to boil for 5 minutes at which point the 
solution colour turns from blue to ruby red, and was then left stirring overnight at room 
temperature. The Citrate gold nanoparticles (AuNPs+Citrate) obtained were used without 
a washing process in order to avoid the loss of nanoparticles during the centrifugation and 
subsequent washing cycles. 
AuNPs+Citrate were analysed by UV-Vis spectroscopy, Dynamic Light Scattering (DLS), Zeta 
Potential analysis and Transmission Electron Microscopy (TEM). Samples were prepared 
foƌ TEM ďǇ alloǁiŶg a ϱ ʅl dƌop of sample dry on TEM copper grids which were  coated 
ǁith Foƌŵǀaƌ/ĐaƌďoŶ ǁith a ϰϬϬ ŵesh ;poƌe size ϰϮ ʅŵͿ.  Zeta potential analysis provides 
a quantitative measure of the electrostatic charge between particles, and provides an 
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indication of the stability of a colloidal system. By UV-Vis, the red/pink colloidal solution of 
AuNPs+Citrate present a Surface Plasmon Resonance (SPR) band at ca. 519 nm. In TEM 
analysis it was observed that the Au+Citrate NPs present a quasi-espherical shape with an 
average size of 12.7 ± 2.5 nm (Figure 2.2). DLS studies indicated that Au+Citrate NPs have 
a z-average of 19.28 nm; z-average indicates the average radii of particles based on 
intensity measurements. The Zeta-Potential value obtained (-43.6 mV/cm) confirms the 
high colloid stability provided by citrate molecules adsorbed on the surface of the 
nanoparticle. Assuming that the gold reduction in gold nanoparticles was quantitative and 
of high monodispersity, the concentration of initial gold colloid is equal to 8.61x1013 
NPs/mL. The Molar concentration was calculated using previously reported methods (Liu 
et al., 2007; Fernandez-Lodeiro et al., 2013). Assuming a spherical shape and uniform face 
centered cubic (fcc) structure, the molar concentrations of the gold nanoparticle (AuNP) 
solutions were calculated using Equations 2.1 and 2.2 
 
 
                                       (equation 2.1) 
Where N is the number of atoms per AuNP, D is the average core diameter ((nm) of 
particles, ρ [g.cm-3] is the density of face centered cubic (fcc) of gold (19.3 g.cm-3), and M 
[g.mol-1] is the atomic mass of gold (196.97 g.mol-1) 
  
 
                                         (equation 2.2) where C is the molar 
concentration of AgNPs or AuNPs, NT is the total number of gold atoms added as HAuCl4, 
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N is the number of NPs, V is the volume of the reaction solution in litres, and NA is 
Aǀogadƌo͛s ĐoŶstaŶt ;Ŷuŵďeƌ of atoŵs peƌ ŵoleͿ. 
From equation 2.1, the result is N= 30.896D3 
With a 12.7 nm diameter and 0.1375 L of total volume reaction, using equation (2.2), a 
concentration equal to 1.4x10-8 Molar is obtained.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: UV-Vis spectrum, histogram and images TEM of AuNPs+Citrate. (The histogram 
was generated counting 200 nanoparticles using the software package ImageJ). 
 
The functionalisation of AuNPs+Citrate with EHL protein was facilitated by incubation of 
gold nanoparticles with a PBS+protein solution (the addition of Tris HCl buffer caused 
immediate aggregation of gold nanoparticles preventing proper bioconjugation). The 
B 
C 
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protein was suspended in PBS buffer by centrifugation and the concentration quantified 
using the Bradford technique indicating a composition of 1090 ± 40 µg/mL. 
A series of six experiments were conducted examining differing protein solution amounts 
added onto AuNPs+Citrate (25 µL, 50 µL, 100 µL, 200 µL, 300 µL and 500 µL) in order to 
analyse nanoparticle stabilisation as a function of protein quantity. The amount of protein 
solution used for each sample was added to  5 mL of AuNPs+Citrate and left under vigorous 
stirring at room temperature in darkness for 2 hours to maintain protein integrity and 
promote effective functionalisation. 
The NPs obtained were then centrifuged at 18187 x g for 25 minutes and suspended in PBS. 
A second centrifugation cycle was performed and the nanoparticles were suspended in 
milliQ water. The first supernatant was filtered (cellulose filter 0.22 micrometers) and 
quantified by the Bradford technique in order to determine the protein concentration at 
the NP͛s surface. Each set of EHL functionalised gold nanoparticles (AuNPs+EHL) were 
analysed by UV-Vis spectroscopy, DLS, Zeta Potential techniques and TEM. All the results 
obtained are indicated in Table 2.1 
2.2.6 Differential agglutination test 
EHL was applied in 30 ʅl aliquots to 4 differing blood types in a 12 well plate, the first well 
at the top of the images in figure 2.4 (see results) having 1 aliquot, then 2 in the second 
well and 3 in the third (total voume of 30,60 and 90 ʅlͿ.  The type B sample was applied 
to a single well due to limited quantity and was therefore given the maximum 3 aliquots. 
Samples were incubated for 5 minutes at room temperature and photographed. 
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2.3 Results 
2.3.1 Purification and characterization of EHL 
The concentration of natural yields of EHL obtained varied widely initially between 
200ug/ml and 2.8mg/ml, with the improved protocol, AKTA system and the use of the 
Qubit flourometer however, a consistent and typical yield of around 1.5 mg/ml was 
established. An intense agglutination response of rabbit erythrocytes was exhibited when 
the purified extract was applied to cells and thus confirmed the presence of EHL (Figure 
2.3a and b). SDS-PAGE analysis produced characteristic reduced protein bands at circa 31 
and 28 kDa as well as an unreduced band circa 50-60kDa (Figure 2.3c); these values are 
consistent with those previously reported in the literature (Kumar et al., 1993; Cammue, 
Peeters and Peuman, 1985; George et al., 2011).  A preliminary investigation as to whether 
EHL showed any specificity towards erythrocytes was also carried out. EHL shows greatest 
affinity towards type O, and a reduced agglutination towards type B. However as lectin 
specific to Type B are rare, this is of particular note for further research. Agglutination on 
addition of EHL was absent in the type A and AB samples (Figure 2.4). Although the 
agglutination titre assay requires significant modification to establish the exact relationship 
between the amount of EHL required to agglutinate a specific blood type more 
quantitatively, visual inspection is however sufficient to give initial guidance. The findings 
herein reported have value at an observational scale, to inform future experiments.  
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Figure Ϯ.ϯ EHL is a heteƌodiŵeƌiĐ TǇpe II ‘IP ǁhiĐh iŶduĐes agglutiŶatioŶ of eƌǇthƌoĐǇtes 
;AͿ ϭϬϬ ǆ ŵagŶifiĐatioŶ, ‘aďďit eƌǇthƌoĐǇtes tƌeated ǁith PB“, Ŷo ĐluŵpiŶg of eƌǇthƌoĐǇtes 
oďseƌǀed ;BͿ iŶĐuďatioŶ ǁith EHL ƌesults iŶ iŶteŶse agglutiŶatioŶ. ;CͿ ϭϮ% “D“-PAGE 
aŶalǇsis of EHL.  LaŶes: M, MoleĐulaƌ ǁeight ŵaƌkeƌ; ϭ, β-ŵeƌĐaptoethaŶol ƌeduĐed EHL; 
Ϯ, ŶoŶ-ƌeduĐed EHL. 
 
 
 
 
 
 
 
 
Figure 2.4 EHL shows blood type specific agglutination of erythrocytes. a) Blood Type (BT) 
O, b) BT A, c) BT AB, and d) BT B (sample availability restricted), e) left to right BT O; A; 
AB; B.  f) Zoom image of BT O under 65 x magnification on a dissecting microscope with 
cross linkage of erythrocytes visible.  
a b c 
d 
e 
f 
C 
50 ʅm 
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Figure Ϯ.ϱ “D“ PAGE ϭϮ% ƌeduĐiŶg ĐoŶditioŶs iŶ laŶes ϭ-ϴ shoǁiŶg eǆtƌaĐtioŶ pƌoĐess 
fƌaĐtioŶs. LaŶe ϭͿ Cƌude eǆtƌaĐt, ϮͿϰϬ% A“P supeƌŶataŶt, ϯͿ ϰϬ% A“P Pellet, ϰͿ ϴϬ% A“P 
supeƌŶataŶt, ϱͿ ϴϬ% A“P pellet, ϲͿ AffiŶitǇ ĐoluŵŶ floǁ thƌough; uŶďouŶd pƌoteiŶ, ϳͿ 
AffiŶitǇ ĐoluŵŶ floǁ thƌough; ŶoŶ-speĐifiĐ ďouŶd, ϴͿ AffiŶitǇ ĐoluŵŶ taƌget pƌoteiŶ ;EHLͿ 
ƌeduĐed ǁith β-ŵeƌĐaptoethaŶaol, ϵͿ ŶoŶ ƌeduĐed EHL aŶd ϭϬͿ MoleĐulaƌ Maƌkeƌ. 
 
2.3.2 EHL conjugated gold nanoparticle synthesis 
The results presented in Table 2.1 show that adding lower quantities of protein (25 and 50 
µL) is not sufficient to properly stabilize the AuNPs. Indeed, the high DLS values confirm 
the aggregation of AuNPs+EHL with a lower amount of protein (Figure 2.2). With the 
addition of a higher protein quantity (200, 300 and 500 µL), it was observed that there was 
a saturation on the NP͛s surface shown by the protein concentration values obtained in the 
supernatant. This demonstrates that there is an excess of protein in the medium. For these 
cases (200 and 300 µL), the first supernatant was not completely clear and still contained 
NPs which can produce an erroneous reading using the Bradford technique. This is because 
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in spectroscopic quantification the wavelength used may overlap with the Plasmon band 
of AuNPs, resulting in the appearance of increased protein values. 
 
Volume Protein added (in 
PBS) (µL) 
25 50 100 200 300 500 
Volume total of reaction 
solution Vtot (µL) 
5025 5050 5100 5200 5300 5500 
Protein mass in the reaction 
Vtot (µg) 
27.25 54.5 109 218 327 545 
Protein concentration in the 
supernatant (µg/mL)  
3.1 ± 0.1 7.4 ± 0.3 4.0 ± 
0.1 
40 ± 2 61.1 ± 
0.4 
84 ± 3 
Protein concentration in the 
Vtot supernatant (µg) 
15.6 37.4 20.4 208 323.8 462 
Protein concentration into 
the functionalised NPs 
solution Vtot (µg) 
11.7 17.1 88.6 10 3.17 83 
Z-Average value (nm) 266.37 90.26 54.41 51.72 60.79 51.23 
Zeta Potential (mV/cm) -23.13 -19.83 -27.8 -24.63 -20.23 -29.37 
 
Table 2.1: AuNPs+EHL solution composition for each experiment, DLS and Zeta Potential 
Values and protein amount on the nanoparticles. 
 
These data indicate that a better functionalisation was achieved with the addition of 100 
µL of protein (1090 ± 40 µg/mL) into 5 mL of nanoparticle solution. The AuNPs+EHL are 
more stable in this condition due to the high percentage of protein initially functionalised 
and the stability of the colloidal solution.UV-Vis spectroscopy confirms that the 
functionalisation of the nanoparticles is optimal with the addition of 100 µL of protein 
(Figure 2.6). A redshift in the SPR band from 519 nm to 528 nm indicates a compositional 
change of the NP͛s surface, which confirms a NP surface/ligand exchange between the 
citrate molecule and the EHL protein. The z-average obtained for AuNPs+citrate of 19.28 
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nm increased to 54.41 nm and hence demonstrates the absorption of protein on the gold 
surface. 
 
 
Figure 2.6: Au+EHL NPs UV-Vis spectra as a function of protein amount added (25µL, 50µL, 
100µL, 200µL, 300µL and 500µL) in 5mL of Au+Citrate NPs. 
 
Furthermore, 25 µL of protein did not allow the stabilisation of the colloidal system and 
induced nanoparticle aggregation due to partial functionalisation, with an SPR band 
centered ca. 573 nm. The presence of aggregate NPs was observed in TEM analysis (Figure 
2.7).  
Due to the dimeric structure of the protein, it can interact as a linker between two discrete 
NPs.  Alternatively, due to incomplete functionalisation of the AuNP͛s surface, it can modify 
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the isotropy charge produced by the citrate adsorbed, resulting in the formation of 
aggregates. With the addition of 500 µL of EHL, the NPs also presentated aggregates (Figure 
2.7). One possible reason for observing more aggregated NPs with 500 µL of protein 
solution might be as a resulting product of adding 10% v/v of phosphate buffer, giving high 
concentrations of salt which can then induce aggregation by the citrate blocking charges 
on the ŶaŶopaƌtiĐle͛s surface during the adsorption of the protein. 
 
Figure 2.7: TEM images of AuNPs@Lectin with different amounts of protein added (A) 50 
µL, (B) 100 µL, (C) 300 µL and (D) 500 µL. (The nanoparticles are submitted to two 
centrifugation cycles (18187 x g x 25 minutes) followed by resuspension in MQ water). 
 
From the UV-Vis, DLS, Zeta Potential measurements and TEM image results, it was 
concluded that the amount of EHL protein needed for an optimal functionalisation of 
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AuNPs+Citrate was 100 µL. For lower values, protein quantity added was insufficient to 
ensure complete NP functionalisation, and for a value higher than 100 µL, due to the excess 
of protein added with the PBS volume used, the functionalisation was also not effective or 
complete. 
A second batch of AuNPs+Citrate (denoted as AuNPs+Citrate-2) were synthesised, with 
functionalisation being completed without the centrifugation cycles and following the 
protocol described previously. The protein concentration used in this part of the study was 
1.1 mg/mL in PBS to simulate the initial conditions in batch 1. 
In UV-vis, the red/pink colloidal solution of AuNPs+Citrate-2 present a surface plasmon 
resonance band at ca. 519 nm (Figure 2.8). DLS studies indicated that AuNPs+Citrate give 
21.56 nm in Z-average and a Potential zeta equal to – 39 mV/cm, thereby confirming the 
NPs stabilisation by citrate molecules. These NPs were functionalised with 100 µL of EHL 
solution (1.1 mg/mL) to ensure optimal functionalisation, centrifuged at 18187 x g for 25 
minutes and suspended in PBS. A second centrifugation cycle at 18187 x g for a further 25 
minutes was carried out and finally suspended in MQ water. AuNPs+EHL-2 presents an SPR 
band at ca. 527 nm and a Z-average of 51.52 nm. 
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Figure 2.8: UV-Vis spectras of AuNPs+Citrate-2  and AuNPs+EHL-2. 
 
The results obtained for this second batch confirm the reproducibility of the Au+Citrate 
NPs functionalisation and are summarised in Table 2.2. 
  
 
Table 2.2: UV-Vis, DLS and Zeta Potentials obtained for the two batches synthesised. 
Batch  Batch 1  Batch 2  
Nanoparticles AuNPs+Citrate AuNPs+EHL AuNPs+Citrate-2 AuNPs+EHL-2 
SPR Band 
(nm) 
519 528 519 527 
Z-Average 
(nm) 
19.28 54.41 21.56 51.52 
Zeta Potential 
(mv/cm) 
-43.6 -27.8 -39.8 -24.9 
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To demonstrate that the protein is present at the surface of the NPs, a study was carried 
out by adding 200 ʅL of NaCl 2M into the colloidal system. When NaCl is added to the 
AuNPs+Citrate-2 system, as a result of reduced separation between particles due to the 
blockage of the citrate surface charge (and therefor repulsive force) by the sodium anions, 
aggregation occurs. This also results in an increased zeta potential of the NPs which were 
previously stabilised by the electrostatic charge blockage of the citrate molecules. This then 
showed a redshift of the SPR band and a base line increase (Figure 2.9). With the addition 
of NaCl into the  AuNPs+Lectin-2 system, no destabilisation was observed, which confirmed 
that the EHL was present on the NPs surface. 
 
 
Figure 2.9: UV-Vis studies of the addition of 200 uL NaCl 2M in the NPs obtained Au+Citrate 
NP-2 and Au+EHL NP-2 
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2.4 Discussion 
The method published in McConnell et al. (2015) and reported in detail herein has 
effectively achieved the objective of the work, which was to extract and purify EHL to a 
quality and quantity to allow further experimental work to be carried out as required.  
Towards the conclusion of this research and following crystallisation and all biological 
assays, the introduction of a protease inhibitor cocktail (Sigma Aldrich) was added in the 
initial homogenization step of some of the final extractions in an effort to further reduce 
any heterogeneity of the sample prior to affinity chromatography. Overall this later 
addition of a protease inhibitor cocktail in the natural crude extract appeared to have a 
negative impact on downstream studies, with vastly reduced agglutination activity 
apparent. This potentially indicated that a proteolytic event contributes to the functional 
activity of the protein such as that seen in the post translation processing of Ricin (Peumans 
and Van Damme, 2010) but further investigation is required to establish the exact nature 
of the change in activity. Further support for this hypothesis was that the ammonium 
sulfate precipitation (ASP) process also appeared to be altered. Lectin activity was retained 
in the 80% ASP fraction rather than the 40% albeit at minimal levels. This could possibly 
indicate that with highly variable temperatures in the laboratory as well, the protein may 
be salted out on the boundary between 40 and 50%. Further investigation of this 
observation will aim to identify the precise percentage saturation that applies to a protease 
inhibited sample. The success of the nanoparticle conjugation by the BioScope group opens 
a new opportunity for EHL research, both in terms of the structural and functional impact 
on gold nanoparticles on the native protein, and for the potential of a bioconjugate with 
biomarker specificity.  
61 
 
Chapter 3: Studies investigating the genetic and amino acid sequence of EHL 
De novo sequencing was carried out at the Proteomics laboratory at the Bioscience 
Technology Facility, Department of Biology, University of York on a commercial basis. 
 
3.1 Introduction 
Protein purification using a natural crude extract has, as described in Chapter Two, 
additional challenges which can hinder progress with structural work. The availability of 
plant tissue and natural variation in the condition and growth stage of the plant can affect 
the levels of protein expression which can impact on consistent output and experimental 
control. The purification protocol requires a relatively long period of approximately 7 -10 
days in total. Ultimately, the objective would be to design a construct for a recombinantly 
expressed protein. The underlying gene sequence is required in order to design such an 
expression system. One major benefit of recombinant expression would be the possibility 
to add a histidine tag to the protein for ease of purification. A His-tag is achieved by the 
insertion of a DNA sequence which codes for a histidine rich repeat of between six and nine 
residues attached to the N or C terminal of the vector expressed protein. The resultant 
protein can be purified with accuracy and specificity using affinity chromatography with 
immobilised metal ions which bind the histidine tag. (Arnau et al., 2006). These columns 
can be stripped and cleaned and reused many times aiding in an economically improved 
protocol. A His-tagged recombinant protein would also open the possibility of conducting 
assays with anti-His-tag antibodies, which can support more in-depth studies and imaging 
techniques, or alternatively His-tags can be easily removed by a further purification step 
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(Arnau et al.,2006). Ultimately this would aid the speed and accuracy of the extraction and 
purification protocol. 
A second reason for requiring knowledge of the gene sequence of the protein is of course 
to inform the crystallographic data and complete the model which has been constructed 
from the electron density maps (see Chapter Four). The diffraction data which have been 
collected are both complete and of a reasonably high resolution. However an atomic 
resolution of approximately 1.5 Å (at which point hydrogen atom begin to become 
distinguishable) is required to assign certain amino acids to the electron density. This is due 
to the ambiguity in the structures of the side chains i.e. valine/threonine only differ by a 
methyl/hydroxyl group (Lesk, 2010). Thus, despite the quality of the crystallographic data 
obtained, in the absence of the peptide sequence or gene sequence, the structure can only 
be partially assigned. Completion of the structural model would be enabled by the 
elucidation of the gene sequence, and would serve to inform the evolutionary phylogeny 
of ribosome inactivating proteins further.  
With the resources available to this study, two approaches were taken in order to obtain 
the sequence. In the first instance, work focused on the DNA of the plant. Based on a small 
section of previously published fragments of amino acid sequence (Kumar et al., 1993) (See 
figure 3.1), four degenerate primers were designed. When a sequence is unknown, 
degenerate primers become a useful mechanism to explore the genomic DNA with. A 
degenerate primer consists of a set of oligonucleotide sequences which contain a number 
of possible bases at various points. This is to accommodate the nature of the triplet coding 
redundancy i.e. more than one combination of nucleotides in a codon may code for one 
amino acid (Iserte et al., 2013). These primers are designed such that for the target protein, 
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all possible combinations of nucleotide sequence are contained within the primer species. 
Primers with high degeneracy will increase the possibility of unspecific annealing of the 
designed primers as they become less sequence specific and potentially target closely 
related non target sequence. As a starting point in primer design, a back translation of the 
amino acid sequence must be undertaken. There are many online tools available to help 
the researcher with this and related tasks in designing primers which observe the required 
conditions for optimum amplification of target sequence. In this work, the peptide 
fragments were back translated using the Colorado State University Molecular toolkit, the 
results of which are presented in figure 3.1. 
Once the primers were designed, genomic DNA was required from the target species (see 
figure 3.2). Winter Aconite DNA was successfully extracted using the spin column method 
with a geneJETplant extraction kit (Thermo Scientific) and the sequence probed under 
various temperature conditions with the designed primers.  
Despite the degeneracy in the primers, the Polymerase Chain Reaction did return positive 
amplification of an appropriately sized DNA band when the correct conditions were found 
(figure 3.3). A number of steps were taken to improve the definition of the band such as 
running gradient PCR, and using a commercially available PCR clean up kit to remove primer 
dimer bands from the gel. Ultimately, PCR products were sent for Sanger sequencing which 
works by adding nucleotides to a single stranded DNA template using DNA polymerase. 
The template specific oligonucleotide primer anneals to the template and the chain is 
eǆteŶded ďǇ the polǇŵeƌase fƌoŵ the ϯ′ hydroxyl group of the primer. The 
deoxynucleotides added to this chain are base-pair matched to the template (Sanger, 
Nicklen and Coulson 1977). The free nucleotides in the reaction include dideoxynucleotides 
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which have the hydroxyl group absent, so that elongation of the sequence chain is 
terminated when a dideoxynucleotide is incorporated. Only one species of 
dideoxynucleotide is present in each of four nucleotide reaction vessels and strands will be 
generated of all possible lengths, due to the millions of template strands in the reaction. 
These randomly terminated strands of all lengths are then effectively separated on the 
basis of size and ordered on an electropherogram (see figure 3.4) which allows the 
complementary sequence to be read. A number of factors can affect the success of this 
process such as quality of DNA supplied. Whilst the initial set of sequencing based on the 
original primers appeared to work reasonably well, a second set of sequence specific 
primers based on that output failed. Unfortunately, the sequencing results from this 
second set of primers was poor, and whilst  Basic Local Alignment Tool (Altschul et al., 
1990) hits had initially been promising, the second set of sequence returned showed no  
known similarity to any sequences in the database. 
With many techniques available to try to improve sequence signal such as a better primer 
design based on homology alignment or using the EHL peptide sequence, the decision to 
move towards sequencing the protein was taken. A purified protein sample was sent for 
commercial de novo sequencing at the University of York.  The results obtained were 
limited to a small number of confidently assigned fragments, but revealed a strong 
homology to other known type II RIPs.  
The work reported here has yielded the crystallographic structure of EHL to 1.6 Å, which 
combined with the gene sequence, would allow the structure to be fully refined and 
deposited in the Worldwide Protein Data Bank (PDB). Without the underlying DNA/mRNA 
sequence, ambiguity in assigning some structural amino acid residues would remain and 
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would hold the structure solution progress back. As the sole representative so far defined 
as having RIP activity from the family Ranunculaceae, sequencing the genome would 
provide an additional branch in the phylogenetic tree of these remarkable toxins and 
further inform the understanding of the evolutionary convergence of the genes involved. 
Obtaining the gene sequence and whole genome would allow the completion of the 
project from a structural and molecular perspective. 
Fortunately, towards the end of the project, additional funding was secured in order to 
sequence the plant genome. Genomic DNA was extracted for a second time under 
conditions applied by the University of Edinburgh commercial sequencing facility 
(Edinburgh Genomics). At the point of writing this thesis, the quality standards had been 
achieved and the sequencing of the EHL genome was underway. It is not within the scope 
of this thesis to present these data, and it will form the basis of future work on this protein. 
The raw ͚reads͛ of primary sequence which were returned will require considerable 
processing and bioinformatics to create the contiguous fragments that will ultimately be 
assembled to present the genome. This will be the source of the gene sequence which will 
be mined using RIP homologs using the highly conserved regions within the EHL model.  
3.2 Materials and Methods 
3.2.1 Genomic DNA extraction 
Using the GeneJET Plant Genomic DNA Purification Kit (Thermo Scientific) genomic DNA 
was extracted using the following method: firstly 350 µL of Lysis Buffer A from the kit was 
added into a 1.5 mL pre sterilised microcentrifuge tube. Previously frozen plant tissue (-
80°C) weighing 100 mg was ground using a pre cooled and sterilised micro pestle and 
centrifuge tube, itself placed in a falcon tube with pre-cooled ethanol (-80°C) as an 
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alternative to  liquid nitrogen. The ground tissue was immediately transferred into a 1.5 
mL microcentrifuge tube containing 350 µL of Lysis Buffer A. This was then vortexed for 
approximately 20 seconds. Subsequently 50 µL of Lysis Buffer B and 20 µL RNase A was 
added to the tube. For the genome sample sent to Edinburgh Genomics, a further reagent 
was added to this ste: 1 ʅl of Riboshredder RNase blend (Epicentre) with an amendment 
to the published protocol. This was to ensure the level of purity required for genomic 
sequencing. The sample was then incubated for 10 min at 65°C using a shake cycle on an 
Eppendorf thermomixer. Once the incubation was complete, 130 µL of Precipitation 
Solution was added and mixed. The mixture was then incubated for 5 min on ice. The tube 
was centrifuged for 5 min at 17,572 x g and the supernatant collected and transferred to a 
clean microcentrifuge tube. Next, 400 µL of Plant gDNA Binding Solution and 400 µL of 96% 
ethanol was added and mixed. Half of the sample (600µL) was added to the spin column 
and centrifuged for 1 min at 7084 x g. The flow-through solution was discarded and the 
remaining mixture applied onto the same column which was also centrifuged for 1 min at 
7084 x g. 500 µL of Wash Buffer I containing guanidinium hydrochloride was added to the 
column and centrifuged for 1 min at 11,068x g. The flow- through was again discarded and 
the column placed back into the collection tube. Wash Buffer II (500 µL) was then added 
to the column and subject to a centrifuge cycle of 3 min at 17,572 x g. The collection tube 
was emptied and the purification column placed back into the tube and spun for a further 
1 min at 17,572 x g. The column was transferred to a sterile 1.5 mL microcentrifuge tube 
and the genomic DNA eluted by adding 100 µL of elution buffer (10 mM Tris HCl, pH 9.0, 
and 0.1 mM EDTA) to the centre of the column membrane with a 5 min room temperature 
incubation. This was then centrifuged for 1 min at 11,068 x g  and a second elution step 
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using 100 µL Elution Buffer performed. The purified DNA was stored at -20°C for PCR and 
genomic sequencing.  
3.2.3 Polymerase Chain reaction 
Many differing combinations of parameters were used to optimize the PCR reaction, 
including changing the amount of primers added, the concentration of stock DNA and the 
annealing temperature. The method used 2 x concentrated ReadyMix Taq PCR Reaction 
Mix with MgCl2 (SigmaAldrich), which contains. 20 mM Tris-HCl, pH 8.3, 100 mM KCl, 3 mM 
MgCl2, 0.002 % gelatin, 0.4 mM dNTP mix (dATP, dCTP, dGTP, TTP), stabilizers, and Taq 
DNA Polymerase (10 ʅl in a total reaction volume of 20 ʅlͿ.  To this was added 2 ʅl each of 
forward and reverse primers, template DNA, and 4 ʅl of sterile dH2O. 
3.2.4 De novo Sequencing Analysis  
As performed and reported by The University of York protein identification service.  
In-gel tryptic digestion was performed after reduction of an EHL SDS PAGE gel band with 
Dithioerythritol (DTE) an epimer of DTT, and S-carbamidomethylation with iodoacetamide. Gel 
pieces were washed two times with 50% (v:v) aqueous acetonitrile containing 25 mM ammonium 
bicarbonate, then once with acetonitrile, and dried in a vacuum concentrator for 20 min.  
Sequencing-grade, modified porcine trypsin (Promega) was dissolved in the 50 mM acetic acid 
supplied by the manufacturer, then diluted 5-fold with 25 mM ammonium bicarbonate to give a 
final trypsin concentration of 0.02 ʅg/ʅL.  Gel pieces were rehydrated by adding 10 ʅL of trypsin 
solution, and after 10 min enough 25 mM ammonium bicarbonate solution was added to cover the 
gel pieces.  Digests were incubated overnight at 37oC. 
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3.2.2  Primer design 
 
Figure 3.1 Primer design. Amino acid sequence entered as fragments as seen in Kumar et 
al. (1993), back translated using: 
http://www.vivo.colostate.edu/molkit/rtranslate/index.html 
1       MetValSerGluAlaAlaArgIleArgTyrIleGluHisLeuValArgArgSerThrArg 
        ATGGTTTCTGAAGCTGCTCGTATTCGTTATATTGAACATCTTGTTCGTCGTTCTACTCGT 
             CAGC  G  C  CA C  CA C  C  C  G  CT C  CA CA CAGC  CA C 
             A  A     A  A  A  A  A     A        A  A  A  A  A  A  A 
             G  G     G  G  G     G              G  G  G  G  G  G  G 
 
2       IleIleGlyArgAspGluLeuValAspValAspGlyGlnAsnAsnAsnGly 
        ATTATTGGTCGTGATGAACTTGTTGATGTTGATGGTCAAAATAATAATGGT 
          C  C  CA C  C  GT C  C  C  C  C  C  G  C  C  C  C 
          A  A  A  A        A  A     A     A              A 
                G  G        G  G     G     G              G 
 
3       MetIleTyrAspThrAspSerAlaValProAspAlaThrVal 
        ATGATTTATGATACTGATTCTGCTGTTCCTGATGCTACTGTT 
             C  C  C  C  CAGC  C  C  C  C  C  C  C 
             A        A     A  A  A  A     A  A  A 
                      G     G  G  G  G     G  G  G 
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A 1 ʅL aliquot of each peptide mixture was applied to a ground steel MALDI target plate, 
followed immediately by an equal volume of a freshly-prepared 5 mg/mL solution of 4-
hydroxy-α-cyano-cinnamic acid (Sigma) in 50% aqueous (v:v) acetonitrile containing 0.1%, 
trifluoroacetic acid (v:v). 
Positive-ion MALDI mass spectra were obtained using a Bruker ultraflex III in reflectron 
mode, equipped with a Nd:YAG smart beam laser.  MS spectra were acquired over a range 
of 800-5000 m/z. Final mass spectra were externally calibrated against an adjacent spot 
containing 6 peptides (des-Arg1-Bradykinin, 904.681; Angiotensin I, 1296.685; Glu1-
Fibrinopeptide B, 1750.677; ACTH (1-17 clip), 2093.086; ACTH (18-39 clip), 2465.198; ACTH 
(7-38 clip), 3657.929.). Monoisotopic masses were obtained using a SNAP averagine 
algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) and a S/N threshold of 2. 
For each spot the ten strongest precursors, with a S/N greater than 30, were selected for 
MS/MS fragmentation. Fragmentation was performed in LIFT mode without the 
introduction of a collision gas. The default calibration was used for MS/MS spectra, which 
were baseline-subtracted and smoothed (Savitsky-Golay, width 0.15 m/z, cycles 4); 
monoisotopic peak detection used a SNAP averagine algorithm (C 4.9384, N 1.3577, O 
1.4773, S 0.0417, H 7.7583) with a minimum S/N of 6.  Bruker flexAnalysis software (version 
3.3) was used to perform spectral processing and peak list generation. 
De novo sequencing of tandem mass spectra was performed by hand, with a-, b-, b0-, y-, 
y0- and y*-ions considered as possible fragment ions. De novo derived peptides sequences 
were matched to homologous protein sequences using the on-line MS-BLAST service 
provided by Washington University,( St louis, Missouri,USA) (Shevchenko et al., 2001). 
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Peptide fragmentation and analysis were carried out using MALDI-TOF/ MS/MS and de 
novo sequencing. The peptide mixture produced was analysed by MALDI-TOF with the ten 
most intense peptide ions selected for MS/MS fragmentation.  The resulting fragmentation 
spectra were searched against the NCBI database restricted to viridiplantae using the 
Mascot search program but no matches were produced.  
Manual inspection of the fragmentation spectra showed that they were of sufficient quality 
to expect a match from database searching, if the corresponding protein was present in 
the database. Database searches did not produce any matches.  
In an attempt to identify the protein, de novo sequencing was performed on the 
fragmentation spectra generated. De novo sequencing was undertaken by hand at York 
University with annotated spectra produced subsequently in BioTools or DataAnalysis 
software packages. 
The resulting suggested de novo sequences were submitted to MS-BLAST search using the 
on-line service provided by Washington University.  The MS-BLAST search allows for more 
divergence between the theorised sequences and those held in the database, by allowing 
for: amino acid substitutions, deletions or insertions. Where a match is made across 
multiple de novo sequenced peptides, there is confidence that the protein matched has 
good homology with the protein sequenced (Proteomics Laboratory at the Bioscience 
Technology Facility, Department of Biology, University of York).  
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3.3 Results 
3.3.1 Genomic DNA Extraction 
DNA extraction carried out using a geneJET plant genomic DNA extraction kit 
(Thermofisher) as described, the results of which can be seen on the 1.5% agarose gels 
below in figure 3.2. Qubit fluorimetry (Invitrogen) showed a concentration range of 28 -32 
µg/ml. Sample A was used for PCR work and Sample B was sent to the Edinburgh Genomics 
centre for sequencing towards the conclusion of this work. 
 
Figure 3.2 Genomic DNA extractions for PCR and genome sequencing.  
 
3.3.2 Polymerase Chain Reaction 
A large number of reactions were carried out under varying combinations of temperature 
and concentration of primers.  A gradient PCR produced the sharpest bands at 52°C as seen 
in figure 3.3.  This product was sent for sequencing.  
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Figure 3.3 PCR amplification of region of Winter Aconite gDNA from primers and with a 
15°C temperature gradient between 45 and 60°C. 
 
3.3.3 Sanger sequencing 
The results of Sanger sequencing were limited and in the interest of pursuing other 
experimental studies, this approach was postponed early in the project with a view to 
achieving funding for entire genome sequencing of EHL. The electropherogram shown in 
figure 3.4 demonstrates the low background noise signal from the successful sequencing 
output. 
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Figure 3.4 Electropherogram of the PCR product sequenced by the Sanger Method (Sanger, 
Nicklen and Coulson, 1977) at Source Biosystems.  
 
3.3.4 De novo sequencing 
De novo sequence analysis of fragmentation spectra was carried out and suggested two 
confidently assigned peptide fragment sequences as shown in Figure 3.5 (a and b), with 
the following tags,  QQWA[L/I]YSDST[L/I]R and NWNNNGNP[L/I]Q[L/I]WQCTQQQNQR. 
Peptide fragment homology searches produced matches to various Type II RIPs all within 
the ricin-b domain (carbohydrate binding) regions.   
This result confirms the status of EHL as a Type II RIP, as has been reported in previously 
published sequence data (Kumar et al., 1993).  Sequence tags QQWA[L/I]YSDST[L/I]R and 
NWNNNGNP[L/I]Q[L/I]WQCTQQQNQR were matched to two regions in Nigrin-b (SNA-V; 
Sambucas nigra agglutinin-V) UniProtKB P33183.2 correlating to residues 470-481 and 325-
345 respectively using the FASTS search facility against the SwissProt database. Close 
homology to other Type II RIPS was also matched within the ricin b domain of Abrin-a 
(P11140) and Ricin (P02879). PDB structures were searched using the SSearch algorithm 
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and also showed matches to SNA-II (3C9Z) (Sambucas nigra agglutinin II), Abrin-a (1ABRB) 
and Ricin (1RZOB) in the ricin b domain as well as ML1 from Viscum album (1QNKB). 
The MS-BLAST search for the suggested de novo sequences gave strong matches to plant 
ribosome inactivating/ricin-agglutinin proteins. The top three matches of which were: 
 gi|7141131|gb|AAF37219.1|AF213984_1 ribosome inactivating protein RIPt             
[Polygonatum multiflorum]/   
 gi|255585867|ref|XP_002533608.1| ricin-agglutinin family protein [Ricinus             
communis]//:gi|223526509|gb|EEF28777.1| ricin-agglutinin family protein 
[Ricinus communis]  
 gi|255582840|ref|XP_002532193.1| ricin-agglutinin family protein [Ricinus             
communis]//:gi|223528125|gb|EEF30196.1| ricin-agglutinin family protein 
[Ricinus communis]/ 
These matches also help to give further evidence to the suggested de novo sequences. 
The results of these were consistent with the in-house homology search results conducted 
on confidently assigned sequences using the University of Virginia UVa FASTA Server. The 
FASTS and SSearch algorithms were used for homology searching against the SwissProt 
(NCBI) and PDB databases.  The results of crystallographic studies presented in Chapter 
Four indicate an amino acid sequence which is in agreement with the peptide fragments 
published by Kumar et al., (1993) calculated for 71/72 residues. This confirmation is based 
on the electron density maps calculated from the diffraction data. The de novo sequencing 
fragments have been docked within the model sequence also where possible, but only 
utilizing the confidently assigned peptides to do so and even so with a truncation of 
ambiguous regions where the ion series is not corroborated. 
75 
 
 
Figure 3.5a De novo peptide sequencing based on the MALDI-TOF MS/MS fragmentation spectra of EHL in-gel tryptic digestion after reduction 
with DTE and S-carbamidomethylation with iodocetamide. A) QQWA(L/I)YSDST(L/I)R – The most confidently assigned peptide in the batch, with 
a good level of overlapping y- and b-ion series. 
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Figure 3.5b De novo peptide sequencing based on the MALDI-TOF MS/MS fragmentation spectra of EHL in-gel tryptic digestion after reduction 
with DTE and S-carbamidomethylation with iodocetamide. B) NWNNNGNP[L/I]Q[L/I]WQCTQQQNQR – A strong y-ion series is observed 
throughout the peptide
77 
 
These are identified as:  A-Chain - LSSGSHVHDFLPQR (note the leucine and glutamine are 
inverted and the proline interjects between the residues in the model rather than precedes 
them as in the experimental ion series) and B-Chain - QQWALYSDSTIR; 
NNNGNPIQLWQCTQQQNQR. Combined with the Kumar fragments and the electron 
density maps, the model can be viewed with particular confidence in 115 residues that 
have been independently corroborated using a variety of methods. The resulting amino 
acid sequence was used to conduct a BLASTp search using the NCBI server and database 
(Altschul et al., 1990).  The results of which (Figure 3.6) confirm the identity of EHL as an 
evolutionary divergent Type II RIP. A sequence alignment confirmed the conservation of 
motifs present in other RIPs such as the (QxW)3 regions highlighted in Figure 3.7. 
 
 A-Chain 
AAISYANSASPNVVAYVAFITALRARLSSGSHVHDFPQLRAPSALPSACRFILVDLENGGGHTITVPIDVFNAA
VGGYLVGAAFLYFSCGPPAAAAIFPAAVSRSNGFGGGYGALGARAAESLGHAALLSAILALFYSYSQRTSFLTI
IQMVSEAARIRYIEHLVRRSTGASGDFLPDPSAACLELCWDPLSTQIQACGGSGVFTRPTWCAACCYAAVAI
LAIGEVNSGAALALLLFG 
B-Chain 
MTTTRVIIGRDELCVDVRDGENNNGNPIQLWQCTQQQNQRWTFAIDGTIRSNGKCLTTYGYAAGAYIMIY
DCDSAVPDAVVWACSGNGTISNPASGLALTASSCSPGTTLTCQTLINASREAWTVGQYSQPATTSYISGFRA
MCMEANDLNTLTWDMSCASGQECQQWALYSDSTIRVFCNPSLATTSGGASASLVIGIASGSGWGLQRW
AFSANGVILLPDACLTMDVRGSNVSLRQIILYEPTGNPNQQWLAYS 
 
Figure 3.6 EHL BLASTp results and sequence used. EHL is confirmed as a Type II RIP 
with conserved domains, (QxW)3 motif and 14 putative sugar binding sites identified 
(Marchler-Bauer et al., 2014). 
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Figure 3.7 BLASTp multiple sequence alignment. EHL is identified as Query_10001 shaded 
in green. Areas in pink boxes show the conserved (QxW)3 motif.  
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Key to sequence used in BLASTp alignment figure 3.7:  XP_010922360.1 Elaeis guineensis  AAK82460.1 type 2 ribosome-inactivating protein cinnamomin III (Cinnamomum 
camphora)  AAK82459.1 type 2 ribosome-inactivating protein cinnamomin II (Cinnamomum 
camphora)  AAK82458.1 type 2 ribosome-inactivating protein cinnamomin I (Cinnamomum 
camphora)  ABU95610.1 articulatin precursor [Viscum articulatum]  XP_008357384.1 nigrin b-like [Malus domestica]  AAR25548.1 lectin precursor [Viscum album]  ADF45510.1 type 2 ribosome-inactivating protein precursor [Camellia sinensis]  AAA32624.1 abrin-a [Abrus precatorius]  AAL04123.1 ribosome-inactivating protein [Sambucus nigra]  AEL79474.1 ribosome-inactivating protein precursor [Viscum ovalifolium]  CAC33178.1 ribosome-inactivating protein precursor [Sambucus ebulus]  P02879.1 Ricin (Ricinis communis)  AAF37219.1 ribosome inactivating protein RIPt [Polygonatum multiflorum]  lcl|Query_10001 EHL (Eranthis hyemalis) 
 
3.4 Discussion 
The aim of this part of the work was to find the gene sequence of EHL. Whilst progress was 
limited initially, the combined result of all the techniques used has resulted in a confident 
and plausible protein sequence, which can be used for bioinformatics analysis. 
A comparison and analysis of the sequence of EHL shows that the B chain is most conserved 
amongst homologous RIPs with sequence identity of 53% with Mistletoe Lectin (ML1) and 
48% similarity with Ricin. Using the sequence as it currently stands for alignment. The A 
chain appears much more divergent with only 35% similarity with Mistletoe and 38% with 
Ricin. These comparisons identify EHL as belonging to an outlying group in the RIP 
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phylogeny which have been identified in approximately 100 plant species (Van Damme et 
al., 2001) (Figure 3.8).  
 
Figure 3.8 COBALT Neighbour Joining phylogenetic tree from Blastp alignment of the whole 
EHL sequence made using COBALT Software by Papadopoulos and Agarwala (2007). 
 
This small sequence alignment analysis already demonstrates the absence of a region of 
sequence at the N-terminal of EHL which is present in other RIPS such as ricin, 
corresponding to a 35 residue signal peptide (Van Damme et al., 2001). This highlights once 
82 
 
again the requirement for the whole gene sequence so that any signal peptide and linker 
regions (which may be apparent in unbuilt electron density) can be identified.  
Once the structure is completely refined and the genomic sequence available, this 
phylogeny will of course be subject to further analysis, which may cause this apparent 
evolutionary divergence to be reassessed.   
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Chapter 4:  Crystallographic studies of EHL  
Diffraction data collection was carried out at Diamond Light Source on Beamline 104-1 
(Beamtime allocation number MX8997)  
Crystal data were collected by Dr. Colin Levy from the Manchester Institute of 
Biotechnology for which the author is grateful.  
Strategies for density modification and structure building were supported by senior 
academic staff including Dr. Edward Lowe at The Oxford University Biochemistry 
Department. 
Support from Dr Clare Naylor at Birkbeck College in establishing the data processing 
strategy is gratefully acknowledged. 
 
4.1 Introduction 
͞X-Ray crystallography has been an essential technique for structural analysis over 
the last one hundred years. It has allowed us to view the world on a scale that was 
previously impossible, giving 3 dimensional information and insight in the structural 
mechanism and functions of important materials and biological ŵoleĐules͟ 
(Brooks-Bartlett and Garman, 2015). 
Key to understanding the function or mechanism of action for any protein is finding the 
three dimensional folded structure. Macromolecular X-ray crystallography provides a 
means to elucidate the underlying structure and help to define the function and biological 
activity of a protein and other molecules. The interpretation of the diffraction of X-rays by 
crystals (X-ray crystallography) is a technique that has been used for over one hundred 
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years and has provided structures of biologically fundamental molecules such as Insulin 
(Adams et al., 1969), Vitamin B12 (Hodgkin et al., 1956), Penicillin (Crowfoot et al., 1949), 
and the double helix structure of DNA (Watson and Crick, 1953). With more recent 
advances in reducing the rate of radiation damage from the intense synchrotron X-ray 
beams used such as cyro-cooling (Garman, 2003), increasingly more complex structure 
determinations have been made possible, such as that of the ribosome for which a Nobel 
prize was  awarded to Venekatraman Ramakrishnan, Thomas Steitz and Ada Yonath in 2009 
(Brooks-Bartlett and Garman, 2015). 
Unlike photons with energy in the visible light spectrum which reflect from the external 
outline of an object, X-rays penetrate through the whole of a molecular structure providing 
detail on the internal three dimensional structure. The electrons of the atoms are excited 
by the X-rays which leads to the emission of X-ray photons. When these are of the same 
wavelength as the incoming X-rays, elastic (cohesive) scattering results.  The scattering 
fƌoŵ all atoŵs ǁill iŶteƌfeƌe to pƌoduĐe a diffƌaĐtioŶ patteƌŶ aĐĐoƌdiŶg to Bƌagg͛s laǁ 
(equation 4.1) which is captured on a detector. The scattering can be expressed as 
structure factors which contain both the amplitude and the phase of the diffracted photon. 
The mathematical principle of the Fourier transform allows a conversion of these structure 
factors into a density map of the positions of electrons in the structure (Blow, 2002).  
Within the crystal lattice is contained the smallest translatable repeating unit, or unit cell; 
the smallest volume of space that can be used to fully describe the crystal. By convention, 
the unit cell has an origin at the bottom left hand corner, from which distances a, b and c 
are measured in Angstroms. The values of a,b and c define the volume of the unit cell. 
Alpha ;αͿ, ďeta ;βͿ aŶd gaŵŵa ;γͿ, defiŶe the aŶgles of the unit cell edges between b-c,a-c 
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and a-b respectively (Blow, 2002). The origin of the unit cell defines the parameters from 
which all measurement indices (Miller indices) (h,k,l) of the reflections are generated. The 
lattice planes or Bragg planes are planes within the crystal from which X-rays reflect such 
that Bƌagg͛s laǁ is oďeǇed.  The Bƌagg plaŶes geŶeƌate a set of iŶdiĐes ;h,k,l) for each 
reflection based on the spacing and direction of the planes such that a set of coordinates 
is generated for each diffraction spot on the detector; critically all atoms in the unit cell 
contribute to all intensities in the h,k,l reflection.  The intensities of the diffraction spots 
are proportional to the square of the stƌuĐtuƌe faĐtoƌ͛s aŵplitude. The stƌuĐtuƌe faĐtoƌ 
contains information on the number of electrons in each atom (the amplitude) and its 
position (the phase). It is not possible to measure the phase directly from the structure 
factors and a variety of methods can be applied to do so indirectly (Blow, 2002). In this 
work, initially phases were extracted from a homologous protein using molecular 
replacement software PHASERMR (McCoy et al., 2007). This exploits the difference 
between the experimentally observed structure factors and the calculated structure 
factors from a homologous model. With phases derived from the molecular replacement 
model, the Fourier transform then allows an electron density map to be assembled.  This 
forms the basis for building and refining the structure. 
W.L Bragg proposed the idea in 1913 (Bragg and Bragg, 1913) that there can be considered 
to be planes of atoms within the lattice, and that some of these planes will produce strong 
and weak reflections if the angle of incidence of the X-ray is equal to the angle of reflection. 
Wheƌe the diffeƌeŶĐe ďetǁeeŶ ƌefleĐtioŶs is a ǁhole Ŷuŵďeƌ of ǁaǀeleŶgths, Bƌagg͛s laǁ 
will be observed. 
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 In ordeƌ foƌ Bƌagg͛s laǁ to ďe oďeǇed, i.e. the incident beam for a given order of diffraction 
to be reflected from a plane and in phase with the reflected beam in successive planes in 
the same h,k,l family which contribute to the intensity of a reflection h,k,l, the following 
condition must be fulfilled (Hammond and Hammond, 2009); �� = 2�hklsinθ 
Equation 4.1 Braggs Law (Bragg and Bragg, 1913) 
That is to say, the distance between the incident and reflected beam of two parallel photon 
streams from a monochromatic source is a whole number of wavelengths apart (n is an 
integer) (Blow, 2002). Where this condition is not fulfilled, the resultant reflected beam 
will not be in phase with the first beam and so will result in destructive interference and 
no signal. 
A characteristic diffraction pattern from the EHL crystal can be seen in Figure 4.1 with the 
rings showing the resolution and the diffuse reflections in the region between 3 and 4 Å 
indicative of solvent scattering. The spots observed are the reflections from the Bragg 
planes in the crystal and are termed the reciprocal lattice. The resolution of the data relates 
to the spacing between successive planes in a family of hkl reflections i.e d=1.6 Å (�� = 2�hkl 
siŶθͿ ;Bloǁ, ϮϬϬϮͿ.  
The crystallisation process begins with purifying the protein to a high and homogeneous 
level and then finding the conditions which allow the protein to crystallise. This is done 
through screening a theoretically infinite number of conditions. In practice, with the 
introduction of commercial screens which allow a rational and logical sequence of 
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screening, this has resulted in, on average, screening 300-500 conditions to provide leads 
in globular proteins likely to crystallise (Chayen and Saridakis, 2008).
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Figure 4.1 Diffraction pattern of EHL at 1.6 Å (outer resolution limit marked by ring) and zoomed in image of reflections. Inner resolution rings marked to 
show the shadow region between 3.1 and 4.0 Å indicative of disordered solvent from mother liquor and solvent channels within protein and crystal.
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In order for protein to crystallise, it must undergo a phase transition, which requires in the 
first instance the protein to reach a point of supersaturation in order to spontaneously 
nucleate. If the solution is too highly supersaturated, then the protein will form a 
precipitate, if it is under saturated it will remain soluble and will not crystallise. Once 
nucleation has occurred, the saturation will reduce slightly and allow the protein to enter 
what is termed the metastable zone. Here crystal growth may occur, and the solution is in 
equilibrium with the reservoir of the crystallisation condition (Chayen and Saridakis 2008). 
The crystallographic method of vapour diffusion relies on the initially under saturated 
protein passing through the metastable zone into the nucleation zone and returning 
without forming a precipitate to the metastable zone. Commercial screens provide a 
systematic and economical method for sampling the crystallographic space. Promising 
leads or ͚hits͛ can then be optimized by varying the parameters of the hit, such as adding a 
pH gradient vs precipitant or salt concentration gradient of the additive.   
In the majority of modern structures, the underlying gene sequence and resultant amino 
acid sequence of the protein would be known. The protein would likely have been cloned, 
tagged and overexpressed in an expression system such as E.coli or yeast. After 
purification, crystallisation and diffraction experiments, a homologous structure can be 
used with molecular replacement programmes to extract phase information and is then 
used for structure building and refinement using the crystallographic software suites 
available, this work uses CCP4 (Collaborative Computational Project, Number 4) (Winn et 
al., 2011). Whilst as reported in Chapter Three, some attempts were made to achieve this 
using molecular biology techniques such as degenerate PCR and de novo protein 
sequencing, positive results were limited. Research funding was granted at the end of this 
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project to sequence the entire genome of the Winter Aconite plant, and this will ultimately 
at a future date confirm the amino acid sequence of EHL in its entirety. All discussions of 
the model built and herein presented are underpinned with the caveat that the structure 
cannot and is not considered complete until such time as the protein sequence can be 
verified by other methods. For this reason, solvent content such as water molecules have 
not been added to the model and the hydrogen bonding not resolved as even at the 
reasonably high resolution of 1.6 Å individual atoms are still ambiguous. The local 
environment of a particular residue may indeed give further weight to a particular side 
chain being assigned, however caution has been taken not to overstate the structure. The 
method used which is discussed more in depth later was to minimize model bias, in the 
absence of sequence data and to prevent an overreliance on the molecular replacement 
solution. As discussed in Hou et al. (2007) whilst high resolution data and the resulting 
electron density maps can be used to inform sequence, ambiguity however cannot be 
resolved for residues such as Asparagine/Aspartic Acid, Glutamine/Glutamic acid, 
Valine/Threonine, and in some cases due to disordered side chains this is also the case for 
Cysteine/Serine, Lysine/methionine and potentially Isoleucine. 
Whilst the RMSD for bond angles and the R factors of the refined model, though higher 
than would be ideal, are in good agreement, and the Ramachandran plot shows a 
reasonable standard of geometry, the model of EHL presented here, is not a complete 
structure. The interesting features of the model are highlighted and with the consideration 
that these were built from a main chain poly-alanine backbone trace in shelxE4 (Sheldrick, 
2010), the model does at this point certainly confirm the RIP nature of the protein as well 
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as its active site homology to various other rRNA N-glycosidase proteins such as Mistletoe 
Lectin and Ricin (Krauspenhaar et al., 2002, Weston et al.,1994).  
In the case of EHL the strategy employed was first to screen for crystal growth using the 
sitting drop vapour diffusion method with four differing commercially available screens.  
The resultant crystals of those initial experiments diffracted to reasonably high resolution 
so that optimisation was at this time not required, as the primary aim of the crystal is to 
provide good diffraction data (Chayen and Saridakis 2008). 
Literature suggests starting crystallisation studies with a purified protein with a 
concentration upwards of 5 mg ml-1 (Bergfors, 2009, Chayen and Saridakis 2008). EHL 
fractions were pooled and concentrated in an attempt to reach this ideal concentration. 
However it was found that above 4 mg ml-1 using the stated protocol, EHL formed a 
precipitate and this presented a requirement for a methodological change which was not 
viable at that time. A decision to proceed with screening of protein at 4 mg ml-1 was taken. 
4.2 Materials and methods 
Preliminary crystal screens were set up to identify favourable crystallisation conditions 
using 4 commercial screens covering 384 conditions at two different temperatures (4°C 
and ambient temperature). 
 JCSG-plus   PACT premier   MIDAS  Morpheus 
Primary screening was carried out using a strategy developed by Newman et al. (2005). 
This strategy combines a systematic grid screen of pH, anion and cation testing (PACT) and 
the sparse matrix screen developed by the Joint Centre for Structural Genomics (JCSG). The 
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JCSG+ screen is based on previously successful crystallisation parameters, which maximises 
coverage of crystallographic space with no redundancy (Jankarik and Kim, 1991). This 
combined strategy is designed to minimise the amount of conditions required to be 
screened. The MIDAS screen (modern intelligent dynamic alternative screen) is based on 
alternative polymeric precipitants developed by Dr Clemens Grimm and was also used due 
to its non-reliance on polyethylene glycols (PEG) as precipitants. MIDAS also contains a 
restricted range of pH and salt concentrations designed around physiological parameters 
(Grimm et al., 2010). The final screen used was Morpheus, which also incorporates a cryo-
protectant in each condition and contains a selection of low molecular weight ligands 
previously found in many PDB structures. Morpheus has been designed by Fabrice Gorrec, 
in collaboration with the Medical Research Council Laboratory of Molecular Biology (LMB) 
at Cambridge (Gorrec, 2009). Each screen was produced under licence and purchased from 
Molecular Dimensions Ltd. The chemical conditions of each screen as stated by Molecular 
Dimensions can be found in Appendix 2. 
The screens were manually set up using 48 well MRC maxi sitting drop plates (Medical 
Research Council supplied by Molecular Dimensions) with a reservoir volume of 200 ʅl and 
a 2 ʅl drop volume with a 1:1 ration of protein to well solution. Plates were checked daily 
to begin with and then weekly after a period of six weeks. Initial hits were identified in the 
JCSG+ condition H4 in the form of a series of microcrystals and needles (Figure 4.2). Other 
crystals grew over a period of between 8 weeks and over 12 months as outlined in the 
results section.  
Data were collected on PACT D10 crystal at the Diamond Light Source on beamline I04-1 
under proposal MX8997-34 . The crystal was cryoprotected with a 1:4 ratio of PEG 400 to 
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well solution. Data were collected at a wavelength of 0.9795 Å and reflections recorded by 
a Pilatus 6M detector . The crystal diffracted to a resolution of 1.6 Å.  A Crystal grown in 
PACT condition B12 was also cryoprotected and data were collected to a resolution of 1.8 
Å at an oscillation angle of 0.10 degrees.  A third crystal (PACT E5) was analysed using a 
Rigaku FRE+ Superbright copper rotating anode X-ray source with an incident wavelength 
of 1.54 Å ;CuKαͿ. The crystal was cryoprotected with combination of glycerol and well 
solution. The detector used was a Saturn 944+ and data with resolution of 1.9 Å were 
collected. 
Data processing beginning with spotfinding, indexing and integration of the diffraction data 
were completed with iMOSFLM (Battye et al. 2011). Scaling and merging of data were 
completed through SCALA (Aimless, Pointless and ctrunctate) (Evans, 2006; Evans, 2011) 
using the CCP4i GUI. PHASERMR (McCoy et al., 2007) generated a single solution using 
1M2T.pdb used as a molecular replacement search model. A poly-alanine back bone trace 
was created with SHELXE4 (Sheldrick, 2010). CHAINSAW (Stein, 2008) was used to create a 
poly-alanine model from the molecular replacement solution. The MR model was 
superposed in COOT (Elmsley et al., 2010) to the SHELXE4 trace with residues subsequently 
built into the MR solution where density from the shelxe4 maps supported it. Four rounds 
of refinement were carried out in REFMAC5 (Murshudov, 2011; Murshudov, Vagin and 
Dodson, 1997). Previously published residues (Kumar et al., 1993) were manually docked 
into the model using CCP4 (Winn et al., 2011) Molecular Graphics (CCP4MG) sequence 
viewer.  
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4.3 Results 
4.3.1 Crystal screening  
The first EHL crystals were observed in the 4°C JCSG screen which appeared to have 
yielded needle form crystals (Figure 4.2a) as well as the larger cluster seen in Figure 4.2b. 
In the 20°C screen, a spread of microcrystals was observed (Figures 4.2 c and d).  All scale 
bars are estimated due to equipment limitations. The crystallisation conditions are 
summarised in Table 4.1 and a full account of the screens in Appendix 2.  A second set of 
larger crystals was observed in the JCSG screen after approximately 20 weeks which can 
be seen in Figure 4.3. Further crystals grew in the PACT screen and were observed after 
approximately 24 weeks, a large rhomboid form crystal grew in PACT condition D10 at 
20°C and also a crystal found at 4°C in PACT condition B12 as seen in Figure 4.4. Data was 
collected on both crystals at Diamond Light Source synchrotron beamline I04-1 to 1.6 and 
1.8 Å respectively. A Final series of crystals was observed after 15 months in various PACT 
conditions at 20°C as seen in Figure 4.5. Data were collected on crystal B grown in PACT 
condition E5 using a Rigaku FRE+ source and Saturn 944 CCD detector at Oxford 
University Chemistry department to 1.9 Å 
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Figure ϰ.Ϯ Fiƌst ĐƌǇstals oďseƌǀed foƌ EHL aͿ Ŷeedle foƌŵ ĐƌǇstals JC“G Hϰ ďͿ Đlusteƌ of 
Ŷeedles JC“G Hϰ ĐͿ ŵiĐƌoĐƌǇstals iŶ JC“G at ϮϬ°C dͿ ŵiĐƌoĐƌǇstals iŶ JC“G Hϰ at ϮϬ°C. 
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Figure ϰ.ϯ “eĐoŶd set of ĐƌǇstals oďseƌǀed afteƌ appƌoǆiŵatelǇ ϮϬ ǁeeks. AͿ JC“G GϮ ĐƌǇstal ǁas used to assist iŶ 
eǆpeƌtise aŶd pƌaĐtiĐe ŵaŶipulatioŶ teĐhŶiƋues.  BͿ JC“G GϮ at ϰ°C a laƌge ĐƌǇstal ǁas oďseƌǀed aŶd data ǁeƌe 
ĐolleĐted at sǇŶĐhƌotƌoŶ to ϯ.Ϯ Å. 
μm 
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Figure ϰ.ϰ CƌǇstals iŶ PACT sĐƌeeŶ oďseƌǀed afteƌ appƌoǆiŵatelǇ Ϯϰ ǁeeks AͿ ƌhoŵďoid foƌŵ iŶ PACT 
ĐoŶditioŶ DϭϬ at ϮϬ°C BͿ “iŵilaƌ ŵoƌphologǇ ĐƌǇstal fouŶd at ϰ°C iŶ PACT ĐoŶditioŶ BϭϮ.  Data ĐolleĐted 
oŶ ďoth ĐƌǇstals at DiaŵoŶd Light “ouƌĐe sǇŶĐhƌotƌoŶ ďeaŵliŶe IϬϰ-ϭ to ϭ.ϲ aŶd ϭ.ϴ Å ƌespeĐtiǀelǇ. 
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Figure ϰ.ϱ FiŶal seƌies of ĐƌǇstals oďseƌǀed afteƌ ϭϱ ŵoŶths iŶ PACT ĐoŶditioŶs at ϮϬ°C, data ǁeƌe 
ĐolleĐted oŶ ĐƌǇstal B gƌoǁŶ iŶ ĐoŶditioŶ Eϱ usiŶg a ‘igaku F‘E+ souƌĐe aŶd “atuƌŶ ϵϰϰ CCD at Oǆfoƌd 
UŶiǀeƌsitǇ CheŵistƌǇ depaƌtŵeŶt to ϭ.ϵ Å AͿPACT Gϱ ŵultiple sheet like ĐƌǇstals siŵilaƌ to those seeŶ iŶ 
JC“G GϮ BͿ uŶusual ŵoƌphologǇ iŶ PACT Eϱ. 
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4.3.2 Data collection and analysis  
Data were collected at the Diamond light source Synchrotron on beamline I04-1 on the 
crystal grown in PACT premier condition D10. It was characterized as belonging to the 
monoclinic space group P1211 with unit cell dimensions a = 46.84 Å b = 94.39 Å c = 71.12 Å 
and α = 90° β = 96.47° γ = 90°. Based on these cell parameters the contents of the 
crystallographic asymmetric unit is a single heterodimeric molecule with a Matthews 
Coefficient (Matthews, 1968) of 2.60 and a solvent content of 53% (Collaborative 
Computational Project, Number 4. 2011). Data collection statistics are shown in Table 4.2 
for this crystal. These data were used for model building . Data were also collected on PACT 
B12 at the DLS synchrotron (MX8997-34 on I04-1) and E5 crystals at the University of 
Oxford Chemistry department using a Rigaku FRE+ Superbright copper rotating anode X-
ray source details of which can be found in Table 4.1. 
The SHELXE4 (Sheldrick, 2010) model  as described in the methods section underwent 
many cycles of building and refinement in COOT (Elmsley et al., 2010) and REFMAC 
(Murshudov et al., 2011, Murshudov, Vagin and Dodson, 1995)  until the final model which 
can be seen in Figure 4.7 was arrived at.  
A Ramachandran plot of the refined model was generated in COOT (Elmsley et al., 2010) 
(Figure 4.6) which shows the energetically favoured protein backbone torsion angles of phi 
and psi (the angles between N-Cα and Cα-C respectively) for a given amino acid residue 
sequence. Residues should lie in favoured regions on the plot when a geometrically 
plausible model has been built. A percentage of between 1-2 % outside of allowed regions 
is normal (Rupp, 2009)  
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Screen Well [Conc} Morphology Time to appear Resolution Source Space 
group 
JCSG + H4 0.2 M Calcium Chloride 
dehydrate, 0.1M BIS-Tris at pH 5.5 
in 45% v/v 2,4-methyl pentanediol 
(MPD) 
4.0 
mg/ml 
Needles and 
microcrystals 
8-10 weeks     
 JCSG + G2 0.02M Magnesium chloride 
hexahydrate 0.1M HEPES buffer at 
pH7.5 with precipitant 22% w/v 
Poly (acrylic sodium salt) 5100 
 4.0 
mg/ml 
Prism/sheets 12 weeks 3.2 Å DLS Synchrotron P212121 
PACT  D10 0.2M Magnesium Magnesium 
chloride hexahydrate 0.1M Tris, pH 
8.0 20% w/v PEG ʅ0 
 4.0 
mg/ml 
Multifaceted prism 
rough end sections 
 24 weeks 
approx. 
 1.6 Å DLS Synchrotron P1211 
 PACT B12 0.01M Zinc Chloride, 0.1M 
MES pH 6.0 20%w/v PEG 6000 
 4.0 
mg/ml 
Multifaceted prism 
rough end sections 
   1.8 Å DLS synchrotron P212121 
 PACT E5 0.2M Sodium Nitrate, 20% w/v 
PEG 3350 
 4.0 
mg/ml 
 prism with 
embedded sheet 
 12 months +  1.9 Å Rigaku  FRE+ 
Superbright copper 
rotating anode. 
P2 
 PACT G5 0.2M Sodium Nitrate, 20% w/v 
PEG 3350, 0.1M BIS-Tris Propane, 
pH7.5, 20% w/v PEG 3350 
 4.0 
mg/ml 
sheets  8 months 
approx. 
    
 PACT H5 0.2M Sodium Nitrate, 20% w/v 
PEG 3350, 0.1M BIS-Tris Propane, 
pH 8.5, 20% w/v PEG 3350 
 4.0 
mg/ml 
 irregular prism  12 months +     
 PACT F6 0.2 M Sodium Formate 0.1M 
BIS-Tris Propane pH6.5 20% w/v 
PEG 3350 
 4.0 
mg/ml 
 irregular prism  12 months +     
 
Table 4.1 EHL crystal hits obtained from initial commercial screens JCSG and PACT 
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Table 4.2 Data collection statistics for EHL crystal PACT D10 from which model was built. 
Crystal EHL PACT D10 20°C 
Data Collection    
Source DLS I04-1 Pilatus 
Detector 6M 
 
Wavelength (Å) 0.92819   
Space group P1211   
Cell dimensions    
a,b,c (Å) 46.84, 94.39,71.12   
α,β,γ ;°Ϳ 90° 96.47°  90°   
 Overall Inner Shell Outer Shell 
Low Resolution (Å) 47.19 47.19 1.63 
High Resolution (Å) 1.60 8.76 1.60 
Rmerge 0.107 0.038 0.678 
I/σI 11.2 24.0 4.7 
Completeness (%) 99.6 99.6 99.3 
Multiplicity 3.1 3.2 3.2 
    
Refinement     
Resolution (Å) 70.667 - 1.6   
No. reflections 80904   
No. non Hydrogen Atoms 3664   
R factor 0.2381   
R free 0.2597   
R.m.s deviations    
Bond lengths (Å) 0.0264   
Bond Angles (°) 2.1953   
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Figure 4.6 Ramachandran plot of the EHL model generated with COOT (Elmsley et al. 
2010). This shows the energetically favoured protein backbone torsion angles of phi and 
psi ( the angles between N-Cα and Cα-C respectively) for a given amino acid residue 
sequence and whether the model is agreement with these.
103 
 
 
Figure 4.7. A model of EHL built into electron density and poly-alanine backbone trace made in SHELXE4 (Sheldrick, 2010). Two N-linked 
glycosylation sites were observed in the electron density maps and have been assigned as NAG on chain A at Asn 11 and on chain B at Asn 355.
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4.4 Discussion  
The current strategies for building model structures of a target protein often rely on the 
amino acid sequence of the protein being known and used in conjunction with the 
reflection data collected at the X-ray source to autobuild a structure using a software 
pipeline.  In the event of the sequence being unavailable as with EHL, various techniques 
may be employed to build a model which actually then informs the sequence.  Whilst 
complex techniques such as cross crystal averaged maps are useful, for the purposes of 
this thesis, a more simplified approach was taken. Cross crystal averaging takes advantage 
of the two crystal systems found in the diffraction data sets and can provide extremely 
clear maps to work with for the experienced crystallographer. The phase information is 
strengthened by the increase in signal over noise ratio due to solvent flattening. The 
decision not to use this method was taken in an effort to reduce the possibility of 
introducing systematic error in the complexity of making and working with cross crystal 
averaged maps for the beginner.  From the highest resolution data, a poly-alanine 
backbone trace was built using SHELXE4 (Sheldrick, 2010).  This method does not build a 
model structure, it attempts to build peptide main chain in any place it can reasonably do 
so within the electron density, effectively minimising model bias from the molecular 
replacement solution. Once the protein sequence for EHL becomes available, it will be a 
small step to read in the sequence to the maps already created to complete the structure.   
The limitations of the SHELXE4 maps include having multiple fragments to work with, areas 
of density which have not been built into the backbone, and areas that are difficult to build 
into.. However the maps produced are extremely good and allow ab initio building with 
the caveat that ambiguities will ultimately remain for residues which cannot be reasonably 
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assigned with total confidence such as Asparagine/Aspartic acid, Glutamine/Glutamic acid, 
Valine/Threonine. These side chains require atomic resolution of at least 1 Å to definitively 
assign them unless the local environment strongly suggests a particular choice, such as in 
a hydrophobic pocket or strongly hydrophilic region or as part of a hydrogen bonding 
network (Hou et al., 2007). Using prior knowledge of RIP structures, a molecular 
replacement model was also built.  The peptide fragments which were known for EHL were 
used to find homologs within the RIP family with at least 40% similarity (Schwarzenbacher 
et al., 2004) for phasing. The scaled and merged data (SCALA) (Evans 2011, Evans 2006) 
from the P1211 EHL crystal were used and phases extracted from the mistletoe lectin 
IM2T.pdb (Krauspenhaar et al. 2002) file using PHASERMR (McCoy et al., 2007), and a single 
solution was found.  The next step was to take the output .pdb from PHASERMR and run it 
into CHAINSAW (Stein, 2008) in CCP4. This was in order create a poly-alanine model which 
could be superimposed using SSM in COOT (Elmsley et al., 2010) onto the SHELXE4 back 
bone trace structure to effectively create a visual feedback between the two structures.  
The benefit of this was to highlight the conserved residues which fit the unbiased trace 
build, join peptide chains that were fragmented and to cut out regions of the molecular 
replacement structure where there was no electron density shown in the SHELXE4 
(Sheldrick, 2010) maps. After multiple rounds of refinement using REFMAC5 (Murshudov, 
2011; Murshudov, Vagin and Dodson, 1997) the structure was then opened in CCP4 MG 
(Winn et al., 2011) and the four peptide fragments from the early published work on EHL 
(Kumar et al., 1993) were located at potentially viable coordinates within the sequence 
viewer. Using the refined maps the density was matched to the published small fragments, 
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and with the exception of cysteine 309, which was published as threonine (Kumar et al., 
1993), the structure was found to match in 70/71 residues. 
As shown in Figures 4.8 and 4.9.1,2 and 3, the superposed active site residues of the ricin 
A-chain, the catalytic region where depurination of the rRNA A4234 is bound and hydrolyzed 
(Monzingo and Robertus, 1992), are conserved in EHL as the model stands with one 
exception, tyrosine 80.  The active site of 3rti includes residues Trp 211 (187), Arg 180 (156), 
Glu 177 (153), Tyr 123 (111), Tyr 80 (Ala 73) and Val 81 (74), these all closely matched in 
the EHL model (coordinates in parantheses) except for the Tyr 80 which appears as an 
alanine (73) in the EHL density maps and is proposed to be critical to the binding cleft for 
the adenine substrate in ricin (Yan et al., 1997).  
The aforementioned residues are invariant in the family of ribosome inactivating proteins 
and have been subjected to site directed mutagenesis experiments (Kim and Robertus 
1992) in the ricin A protein.  In these experiments a one hundred fold reduction in 
enzymatic activity was observed when Tyr 80 was mutated to serine (Kim and Robertus 
1992) and whilst the EHL model structure will certainly undergo considerable refinement 
in the future, the variant residue at the EHL A-chain site 73 could be hypothesised to show 
an indication as to the reason for the reduced toxicity of the protein compared to Ricin and 
other Type II RIPs. 
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Figure 4.8 EHL model structure with Ricin (Ricinus communis) 3rti.pdb structure superposed. The 3rti structure is represented in a purple colour 
and the EHL model in cyan.
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Figure 4.9.1 EHL model with suggested A chain (lilac) active site residues highlighted in green.  These are based on the corresponding site and 
residues from the SSM alignment of the Ricin structure 3rti.pdb seen in figure 4.8. 
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Figure 4.9.2 Superposition of EHL and 3rti A chain active site residues in CCP4MG, EHL 
residues in bright green, 3rti in sand colour, both orientations +show conservation of 
tryptophan 211(187), arginine 180 (156), glutamic acid 177 (153), isoleucine 172 (148), 
tyrosine 123 (111) and C)valine 81 (74) tyrosine 80 is not conserved in EHL in this model 
and shows alanine at position A73 of EHL. Values in parentheses are for the EHL model.
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Figure 4.9.3 Theoretical proposed EHL active site surface pocket model of electrochemical interactions (red indicates a negative charge, blue a 
positive charge and white areas neutral, using conserved region from 3rti as a template(Monzingo and Robertus, 1992).
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A number of other conserved features can be identified, such as the (QxW)3 motif on the 
B-chain found in hugely variant lectin sequences and hypothesized to be involved in 
carbohydrate binding (Hazes, 1996). BLASTp identified fourteen putative sugar binding 
sites in the model, as seen in Chapter Three (figure 3.6). A number of disulphide bonds 
were present in the model; Cys 251 with Cys 270, Cys 381 with Cys 396. However, of note 
is the lack of inter chain disulphide bonding, which will be resolved when the genomic 
studies of Winter Aconite become available.  
A representative electron density map showing the overall map quality is shown in Figure 
4.10. Two N-linked glycosylation sites were added to the structure as observed in the 
electron density maps (Figures 4.11 and 4.12), namely Asn 11 and Asn 355 of the A and B 
chains respectively.  
In conclusion, the model herein presented has demonstrated the possibility of building a 
structure, which is plausible both geometrically and biologically in the absence of sequence 
information. Though R-factors are global indicators so will not highlight incorrect modelling 
on a local scale and are on the limits of acceptability for this model, the <2% difference 
between the Rmerge (23.8%) and Rfree (25%) would suggest a sensible model (Wlodawer et 
al., 2008). 
The final addition of the peptide fragments published in Kumar et al. (1993) into the refined 
model has strengthened the proposed structure in 4 regions as discussed in Chapter Three. 
Future work will include the building of a model using the same techniques on the 
remaining 2 data sets, at 1.8 and 1.9 Å respectively and conducting a comparison to this 
higher resolution structure. Ultimately, crystallising EHL with a substrate analog such as 
adenosine mono/triphosphate would show the relationship between the Y80 and Y123 
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binding of the adenine ring from Adenosine4234 of the rRNA  substrate seen in ricin (Yan et 
al., 1997) and the differential effect of the variant A73 in EHL on that substrate binding. 
Finally, to follow this work to conclusion and deposition of the protein coordinates in the 
World Wide Protein Data Bank, the addition of the genomic sequence data to the model 
will allow a high resolution structure to be built into the electron density map.
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Figure 4.10 Representative regions of density from the SHELXE4 back bone trace job.  Untraced regions impact on the completion of building 
the model structure.  
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Figure 4.11  Electron density indicates glycosylation site at A: Asn 11. 
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Figure 4.12 Electron density supports glycosylation of B: Asn 355.
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Chapter 5: Biological activity against C. elegans 
 
Parts of the work reported in this chapter have been published as: 
McConnell et al. (2015), Winter Aconite (Eranthis hyemalis) Lectin as a cytotoxic effector 
in the lifecycle of Caenorhabditis elegans. PeerJ 3:e1206; DOI 10.7717/peerj.1206 
All statistical analyses were undertaken in ͚‘͛ (R Core Team 2013) by Dr Simon Harvey.  
 
5.1 Introduction 
In this experimental chapter, the effect of EHL on the free living nematode Caenorhabditis 
elegans (C. elegans) was investigated. C. elegans is a well-established model organism for 
initial toxicological studies due to the conserved nature of its biological and biochemical 
processes, including the stress response and disease pathways (Boyd, Smith and Freedman, 
2012). C. elegans is an excellent experimental system to use in toxicity studies due to the 
wide range of mutant phenotypes available, the short life cycle of the worms, their well 
documented reproductive and lifespan schedule, and their largely transparent body type 
which makes it possible to observe unusual effects easily (Corsi, Wightman and Chalfie, 
2015). As with many other free living nematodes, C. elegans passes through a well-defined 
set of life stages (Figure 5.1) where they ultimately reach the adult stage at up to 1mm in 
length, having grown from the newly hatched L1 larval stage of approximately 0.25mm in 
3 days. Of particular note is the ability of the nematode to enter an alternate life cycle stage 
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Adult worm capable of egg laying (1110-1150 ʅM)
L1  stage (arrest if no 
food) 250 ʅM
Ex utero 
development 
and hatching 
(9 hours)
L1/L2 molt
Environmental conditions: High 
Temperature? High population 
density? Low food availability?
yes no
Pre-dauer L2d
dauer
Survive up to 4 
months
L4 up to 650 ʅM 
In utero egg 
development (150 mins)
First cleavage (40 mins)
Eggs laid at gastrula 
stage  (30 cells)
L3: 490 – 510 ʅM L2: 360 – 380 μM
12 hours
8 hours 
L2/L3 molt
8 hours
L3/L4 molt
10 hours
Young adult 900-940 ʅM 
L4/adult molt
8 hours
Figure 5.1 The life cycle of the free living nematode C.elegans. based on an original diagram from:  Altun, Z.F. and Hall, D.H. 2005. Handbook of C. elegans
Anatomy. In WormAtlas.http://www.wormatlas.org/hermaphrodite/hermaphroditehomepage.htm 
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known as the dauer larvae.  Naturally induced dauer larval arrest occurs as a result of an 
L2d larva being exposed to environmental stresses such as a depleted food source or 
population overcrowding, though the chemosensory signals are detected by the L1 larvae.  
The worms then develop a cuticle which effectively seals them off from the external 
environment with an enhanced resistance to chemicals, with the mouth parts being 
͚plugged͛ so the worm cannot feed.  This resulting dauer larvae is in an arrested 
developmental state, and can survive for months until conditions improve, when the 
cuticle is shed and normal development resumes (Corsi, Wightman and Chalfie, 2015).  
The research reported here has revealed a range of phenotypes including direct mortality 
and a constitutive dauer formation phenotype that is consistent with neuronal ablation 
(Bargmann and Horvitz, 1991) when C. elegans is exposed to purified EHL. 
5.1.2 Activity against C. elegans N2 strain 
In order to establish if there was any toxic or biological effects of EHL, C. elegans was 
treated with purified protein. Treating larvae in the first life stage (L1) allows later life 
effects to be characterised as part of the treatment.   A range of phenotypic effects were 
observed when L1 stage larvae were incubated in EHL consistent with disruption to the 
chemosensory network.  An assay to observe the effect of treatment on life time fecundity, 
mortality, and constitutive dauer formation was conducted. 
5.1.3 Nematode Nanoparticle assays 
Two furthers experiments investigating the effect of lectin conjugated gold nanoparticles 
(EHL+AuNP) were conducted. The first of these (NP1) was a replication of the other 
experimental work presented and published in McConnell et al. (2015), which was carried 
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out and reported the induction of the constitutive dauer phenotype in lectin treated L1 C. 
elegans. The second experiment (NP2) was carried out using L4 stage (pre-adult) worms 
and had not previously been conducted with EHL. An observation that the EHL+AuNP 
sample did not agglutinate erythrocytes; a characteristic of the native protein, was 
recorded prior to commencement of the experiments.  
A calibration curve was established during this work examining the effect of gradient %v/v 
EHL solutions on N2 L1 larvae and the daf-c phenotype.  The results showed that at a 
concentration of 2.3 mg/ml, an 80% v/v solution is enough to induce approximately 60% 
dauer formation. Above this lethal effects tend to take over, and below this the dauer 
formation is reduced and more delayed developmental effects are apparent.  
To investigate the mechanism of action of EHL on C. elegans, a number of mutant isolates 
were chosen on the basis of the mutations that affect neuronal function. Strains which 
carry the dyf-d mutation (dye filling defective) were treated in order to investigate whether 
blockage of the proposed amphid neuron uptake of EHL would block the daf-C phenotype 
previously observed in N2. In dyf-d mutants the dauer effect was indeed found to be 
blocked. It would also be of interest to determine if those individuals that remained as 
arrested L1s in these experiments were doing so as a consequence of an inability to 
perceive the food, or if an additional mechanism is at work.  
5.2 Materials and methods 
5.2.1 Nematode assay 
Worms were obtained from the Caenorhabditis Genetics Center and maintained using 
standard methods (Stiernagle, 2006) on nematode growth media plates (NGM) using an 
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Escherichia coli OP50 strain food source. C. elegans strain N2 was used for initial testing 
and as a control in other assays. To assess the effect of various mutations on EHL-induced 
dauer larvae formation, the following strains were used: CX2065, odr-1(n1936); CX2205 
odr-3(n2150); PR671, tax-2(p671); PR672, che-1(p672); PR813, osm-5(p813); SP1205, dyf-
1(mn335); and SP1709, dyf-10(e1383). In all experiments, treatments and genotypes were 
blind coded, the position of plates within experimental blocks was randomised, and any 
contaminated plates displaying evidence of fungal growth excluded from all analysis. 
For all assays, arrested and synchronised C. elegans first stage larvae (L1s) were obtained 
by allowing eggs, isolated from gravid hermaphrodites by hypochlorite treatment 
(Stiernagle, 2006), to hatch on NGM plates in the absence of food for 24 hours at 20°C. For 
experiment 1, arrested N2 L1s were washed from plates, resuspended in sterile M9 
nutrient media (3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 ml of 1M MgSO4, made up to to 1 litre 
with dH20). with a series of EHL concentrations from 3.92 to 0 mg/ml and incubated at 20°C 
for 6 hours. Fifteen worms per treatment picked for analysis.  For experiment 2, arrested 
N2 L1s were treated as above except treatments were 2.94 mg/ml and 0 mg/ml EHL and a 
greater number of worms per treatment were analysed (n = 55 and n = 33 for the 2.94 and 
0 mg/ml treatments, respectively).  After incubation, worms were washed 3 times in sterile 
water. For the analysis of development and fecundity (experiments 1 and 2), worms were 
transferred in a small volume of liquid to NGM plates without food, then individually 
transferred from this plate to NGM plates with an E. coli OP50 strain food source and 
maintained at 20°C.  Standard methods were then used to analyse the reproductive 
schedule and lifetime fecundity (Hodgkin and Doniach, 1997).  These data were then used 
to assess the effect of EHL on reproduction as assessed by lifetime reproductive success 
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(LRS), the total number of progeny produced (experiments 1 and 2), and the intrinsic rate 
of increase (r) (experiment 2). This was calculated by iteration from Σe-rxlxmx = 1, where lx 
represents the age specific survivorship to day x and mx represents the fecundity on day x 
(Vassilieva and Lynch, 1999).  
Based on phenotypes observed in the initial screen, the ability of EHL to induce constitutive 
dauer larvae formation - a dauer-constitutive, or Daf-c, phenotype was investigated in 
greater detail. Here, worms were treated with 0.98, 1.96 or 2.94 mg/ml of EHL as described 
above, except that after washing, worms were transferred en masse to plates with food.  
After four days at 20°C, plates were visually scored to assess the proportion of worms that 
had developed as dauer larvae (number of dauer larvae/total number of worms). After 
counting, worms were washed from plates and incubated in 1 % SDS for one hour, a 
treatment that kills all C. elegans stages except dauer larvae (Cassada and Russell, 1975), 
worms were washed once in M9, transferred to fresh NGM plates with food and the 
number of dauer larvae again counted. These dauer larvae were then transferred 
individually to NGM plates with food at 20°C and monitored for the next 14 days to 
determine if they were capable of resuming development. Under these conditions 100% 
of dauer larvae that form due to lack of food and over-crowding would be expected to 
recover and to have molted to adulthood after approximately two days (Green and Harvey 
2012).  
To further analyse EHL-induced dauer larvae formation, N2 and mutant worms (see above 
for line details) were treated, as described above, with 0, or 1.54 mg/ml EHL, washed, and 
transferred en masse to plates (n = 3 per combination of treatment and genotype) with 
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food.  Plates were then incubated at 20°C for four days, at which time the proportion of 
worms that had developed as dauer larvae was scored. 
Dauer larvae formation in PR672, che-1(p672), was further analysed both in standard dauer 
larvae formation assays and in assays of growing populations.  For assays of dauer larvae 
formation in response to defined amounts of pheromone, assays were performed as 
previously described (Golden and Riddle 1984; Green et al., 2014), with worms allowed to 
lay eggs on assay plates containing dauer pheromone extract and limited amounts of food, 
and progeny were scored after two days at 25°C.  Dauer larvae formation in growing 
populations was assessed as previously described (Green et al., 2013), with populations 
initiated with single worms and a defined amount of food being allowed to grow to food 
exhaustion, except that assays were performed at 25°C. 
5.2.2 Nematode Nanoparticle assays 
Experiment NP1: A population of N2 C. elegans were synchronized using a sodium 
hyperchlorate solution and the resulting eggs were placed on NGM agar plates without 
food for 18 hours.  The resulting arrested L1 larvae were incubated in 15 ml eppendorf 
tubes at 20ºC in a solution of one of four treatments (see below) for 6 hours. 3 replicates 
of each treatment were made. 
After incubation, all treatments were subjected to a cycle of 3 washes with dH2O with a 2 
minute centrifugal spin at 2000G. Worms were then added to seeded (Escherichia coli 
OP50) NGM plates and incubated at 20ºC. Plates were then scored on day 3 for survival, 
arrested development and for dauer larvae formation.   
Experiment  NP2: Using the worms from the experiment 1 population, eggs were placed 
on seeded NGM plates and incubated at 20ºC until L4 stage was reached. Treatment was 
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then carried out in the same set of liquid conditions as experiment 1 for 18 hours. Tubes 
were placed in a shaking incubator at 20ºC overnight. Worms were washed 3 times and 
moved onto a single plate.  L4 stage worms were then placed individually onto seeded 
NGM plates, 50 per treatment. Fecundity was measured.  Treatments were as follows:  
1. M9 liquid nutrient media and EHL @ [1.51 mg/ml] 
2. M9 liquid nutrient media and EHL+AuNP 
3. M9 liquid nutrient media and AuNP 
4. M9 liquid nutrient media  
5.3 Results 
5.3.1 Activity agains C.elegans N2 and mutant strains 
All statistical analyses were conducted in ͚‘͛. Acute treatment of arrested C. elegans L1s 
for 6 hours with EHL at different concentrations resulted in a subsequent range of 
developmental, fertility and survival defects (Figure. 5.2), with all EHL concentrations 
reducing LRS (Figure 5.2A, pairwise, Bonferroni corrected, Mann–Whitney U tests against 
N2 showing reduced fecundity in all EHL treatments).  Much of this decrease in fecundity 
is however a consequence of worms not reproducing in the EHL treatments (comparison 
of Figure 5.2A and B), although LRS does still decrease over the range of EHL concentrations 
tested when only those worms that reproduced are considered (Figure 5.2B, Pearson 
product-moment correlation of LRS against EHL concentration: including the 0 mg/ml 
group, r = -0.52, p < 0.001; excluding the 0 mg/ml group, r = -0.38, p = 0.013). EHL-treated 
worms that did reproduce showed a delay in development, with many treated worms 
starting reproduction a day or more after the control worms. Of the worms that did not 
reproduce, some showed no movement from the point at which they were placed on the 
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plate, and no response to stimulus after 24 hours, they therefore died as a consequence of 
the EHL treatment. Other EHL-treated worms were observed to remain as arrested L1s or 
to develop as dauer larvae, a non-feeding developmentally arrested stage. Many of the 
non-reproducing worms were found not on a food source, and more than would be 
expected under these conditions were found to have climbed the sides of the plate; both 
behaviours are indicative of a disruption to chemosensory ability and an inability to detect 
the bacterial food.  
To investigate these reproductive effects and the survival in more detail, a larger number 
of worms were assayed (Figure 5.3). Here, EHL treatment resulted in immediate mortality 
of 41% of EHL treated individuals and again many EHL-treated worms were observed to 
remain as L1s and to arrest as dauer larvae. 
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Figure ϱ.Ϯ EHL ƌeduĐes feĐuŶditǇ iŶ C. elegaŶs. Boǆ plots of lifetiŵe ƌepƌoduĐtiǀe suĐĐess 
;L‘“Ϳ of ;AͿ EHL tƌeated ǁoƌŵs aŶd ;BͿ the suďset of EHL tƌeated ǁoƌŵs that ƌepƌoduĐed 
foƌ a ƌaŶge of leĐtiŶ ĐoŶĐeŶtƌatioŶs. Foƌ ;AͿ, Ŷ = ϭϱ foƌ all tƌeatŵeŶts, foƌ ;BͿ Ŷuŵďeƌs 
assoĐiated ǁith the ďoǆes deŶote the saŵple sizes. 
 
These results suggest that EHL treatment affects the sensory neurons.  Overall, EHL 
treatment reduced subsequent LRS (Figure 5.3A, control vs all EHL treated worms, W = 
2376.0, p <0.001), with the subset of EHL treated worms that did reproduce producing a 
greatly reduced number of progeny (control vs reproducing EHL treated worms, W = 792.0, 
p <0.001). A similar pattern was observed in the analysis of the effects of EHL treatment on 
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the estimated rate of increase (Figure 5.3B, control vs all EHL treated worms, W = 2376.0, 
p <0.001; control vs reproducing EHL treated worms, W = 792.0, p<0.001).  
 
Figure ϱ.ϯ EHL ƌeduĐes feĐuŶditǇ aŶd sloǁs deǀelopŵeŶt iŶ C. elegaŶs. Boǆplots of ;AͿ 
lifetiŵe ƌepƌoduĐtiǀe suĐĐess, L‘“, aŶd ;BͿ iŶtƌiŶsiĐ ƌate of iŶĐƌease, r, of ĐoŶtƌol ǁoƌŵs, all 
EHL tƌeated ǁoƌŵs aŶd of the suďset of EHL tƌeated ǁoƌŵs that ƌepƌoduĐed. Ŷ deŶotes the 
saŵple sizes.  
 
To characterise further the development of EHL-treated worms as dauer larvae, an 
additional population of arrested L1s were treated and analysed. As in the assay for 
reproductive effects (above), some (50) of the population of these EHL treated worms 
developed as dauer larvae (Figure 5.4).  These worms were then SDS treated, with survival 
confirming that they were indeed dauer larvae.  When transferred to food and 
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subsequently maintained at 20°C with food, only one worm out of the fifty in the assay had 
recovered and completed development as a reproductive adult after four days, with 
another worm recovering after a total of fourteen days.  Under these conditions dauer 
larvae would normally recover rapidly and have commenced reproduction approximately 
2 days after transfer to food (Green and Harvey, 2012). 
 
   
Figure ϱ.ϰ EHL tƌeatŵeŶt iŶduĐes daueƌ laƌǀae foƌŵatioŶ iŶ C. elegaŶs. The pƌopoƌtioŶ of 
laƌǀae that deǀeloped iŶto daueƌ laƌǀae oďseƌǀed iŶ populatioŶs iŶ thƌee diffeƌeŶt EHL 
tƌeatŵeŶts ;daueƌ is shadedͿ. IŶ the aďseŶĐe of EHL tƌeatŵeŶt Ŷo daueƌ foƌŵatioŶ is 
oďseƌǀed uŶdeƌ these eǆpeƌiŵeŶtal ĐoŶditioŶs iŶ NϮ. 
 
Analysis of mutant strains indicates that the ability of EHL treatment to induce dauer larvae 
formation varied across the genotypes (Table 5.1) However, all genotypes were observed 
to show a developmental delay in response to EHL treatment, with reproduction of most 
EHL-treated worms not commencing until day 5 after treatment. Analysis of dauer larvae 
formation in PR672, che-1(p672) showed that this mutation does not block dauer larvae 
formation in response to defined amounts of pheromone (data not shown) and that similar 
numbers of dauer larvae are formed in N2 and PR672 in growing populations (F1,33 = 0.05, 
p = 0.82), i.e. this line is not dauer defective. 
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  Mean % dauer ± S.E.   
Isolate Genotype Control Lectin Phenotype 
N2 Wild-type 0 49 ± 2.5 - 
CX2065 odr-1(n1936) X 0 53 ± 6.1 Defective chemotaxis1 
CX2205 odr-3(n2150) V 0 35 ± 3.1 Defective chemotaxis1  
Defective osmotic avoidance1  
PR671 tax-2(p671) I 0 8 ± 1.9 
 
Defective chemotaxis2  
Defective thermotaxis2 
PR672 che-1(p672) I 0 0 Defective chemotaxis2 
PR813 osm-5(p813) X 0 0 
 
Defective dye filling3 
Defective osmotic avoidance3  
SP1205 dyf-1(mn335) I 0 0 
 
Defective dye filling4  
Defective chemotaxis4 
SP1709 dyf-10(e1383) I 0 0 
 
Defective dye filling4  
Defective chemotaxis4 
 
Table 5.1 Mutations affecting amphid structure can block EHL-induced dauer larvae 
formation. The mean dauer larvae formation found on three plates of control and EHL 
treated worms of differing genotypes of C. elegans. 1 Bargmann, Hartweig and Horvitz 
(1993). 2 Dusenbery (1976). 3 Dusenbery (1980). 4 Starich et al. (1995). 
 
5.3.2 Nematode nanoparticle assay 
In experiment NP1, the previously reported lectin effect (McConnell et al., 2015) was 
demonstrated in the EHL treated worms, however dauer formation was not observed in 
the EHL+AuNP treatment.  No other significant effects were reported in any of the other 
treatments. In conjunction with the empirical observation that agglutination properties 
were absent from the EHL+AuNP sample, this would indicate that a conformational change 
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has occurred potentially induced by conjugation to AuNP, which blocks the EHL neuronal 
binding effects.  
In experiment NP2, testing with the L4 stage worms, there was a very small effect on 
lifetime fecundity in the EHL treated worms, and a delay in reproduction in both the EHL 
treated and the EHL+AuNP worms. From this the conclusion is that naked NPs do not 
obviously affect the L4s and that the EHL+AuNPs do have a biological activity. 
For the treated L1s, there was no dauer larvae formation in response to nanoparticles (NP) 
or to EHL conjugated nanoparticles and none in the control, but there is dauer larvae and 
developmental arrest in response to EHL treatment (Table 5.2). EHL also kills L1s, whilst 
the other treatments do not differ in L1 survival (Table 5.2). From this, the conclusion is 
that the assay shows that naked NPs do not obviously affect the L1s and that the EHL 
conjugated nanoparticles do not replicate the EHL effect. 
For the treated L4s, there was a difference between treatments in lifetime fecundity 
(TREATMENT: F3,68 = 2.76, p = 0.049) that is a consequence of a small reduction in lifetime 
fecundity in the EHL treated worms (EHL treatment significantly different to the control 
and nanoparticle-treated worms by Fisher͛s post-hoc testing) (Figure 5.5, panel A). There 
is also variation between treatments in early reproduction (H = 14.22, df = 3, p = 0.003), 
with both the EHL treated and the EHL conjugated nanoparticle treated worms showing a 
reduced early fecundity (p < 0.05 in comparison to control worms via Mann-Whitney test) 
(Figure 5.5, panel B). From this it is concluded that the nanoparticles do not obviously affect 
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the L4s and that the EHL conjugated nanoparticles do produce a similar biological activity 
to that produced by EHL. 
Figure 5.5 EHL conjugated nanoparticles affect early reproduction, but not total reproduction, 
of C. elegans L4s.   
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Treatment Number of 
plates 
L1s per 
plate 
Mean % survival (min 
and max) 
Mean % dauer 
formation (min 
and max) 
Control  11 54.6 ± 3.8 68 (53-81) 0 
EHL 12 64.2 ± 7.0 23 (11-40) 24% (0-45) 
nanoparticle 11 58.6 ± 3.2 73 (54-84) 0 
EHL conjugated 
nanoparticle 
12 48.7 ± 6.6 68 (49-83) 0 
5.4 Discussion 
EHL was used to study potential lectin-mediated toxicity against C. elegans. The bioassays 
performed indicate that EHL has biocidal properties against C. elegans.  Four phenotypic 
effects were identified: reduced fecundity (Figure 5.2 and 5.3), developmental delay, 
chemosensory disruption and constitutive dauer formation (Figure 5.4 and Table 5.1). 
C. elegans physiology is such that at the arrested L1 larval stage, the only cells which are 
not enclosed by a largely impermeable cuticle are the amphids and phasmids.  These are 
bilaterally symmetrical sensory organs that contain the sensory neurons: each amphid 
containing twelve neurons and each phasmid containing two (Ward et al., 1975).  Of the 
twelve amphid neurons, the ciliated nerve endings of eight are exposed to the external 
environment via the amphid pore (Ward et al., 1975).  These neurons control a range of 
Table 5.2 EHL treatment affects survival and development of treated C. elegans L1s. 
When scored, adult worms were only observed on 3 of the 12 EHL plates, with 
worms showing varied degrees of developmental delay.  
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phenotypes, including egg-laying and the decision to develop as a dauer larvae (Albert, 
Brown & Riddle, 1981).  Laser ablation of the ASI, ADF and ASG cells is sufficient to result 
in constitutive dauer larvae development, with ablation of the ASJ cell resulting in an 
inability to recover from dauer arrest (Bargmann & Horvitz, 1991). The observations of 
inappropriate dauer larvae formation and the failure of most such dauer larvae to resume 
development suggest that EHL is interacting with these neurons and are consistent with 
EHL treatment resulting in neuron death.  
In general, biocidal assays with lectins involve ingestion of the lectin by the target 
organism. For example, EHL had previously been tested against the coleopteran pest 
Diabrotica undecimpunctata howardii, resulting in a high mortality rate and an 80% 
reduction in body size of survivors; there were however no previous data on reproductive 
effects (Kumar et al., 1993). A study of the toxic effects of the CCL2 lectin from Coprnopsis 
cinerea (Ink Cap mushroom) on C. elegans reported a phenotype of severe developmental 
delay when the lectin was transgenically produced by bacteria fed to the worms; the lectin 
was adsorbed in the epithelial cells of the intestine, potentially degrading the membrane 
and preventing growth (Schubert et al., 2012). 
The absence of a food source in the assays reported here has enabled the observation of 
entirely new lectin-mediated C. elegans phenotypes induced by EHL, including a Daf-c 
phenotype which has not been previously reported. 
The cause of the developmental delay in EHL-treated worms is not clear. Possibilities would 
include damage to the pharynx and a subsequent reduction in pumping (feeding) ability, 
or, if some feeding is initiated, damage to the epithelial cells of the intestine as observed 
in response to the C. cinerea CCL2 lectin (Schubert et al.
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differences in body size and development are also a consequence of damaged neurons 
(Fujiwara, Sengupta and McIntire, 2002). 
Wild-type C. elegans take up dyes such as DiI and FITC into the amphid neurons AWB, ASH, 
ASJ, ASK, ADL and ASI (Hedgecock et al., 1985). Given the likely mode of action of EHL, it is 
reasoned that mutations that disrupt the normal formation of sensory amphids would 
block EHL-induced dauer larvae formation. Consistent with this, disruption of osm-5, dyf-1 
and dyf-10, all mutations in which the amphid neurons cannot take up dyes, result in no 
EHL-induced dauer larvae formation (Table 5.1). In both odr-1 and odr-3 mutants, where 
dye filling is not affected and EHL would be expected to be able to access the neurons 
normally, there is no reduction in dauer larvae formation in response to EHL treatment 
(Table 5.1). In contrast, dauer larvae formation is reduced in PR671, but some are still 
formed (Table 5.1), indicating that disruption of tax-2 only partially blocks the effect. TAX-
2 forms, with TAX-4, a cyclic nucleotide-gated cation channel that is required for 
chemotaxis in response to AWC-sensed odorants (Coburn and Bargman, 1996). Axon 
outgrowth defects have however been noted in tax-2 mutants, with c. 80% of tax-2(p671) 
animals observed to have abnormal ASJ axons (Coburn and Bargman, 1996). Given that the 
reduction in the EHL-induced dauer larvae formation observed in the tax-2 mutants 
appears to mirror this, therefor it can be inferred that the reduction in dauer larvae 
formation is a consequence of the axon guidance defects rather than the channel 
disruption.   
That EHL-induced dauer larvae formation is also blocked in che-1 mutants further supports 
the hypothesis that EHL is disrupting neurons.  CHE-1 is a C2H2-type zinc-finger 
transcription factor that is required for the identity of ASE neurons (Uchida et al., 2003).  
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Loss of CHE-1 expression eliminates the function of ASE neurons and che-1 mutations have 
previously been shown to suppress Daf-c phenotypes (Reiner et al. 2008). No significant 
structural defects have been observed in che-1 mutants (Lewis and Hodgkin, 1977) and the 
results indicate that dauer larvae formation does not appear altered in either standard 
dauer larvae assays or in growing populations.  This implies that the mutation is specifically 
blocking EHL-induced dauer larvae formation.   
It is well established that lectins bind to glycoconjugates on cell surfaces and that toxicity 
in Type II RIPs is initially due to lectin mediated entry to the cell; this mode of action is 
consistent with the results presented here. In the case of C. elegans the only cells exposed 
are the amphid neurons. As a Type II RIP EHL can be subject to retrograde transport from 
the cell surface along the neuronal processes, at which point the ribosomes are inactivated, 
causing translation to cease (Wiley, Blessing and Reis, 1982). As no post-embryonic somatic 
division occurs in mature individuals, and multiple chemoreceptors are expressed in a 
single neuron, ribosome inactivation of the neurons within the amphids would affect many 
functions derived from chemosensation (Sulston and Horvitz, 1977). Toxicity variables can 
be attributed to differing carbohydrate specificities but there is also evidence of the role 
of individual cell types in how they interact with lectins, indicating that any effects are 
characteristic of both variables (Battelli et al., 1997).  
Successful extraction using affinity chromatography has enabled assays to be conducted 
for biocidal properties against C. elegans. The results obtained demonstrate a significant 
reduction in fecundity, development, growth and a high incidence of abnormal dauer 
development when arrested L1 larvae were treated in the absence of food. The occurrence 
of dauer formation and a failure to recover in the presence of food would support the 
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hypothesis that EHL is binding specifically to amphid neurons. Here, mutant screening has 
demonstrated that EHL can act as a neuronally specific cytotoxin against sensory neurons. 
Further studies will aim to determine if those individuals that remained as arrested L1s 
were doing so as consequence of an inability to perceive food or if an additional mechanism 
is at work.   This research shows that EHL has biocidal and potential cytotoxic activity.  The 
successful conjugation of EHL to gold nanoparticles opens many avenues for further 
research, as a preliminary investigation, this work has shown that the activity of EHL is 
altered by this conjugation and as such resulted in a lessened biological effect.  As lectin 
binding activity is essential for the natural protein to bind and allow entry to cells, 
conformational changes may have affected this binding affinity.  The results show that EHL 
conjugated gold nanoparticles do still retain some activity in L4 assays as seen in Figure 5.5, 
suggesting that ingestion in the absence of glyconjugate binding (which is absent in the L1 
assay) of the molecule may present a low level of toxicity. The observation that EH+AuNPs 
do not agglutinate erythrocytes (cross linkage of carbohydrate surface antigen) would 
suggest that this is a factor. Of course the inverse hypothesis may also be worthy of 
investigation, that the toxic A-chain activity may have been altered and that binding still 
occurs without the cytotoxic effects seen in the intact molecule. As non-RIP lectins have 
been shown to bind to epithelial cells in the gut causing reduced fitness (Stutz et al., 2015) 
this requires further study to establish the exact reason for the reduction in toxicity. Since 
EHL shows specificity for N-acetyl-galactosamine (Cammue, Peeters and Peuman, 1985; 
Kumar et al., 1993), an overexpressed and incompletely glycosylated sugar in the Tn 
antigen which characterizes cancer linked O-glycans (Ju, Otto and Cummings, 2011) and 
other GalNAc specific RIPS, such as Mistletoe lectin and Riproximin, have demonstrated 
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promising therapeutic relevance as anticancer agents (Voss et al., 2006; Bayer et al., 2012; 
Adwan et al., 2014), EHL is viable as a candidate for further onwards study of antineoplastic 
characteristics.   
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Chapter 6: Development of a methodology for investigation of the effect of 
EHL on mammalian cell lines. 
6.1 Introduction 
Due to the cytotoxic nature and selective binding properties of ribosome inactivating 
proteins, they have been considered as potential agents in cancer therapies. Immunotoxins 
and other types of conjugates have been prepared, targeting a variety of different tumour 
specific characteristics such as neoplasia related overexpression of cell surface receptors 
and angiogenic markers (Hanahan and Weinberg, 2011). Of particular note is work 
involving the non-toxic RIPs such as Ebulin and Nigrin. The narrow glycan binding profile of 
these RIPs lessens the occurrence of non-specific binding, as found with the broad range 
highly toxic Ricin and Abrin (Ferreras et al. 2011), despite sharing the identical functional 
enzymatic mechanism of depurinating A4234 in the 28S ribosomal rRNA of the 60S sub-unit 
of eukaryotic cells (Van Damme et al., 2001).  
Gold Nanoparticles (AuNP) have also been shown to have potential therapeutic 
applications in oncology research (Kodiha et al. 2015). Studies shows that cancer cells 
appear more vulnerable to AuNP uptake than healthy cells (Ahmad et al., 2013) even 
without functionalised therapeutic agents attached (Ahmad et al. 2013). AuNPs can be 
functionalised with conjugated antibodies, drug preparations or imaging agents and 
dependent on the cell type and NP morphology, show an increase in permeability across 
the plasma membrane of cancer cells especially to the nuclear compartment (Kodiha et al., 
2015). This allows tumor cells to be targeted, with little effect on local healthy cells. The 
main advantage to using AuNPs is that they can simultaneously carry both functional 
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therapeutics and imaging agents to the cell. Due to the specific targeting, possible toxic 
systemic levels of chemotherapeutics could be lowered, efficacy of drugs improved and 
localised concentration in the tumour cells increased (Patra et al., 2010). As they 
themselves have a low inherent toxicity, and designable surface chemistry, AuNPs hold vast 
potential for targeting specific tumour antigens and infiltrating angiogenic regions (Ahmad 
et al. 2013). To this aim a collaboration was set up with the Bioscope group who 
functionalised AuNP to EHL, in the first instance to investigate the viability of synthesising 
such a large conjugate. When successful functionalisation was complete, the AuNP+EHLs 
were returned for exploratory work with C. elegans (see Chapter Five) and mammalian cell 
lines.  
The changes which occur in neoplastic diseases whereby a healthy cell becomes 
tumorogenic are often marked by epigenetic amendments by the normal cellular 
machinery, such as glycosylation patterns (Stowell, Ju and Cummings, 2015). Changes to 
glycosylation can arise as a result of changes in expression levels of enzymes involved in 
post translational glycan modification to peptides in normal biosynthesis. This can be as a 
result of genetic mutations, for instance the deletion of a gene involved in enzymatic 
activity such as cosmc which regulates the activity of T-synthase (Hofmann et al., 2015). T-
synthase is responsible for converting the incomplete core GalNAc residue Tn antigen to 
the terminal GlcNAc capped T antigen which is found on healthy cells (Stowell, Ju and 
Cummings, 2015). In contrast the Tn antigen is perceived to be a cancer biomarker whereby 
a positive correlation between antigenic abundance and the aggressiveness of the 
carcinoma is indicated (Madariaga et al., 2014). Rarely occurring in healthy tissue, Tn 
antigen consists of a clustered sequence of GalNAc residues (Ju, Otto and Cummings, 2011) 
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and therefore could provide a target for a GalNAc specific carbohydrate binding protein 
such as EHL to differentiate between healthy and cancerous cells. These antigenic changes 
occur in disease progression and are indicators of metastatic potential. The major types of 
protein glycosylation associated with oncogenic changes to the cell are O-linked and N-
linked glycosylation. The Tn antigen is an O-linked glycan with the full structure containing 
several N-acetyl-galactosomine units linked to a serine or threonine on a glycoprotein. It is 
synthesized as an incomplete product of the O-linked pathway. Lectins have been used to 
detect these biomarkers, with GalNAc specific lectins which share specificity with EHL such 
as Soya Bean Agglutinin and Vicia Villosa agglutinin being used in glycan recognition 
(Madariaga et al., 2014). 
Riproximin is an example of a novel type II RIP with antineoplastic properties which 
demonstrated binding to clustered GalNAc in carbohydrate microarrays. It was used to 
analyse binding to MDA-MB-231; notably desialylated for the investigation with an 
unspecified commercial neuraminidase (Roche Scientific) to expose the Tn core residues. 
(Bayer et al., 2012).  This is another avenue for further exploration with EHL which raises 
the question whether EHL will do the same. EHL, like riproximin, shares higher overall 
homology with toxic RIPs such as Mistletoe lectin 1, Polygonatum multiflora RIPm, ricin and 
abrin than to Ebulin or Nigrin (the non-toxic RIPs from Sambucas species). As it would 
appear that binding to glycans is influenced by the surrounding underlying peptide 
sequence and how that interacts with individual carbohydrate binding proteins (Stowell, 
Ju and Cummings, 2015), and that individual cell lines show diverse interactions, many 
areas for study present themselves.  
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Carbohydrates are one of the three main biological macromolecules essential for 
eukaryotic cell function and structure along with lipids and protein. Sugars are linked to a 
wide suite of functions in the cell, and are one of the biggest components involved in post 
translational peptide modifications. Constituent elements of carbon, hydrogen and oxygen 
combine to form a hydrated carbon compound. Mono saccharides are the smallest 
component which cannot be further broken down into a hydrated unit.  Despite the simple 
general molecular formula (CH2O)n, (where n=3,5 or 6) for a mono saccharide, a vast array 
of structures can be formed through the combining of simple mono and disaccharide units 
to form poly or oligosaccharide structures. Further modifications such as methylation 
increase the number of potential carbohydrate structures to an almost infinite number 
(Stowell, Ju and Cummings, 2015). In certain cases, the clustering of saccharide units on a 
cell surface in close proximity can also give rise to unique glycan environments which act 
as a ligand for an equally vast array of substrates. In some cases these will be a lectin or 
Type II RIP. All cells display carbohydrate groups or glycans on their surface as with the 
blood group antigens previously discussed, and this is also the basis of the cross linkage 
due to carbohydrate binding seen in agglutination of erythrocytes (see figure 2.4) and other 
cells by lectins.  
6.2 Materials and Methods  
For the initial development of an EHL treatment protocol and analysis of diseased cells, the 
first experimental lines were chosen on the basis of ease of culture for a novice and with 
well defined characteristics (see Table 6.1). 
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Cell line A431  MDA-MB-468 MDA-MB-231 
Pathology Epidermoid 
carcinoma 
Adenocarcinoma Adenocarcinoma 
Tissue skin Breast  breast 
Site  Solid tumour Metastatic site Metastatic site 
Species Homo sapiens 
85 yr old Female 
Homo sapiens 
 
Homo sapiens 
51 yr old Female 
Notable features p53 TSG missense 
single point residue 
mutation at R273  
Highly mitogen 
sensitive 
p53 TSG missense 
single point residue 
mutation at R273  
mitogen sensitive 
WNT7B oncogene 
EGF  + 
TGFα + 
 
Table 6.1 Summary of cell lines used and properties and characteristics of each.  
The aim of the experiment was to establish a working protocol for future work. All cell lines 
were cultured in a 5% CO2 environment in Dubelcco͛s modified Eagle media (DMEM) 
supplemented with 10% fetal calf serum, 1% pen-strep (Penicillin & Streptomycin) and 1% 
L-glutamine.   
 
Two treatment methods were used in the first set of experiments with A431 cells. As this 
was a preliminary investigation, it was necessary to consider if the carbohydrate 
components of the media could competitively inhibit the lectin binding of EHL. Taking this 
into consideration a first assay was designed to remove excess culture media from the cells 
and after trypsinisation, the four treatments (AuNP, AuNP+EHL, EHL [2.5 mg/ml], and PBS 
(137mM NaCl, 2mM KCl, 10mM Na2HPO4, 1.7 mM KH2PO4) were applied directly to the 
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cells in 24 well plates. A short incubation followed, and after one hour the treated cells 
were split into two fractions. One fraction was used for direct visualisation of the cells on 
a haemocytometer and the other was subject to a cell lysis protocol and the total protein 
content analysed using SDS-PAGE (See Figure 6.1). 
For both parts of the experiment, media was removed from culture flasks, and cells were 
washed twice with PBS prior to the addition of 1000 ʅl of trypsin. Cells were placed back 
in the incubator and checked regularly until they began to lift. The trypsin was then 
removed and replaced with 200 ʅl of fresh trypsin and left to completely lift from the flask.  
Further to this, 5ml of DMEM was added to the flask and 500 ʅl aliquots were placed in a 
24 well plate (12 wells used), media was then added to a total volume of 2000 ʅl and cells 
were incubated overnight. All lectin treatments were prepared from a stock concentration 
of 2.50 mg/ml and PBS which consisted of 137mM NaCl, 2mM KCl, 10mM Na2HPO4, 1.7 
mM KH2PO4. 
For Experiment 1.1, when the appearance of an adherent monolayer of approximately 80% 
confluence was observed in the wells, media was removed and treatments of 250 ʅl were 
added. Treatments were added in a ratio of 1:1 with PBS and left to incubate for one hour.  
Treatment was then removed and wells were washed and trypsinised. For each treatment 
50% was removed and treated with Trypan blue to show a contrast between living and 
dead cells. These samples were placed on a haemocytometer for quantification. The other 
50% of the sample was subject to a lysis protocol using 1000 ʅl RIPA buffer 
(ThermoScientific) supplemented with 10 ʅl each of Halt Protease inhibitor cocktail (100x), 
0.5 M EDTA (100x) (both from ThermoScientific) and Phosphatase inhibitors (Sigma 
Aldrich). 
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For experiment 1.2, standard culture methods were used to remove A431 cells from the 
culture flask and passage cells to a 24 well plate for overnight incubation as reported 
above. Excess media was removed and replaced with 1:1 treatment/media to a total 
volume of 500 ʅl. Cells were returned to the incubator overnight and checked 18 hours 
later. Treatments were then removed, and all wells washed with PBS and trypsinised for 
downstream analysis. The treatments were split as in experiment 1 with 250 ʅl used for 
lysis protocol (see Figure 6.1) and 250 ʅl used for direct imaging.  
A second series of experiments with A431 and MDA-MB-468 cell lines were conducted. For 
experiment 2, the culture method, reagents and consumables were as previously 
described. In Experiment 2, A431, MDA-MB-468, MDA-MB-231 were cultured using 
standard methods. Due to technical limitations only A431 and MDA-MB-468 were subject 
to treatment.  Treatment was applied for 2 hours and populations were used for direct 
imaging (see Figure 6.2) in order to examine the morphological changes observed in 
experiment 1.1 in more detail.  This confirmed that imaging in this way was not an efficient 
method under lectin treatment. 
As a final approach to optimize results, an Alamar Blue assay was added to the method. 
Cell density was first counted using the haemocytometer to make an approximation of cell 
number. Since the Alamar Blue standard protocol states that a wide range of cell densities 
can be used with a linear response seen between 50 and 50000 cells, dependent on cell 
type and treatment applied, a median range was selected in the region of 5000 cells. Cells 
were trypsinised and suspended in 1000 ʅl of media. Subsequently ϭϬʅl of cells was 
removed and mixed with ϭϬʅl of trypan blue and pipetted in equal volumes of ϭϬʅl to each 
side of the haemocytometer. Each of the 8 outer quadrants were counted and an average 
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value calculated; this was multiplied by 100 and used to approximate the number per ʅl of 
cells in the sample.  
As a result of the cell count, a final volume of 10 ʅl each was added to a 96 well plate, which 
equated to approximately 5000 cells per well. Treatments were then added to the wells. 
Measurements were taken using the FLUOstar Omega filter-based multi-mode microplate 
reader. Initially absorbance was read as for figure 6.3A, this was found to be too low 
resolution to quantify the changes. Subsequent cell lines (Figure 6.3B and 6.3C) were 
analysed by fluorescence measurement due to increased sensitivity and higher resolution.  
All analyses of absorbance and fluorescence measurements were conducted in Minitab. 
6.3 Results  
For technical reasons, the Trypan blue staining could not be imaged in either of the initial 
experiments (1.1 and 1.2), all effects can be reported but not evidenced at this stage.  The 
different effects between treatments was of sufficient magnitude that visual inspection 
gave clear outcomes.  In Experiment 1.1, the EHL treatment appeared to have killed A431 
cells outright at the concentration of 1.25 mg/ml. The AuNP+EHL treatment showed an 
approximate 1:1 living to dead cell ratio. However of note was that the EHL treated cells 
had clumped together, whereas the AuNP+EHL cells had not. The PBS and naked NP 
treatments showed no visually observable effect.  
Analysis of the lysis product in lanes 1-4, as seen in figure 6.1 was initially inconclusive and 
inconsistent. However with later results in the Alamar Blue assay hinting towards mitogenic 
stimulus of A431 by EHL, the outcome is more complex than first perceived. A second gel 
produced a comparable outcome.  Experiment 1.2, which was conducted in the presence 
of culture media in the sample and was incubated overnight, showed a much more 
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distinctive suite of effects in the visual inspection. An increase in size of the AuNP+EHL cells 
with a distinctive internal granulated appearance could be observed, as well as severe 
clumping and disruption to the cell membranes of the EHL treatments. This was supported 
by the results observed on the SDS-PAGE analysis, with a successive reduction in overall 
protein content in the AuNP+EHL and EHL treatments (lane 7 & 8) compared to the naked 
NP and PBS (lane 6 &9) (Figure 6.1).The second set of experiments resulted in similar issues 
of agglutination of cells, as can be seen in Figure 6.2 which shows the different 
concentrations of EHL applied and the AuNP treatments.  Whilst clumping can be a 
characteristic of certain cell lines, it would appear that the effect in this experiment was 
absent from control treatments and can therefore reasonably be assumed to be as a 
consequence of the treatment.  
250 
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Figure 6.1: 12% SDS-PAGE analysis of whole cell lysate under reducing conditions on 
cell line A431: Lanes: 1. MM, 2. AuNP Direct treatment(DT), 3.AuNP+EHL DT, 4.EHL 
DT, 5.PBS DT, 6.AuNP 24 hr 7.AuNP+EHL 24 hr 8.EHL  
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 Figure 6.2 Experiment 2 EHL and EHL+AuNP treatment of A431.  Images show 
the limitation of using the haemocytometer, as EHL treatment appears to 
cause clumping of the cells (consistent with glycan binding). 
AuNP + EHL  
AuNP  
EHL 1:1000  
EHL 1:10000 
A431 and PBS treatment 
EHL 1:1  
100 ʅm 
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Figure 6.3. Individual data plots for Alamar Blue assay with MDA-MB-468, MDA-MB-231 
and A431 cell lines.  A) First trial using Alamar Blue & MDA-MB-468, t=18 hours, cell density 
approx. 5000 per well n= 12, Absorbance at ʄϱϳϬnm. B) Second assay using MDA-MB-231, 
t=26 hours n=8 approx. 5000 per well. Fluorescence measured at Exc ʄϱϲϬnm & Em 
ʄϱϵϬnm. C)Third assay using A431 t=26 hours n=8 approx. 5000 per well. Fluorescence 
measured at Exc ʄϱϲϬnm & Em ʄϱϵϬnm. 
Figure ϲ.ϯ AͿ MDA-MB-ϰϲϴ Đells aďsoƌďaŶĐe ƌeadiŶgs deŵoŶstƌate that the ƌeageŶts aƌe 
ďeiŶg ƌeduĐed ǁithiŶ ƋuaŶtifiaďle ƌaŶge as seeŶ the positiǀe ĐoŶtƌol ǀs Ŷegatiǀe. Kƌuskal 
Wallis testiŶg iŶdiĐates that theƌe is a diffeƌeŶĐe ďetǁeeŶ tƌeatŵeŶts ;TƌeatŵeŶt: H = 
ϱϭ.ϰϮ, DF = ϴ, P = Ϭ.ϬϬϬͿ iŶ the aŵouŶt of Đell pƌolifeƌatioŶ iŶdiĐated ďǇ ŵetaďoliĐ ƌeduĐtioŶ 
of ‘ezasuƌiŶ at t=ϭϴ Ŷ=ϵϱ. Post hoĐ testiŶg iŶdiĐates that EHL tƌeatŵeŶts ǀs + ĐoŶtƌol did 
Ŷot sigŶifiĐaŶtlǇ diffeƌ judged fƌoŵ the p-ǀalue ;ϭ:ϭ p = Ϭ.ϵϬϴϭ; ϭ:ϭϬ  p = Ϭ.ϳϱϬϴ, ϭ:ϭϬϬ p = 
Ϭ.ϲϮϯϲ ϭ:ϭϬϬϬ p = Ϭ.ϬϵϵϵͿ. AuNP ǀs AuNp+EHL post hoĐ ;MaŶŶ WhitŶeǇͿ testiŶg iŶdiĐates 
Ŷo sigŶifiĐaŶt diffeƌeŶĐe ďetǁeeŶ tƌeatŵeŶts at p = Ϭ.Ϭϱϯϭ. 
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Figure ϲ.ϯ BͿ MDA-MB-Ϯϯϭ. ‘esults of ĐhaŶgiŶg to aŶ assaǇ ŵeasuƌiŶg fluoƌesĐeŶĐe ƌatheƌ 
thaŶ aďsoƌďaŶĐe. Foƌ the MDA-MB-Ϯϯϭ Đells, Kƌuskal Wallis ŶoŶ paƌaŵetƌiĐ testiŶg 
iŶdiĐates that theƌe is a Ŷo diffeƌeŶĐe ďetǁeeŶ tƌeatŵeŶts eǆĐept +ĐoŶtƌol ǀs –ĐoŶtƌol. 
;TƌeatŵeŶt: H = ϰϲ.ϯϲ, DF = ϴ, P = Ϭ.ϬϬϬͿ iŶ the aŵouŶt of Đell pƌolifeƌatioŶ iŶdiĐated ďǇ 
ŵetaďoliĐ ƌeduĐtioŶ of ‘ezasuƌiŶ at t=Ϯϲ Ŷ=ϲϲ. Post hoĐ testiŶg iŶdiĐates that EHL 
tƌeatŵeŶts ǀs + ĐoŶtƌol ǁeƌe Ŷot sigŶifiĐaŶtlǇ diffeƌeŶt, judgiŶg ďǇ the p-Value ;ϭ:ϭ p = 
Ϭ.ϳϭϯϮ; ϭ:Ϯ p = Ϭ.ϵϱϴϭ, ϭ:ϭϬϬ p = Ϭ.ϰϯϬϵͿ ǁith the ϭ:ϭϬ tƌeatŵeŶt sigŶifiĐaŶt at p = Ϭ.ϬϮϯϵ. 
AuNP aŶd AuNP+EHL post hoĐ ;MaŶŶ WhitŶeǇͿ testiŶg iŶdiĐatiŶg Ŷo diffeƌeŶĐe ďetǁeeŶ 
tƌeatŵeŶts at p = Ϭ.Ϭϲϲϭ. 
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Figure ϲ.ϯ CͿ Aϰϯϭ. With the assaǇ ǁoƌkiŶg ƌeliaďlǇ, the ƌesults deŵoŶstƌate iŶĐƌeased 
pƌolifeƌatioŶ of EHL tƌeated saŵple at higheƌ ĐoŶĐeŶtƌatioŶs aŶd a ƌeduĐed effeĐt as dose 
loǁeƌs.  Foƌ the Aϰϯϭ Đells, Kƌuskal Wallis testiŶg iŶdiĐates that theƌe is a diffeƌeŶĐe 
ďetǁeeŶ tƌeatŵeŶts ;TƌeatŵeŶt: H = ϱϴ.ϲϳ, DF = ϴ, P = Ϭ.ϬϬϬͿ iŶ the aŵouŶt of Đell 
pƌolifeƌatioŶ iŶdiĐated ďǇ ŵetaďoliĐ ƌeduĐtioŶ of ‘ezasuƌiŶ at t=Ϯϲ Ŷ=ϲϱ. Post hoĐ testiŶg 
iŶdiĐates that EHL tƌeatŵeŶts ǀs + ĐoŶtƌol diffeƌed, judgiŶg ďǇ the p-Values ;ϭ:ϭ p = Ϭ.ϬϬϬϵ; 
ϭ:Ϯ p = Ϭ.ϬϬϮϰ, ϭ:ϭϬϬ p = Ϭ.ϬϬϭϱͿ ǁith the ϭ:ϭϬ tƌeatŵeŶt Ŷot sigŶifiĐaŶt at p = Ϭ.ϰϵϰϴ. 
AuNP aŶd AuNp+EHL post hoĐ ;MaŶŶ WhitŶeǇͿ testiŶg iŶdiĐates a diffeƌeŶĐe ďetǁeeŶ 
tƌeatŵeŶts at p = Ϭ.ϬϬϭϱ. 
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6.4 Discussion  
In the initial development of the toxicity assays, achieving an experimental design which 
would ultimately provide a successful and quantitative analysis of cytotoxicity was the 
overarching aim.  With experimental limitations imposed in both temporal and resource 
availability, the main objective of the cell experiments was to gain as much information as 
possible on how to proceed with future research and develop a methodology, rather than 
define the effects of EHL completely and quantitatively. Initial work clearly highlighted 
some of the areas for basic method improvement using the apparatus available. On visual 
inspection, EHL seems to have an agglutinating or clumping effect on A431 which prevents 
samples from evenly distributing across the haemocytometer, preventing accurate 
representation of the total cell population. Removal of the culture media in the initial direct 
treatment experiments also means that degradation of the population will occur as a 
function of their environment, potentially influencing the number of dead cells in the 
sample, and therefore was disregarded in the next set of work. The SDS-PAGE analysis of 
the whole cell lysis products from this method (Figure 6.1) was inconclusive, with 
potentially anomalous results. The attempts to image cells using trypan blue to 
differentiate between living and dead cells using the haemocytometer proved non-viable 
for a number of reasons, mainly due to the clumping of cells giving falsely low cell density 
readings in the quadrants. Initially, the methodological obstacle to be resolved focused on 
imaging the cells directly. To this end a second set of experiments was set up, where the 
aim was to find out if there was a difference in the effect seen on other cell lines. A plan to 
utilise a Dinolite microscope camera to record the outcome of the experiment was made. 
A431, MDA-MB-468, and MDA-MB-231 were originally to be included. The decision to 
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exclude MDA-MB-231 was taken as the cells were not growing well. A two hour treatment 
was applied to A431 and MDA-MB-468, however only the A431 line allowed for any 
reasonable imaging. As a result of the observations made, namely the extensive 
aggregation of cells and different culturing outcomes, a more robust methodology 
measuring intrinsic enzymatic or metabolic linked outcomes was sought. For the final 
experimental opportunity, this would allow the death rate to be measured by comparative 
absorbance or fluorescence and a densitometric value to be calculated. The Alamar Blue 
(Invitrogen) reagent provided a foundation to achieve that outcome. During this 
preliminary work it was noted that lectin treated cells did not disperse evenly due to 
aggregation. The result was that cell counts were not representative of the total sample. 
In order to overcome this characteristic of the treatment and to allow for a more 
representative quantification of the observed effects, a new approach was pursued which 
directly measured the effect on a whole saŵple͛s ŵetaďoliĐ output. Alamar Blue 
(Invitrogen) is a reagent used to measure cell proliferation and is used to differentiate 
between metabolically active cells and those which are non-functioning using a redox 
indicator, Resazurin (Rampersad, 2012). Typically, the oxidation state is dark blue in colour 
and, if cells actively proliferate, the reduced state of the reagent will progress through a 
colorimetric gradient to a bright pink colour and fluorescence will increase over time 
(Figure 6.4). Alamar Blue and its active reagent resazurin show a colometric and 
flourimetric linear response to proliferation of a broad range of cell densities. However this 
can vary widely between cell lines and development times can also be subject to a large 
gradient in rate of change and the range of output values .  
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Figuƌe ϲ.ϰ Alaŵaƌ Blue assaǇ uses the ƌeduĐiŶg pƌopeƌties of ŵetaďoliĐallǇ aĐtiǀe Đells to ĐoŶǀeƌt  the aĐtiǀe iŶgƌedieŶt ƌesazuƌiŶ to 
ƌesoƌufiŶ.  The fluoƌesĐeŶĐe ŵeasuƌed is pƌopoƌtioŶal to the Ŷuŵďeƌ of liǀiŶg Đells. Diagƌaŵ ďased oŶ stƌuĐtuƌes puďlished iŶ O'ďƌieŶ et al. 
;ϮϬϬϬͿ. 
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Therefore this assay also required optimisation as part of a new method. Optimisation of 
the Alamar Blue assay is a timely and complex process in the first instance. However with 
a single opportunity to conduct the experiment for this work, a standard protocol was used 
firstly on cell line MDA-MB-468. Initial exploratory results with MDA-MB-468 indicated that 
a minimum treatment period of 24 hours was required with cell densities in the range of 
approximately 5000 cells per well on a 96 well plate for the lines used (MDA-MB468, A431 
& MDA-MB-231) to begin to observe the predicted colour changes. The initial trial with the 
MDA-MB-468 was ultimately an assessment of what kind of response would be returned 
under these parameters, and absorbance was read over an 18 hour period (Figure 6.3A). 
Absorbance readings did not show as much fine detail as required. Consequently for the 
next and final two trials, with A431 and MDA-MB-231, fluorescence readings were used as 
a more sensitive indicator (Figure 6.3B and C). 
In future research, cell densities 10 fold higher would be likely to display a faster result with 
less anomalous data. The method of application employed was to add Alamar Blue to the 
treatment so as to enable observations over time. The reagent can also be added as an end 
point marker and future work would include an optimisation of this method. Observations 
demonstrate a difference in the lethality of protein which had been purified in the presence 
of protease inhibitor cocktail (Sigma Aldrich) and that which had not, though at this stage 
of the research that difference could be attributable to other factors too. This could be 
related to the observations of Virgilio et al., (2010), who suggested that proteolytic 
cleavage is required for activation of a homologous mature toxin (saporin and ricin), and 
that the recent trial addition of a protease inhibitor to the extraction method may suppress 
this outcome despite a positive agglutination test being observed. The findings of this work 
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are not conclusive, nor are they intended to be so, due to the continued method 
improvement and optimisation. However, of particular note is the observation that in the 
individual data plot of A431 it would appear that EHL treated cells at higher concentrations 
have proliferated more than those cells in lower concentrations or with no treatment 
applied. Whilst this may seem to be in contradiction to the hypothesis that EHL acts as a 
cytotoxic agent, work with adding Gal/GalNAc specific lectins such as Jacalin, Amaranth 
and Peanut lectin to certain cell lines has shown an increase in the proliferation of epithelial 
cancer cells (Yu et al., 2001) with a tentative link to the presence or absence of the T 
antigen. Whilst this is most certainly only a first step towards a full mammalian cell screen, 
it is widely recognised that lectins can act as mitogenic agents (Sharon and Lis, 2007) and 
further work would explore this preliminary finding more deeply. When viewed from this 
perspective, the initial anomalous results observed in the whole cell lysate SDS-PAGE 
become more of a point for discussion. The work presented here in no way attempts to 
report a refined and conclusive experiment, rather the focus is on the development of an 
optimal technique for doing so. 
The statistics presented are a very basic analysis of the findings and have limitations 
therein. However, it cannot go without note for future research that the most striking 
outcome of the A431 assay is that there appears to be a dose dependent correlation 
between increased proliferation and increased concentration of EHL. This mirrors the 
results seen in Yu et al. (2001) in theiƌ ǁoƌk oŶ ĐoloŶ ĐaŶĐeƌ Đells ǁith Galβϭ GalNAc specific 
lectins. As A431 is a p53 tumour suppressor gene mutant (p53-R273H) (Reiss et al., 1991), 
it is reported as therefore being sensitive to mitogenic stimulus (Lamb et al., 1991). With 
other lectins reported as being mitogenic agents (Sharon and Lis, 2007) this would certainly 
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be an avenue for further study.  MDA-MB-468 also showed an increase in proliferation; 
since the first data were produced from an absorbance rather than fluorescence reading 
(with absorbance being less sensitive and furthermore performed under sub optimal 
conditions); the results at this stage cannot be directly compared. Notably, however, MDA-
MB-468 is also a p53-R273H mutant (Muller and Vousden, 2014; Tan et al., 2015) which is 
a missense single amino acid substitution at arginine 273 of the p53 protein. (Freed-Pastor 
and Prives, 2012).  The p53 tumour suppressor gene product, p53 protein, with more than 
half of all tumours exhibiting mutation at this locus, is the most frequent target in human 
cancer mutations (Vogelstein, Lane and Levine, 2000). 
Future work would focus on developing the protocol to include longer treatment times, as 
observations herein suggest that a period of 24 hours would be the minimum appropriate 
for treatment uptake. General points to improve the method would include the following; 
 Using a higher density of cells per well.  
 Using only protein extracted in the absence of protease inhibitors.  
 Using black culture plates to allow fluorescence to be measured maximum 
accuracy. 
 Measuring fluorescence from the bottom of plates containing adherent cell lines to 
minimise buffer effects or correcting for Phosphate buffered saline auto-
fluorescence. 
 Ensuring well volumes exceed 5000 cells by a factor of 10 where possible. 
 Correcting for nanoparticle buffer composition and surface plasmon resonance. 
 Designing a cell panel to contain both Tn + and Tn - cell lines,  
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 Investigating mitogenic effects and relationship to p53 mutations.  
These adjustments would hopefully allow any significant differences between lines and 
treatments to be better quantified. The protocol should include all of the above points and 
would allow more accurate and consistent outcomes to be measured in future studies.   
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Chapter 7: General discussion and future directions 
7.1 Discussion 
The aim of this thesis was to conduct an in depth study of the structure and biological 
effects of the Winter Aconite (Eranthis Hyemalis) lectin (EHL). In order for EHL to be used 
in any future biomedical and biotechnological applications, the underlying structure and 
biological activity of EHL needed to be elucidated. The current extraction and purification 
protocol was refined, with the objective of obtaining consistently high protein yields for 
the additional studies to take place. An investigation of the structure of the EHL protein 
was also carried out.  One aspect of this structural work was using molecular biology 
techniques to find the underlying gene sequence of the protein. Moreover, EHL was 
crystallised, and diffraction data were used to establish the three dimensional structure of 
the protein. The potential toxic effects of EHL in living organisms were explored by 
conducting several biological assays. These assays initially focused on the model organism 
Caenorhabditis elegans, and both wild type N2 strains and genetically mutated strains were 
used on this part of the work. The assays were performed using the natural protein, as well 
as EHL conjugated gold nanoparticles. Finally, preliminary studies of the potential cytotoxic 
effect of EHL on mammalian cancer cell lines was carried out, in order to develop a viable 
method for future research on this area. 
The previously published extraction and purification protocols were refined as described 
in detail in Chapter Two. The method improvement has enabled higher yields of protein to 
be extracted and with techniques such as diafiltration devices being employed, 
concentrations up to 4 mg/ml have been achieved. With the addition of new steps to the 
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protocol such as the ammonium sulfate fractionation, an increased purity has been 
achieved; this has also contributed to the viability of the crystallisation studies performed. 
Onwards improvement for this purification method would potentially seek to remove the  
freeze/thaw step in favour of more a efficient chemical method to clarify the product. 
Whilst for this work the priority was to increase yield, purity and consistency of the output, 
with those objectives achieved, the parameters of the method could even be further 
improved given the opportunity to do so in the future, both in economical and temporal 
aspects. However the overarching aim of this research for the future is to reach an outcome 
whereby EHL protein can be recombinantly expressed, allowing for poly histidine tags to 
be utilised and a supply of EHL to be available regardless of season or bulb quality.  
Molecular biology techniques were used in an attempt to establish the underlying gene 
sequence of EHL, as described in more detail in Chapter Three. Initial work using 
degenerate primers designed from previously published peptide fragments (Kumar et al., 
1993) was of limited success, and subsequently research funding was granted at the final 
stage of this work to sequence the genome of Winter Aconite. Genomic DNA was extracted 
from Winter Aconite and has now been passed by quality standards for genomic 
sequencing. The primary sequence which will be available as a result of this will require 
extensive bioinformatics input to assemble the raw data or ͚ƌeads͛. Whilst this work 
progresses, the EHL amino acid sequence gathered during this research can be used to 
probe the genomic data even prior to assembly, and will be a priority for future research 
in this area. The structure of EHL can be completed as soon as these data become available. 
The taxonomic comparison of EHL against the RIP family of proteins can then be best 
informed by examining closely the apparent divergence of the Type II ribosome inactivating 
159 
 
protein from its homologs. The in depth study of the fully complete and refined 
crystallographic structure will identify all of the glycosylation sites, disulphide bonds and 
active site residues, providing an opportunity for docking and molecular dynamics studies 
to begin. A confirmation of these characteristics amongst other structural motifs and 
domains can provide a means of understanding the regions of evolutionary divergence in 
the protein which are apparent, particularly the potential differences in the active site 
regions. 
Chapter Four described the work carried out to determine the crystal structure of EHL. 
Crystallisation screening was carried out using the sitting drop vapour diffusion method 
and a number of cation/PEG based conditions yielded crystals of diffraction quality. Four 
crystals yielded diffraction data between 3.2 and 1.6 Å. The highest resolution diffraction 
data showed a monoclinic P1211 space group, with unit cell dimensions a = 46.84 Å, b = 
94.39 Å, c = 71.12 Å, and α = 90° β = 96.47° γ = 90°. Electron density maps generated from 
the data allowed an initial structure model to be built.  From the highest resolution data, a 
poly-alanine backbone trace was built using SHELXE4; once the protein sequence data  are 
available, it will be possible to read in the sequence to the maps already created to 
complete the structure. Future work would optimise the crystallisation process by isolating 
successful conditions and exploring the crystallographic space around them in terms of pH 
and salt/ precipitant parameters. Whilst the aim of any crystallographic experiment is to 
yield high resolution data which has already been the outcome herein, there is scope for 
future work on this aspect of the research. The length of time taken for crystal growth and 
the consistent output of large single crystals as opposed to many optimally sized crystals 
limits the work that can be done with them. In order for substrate binding experiments to 
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take place in the future, it would be ideal to have many crystals with a shorter growth 
period in the same condition with which to work. Crystallisation studies with a substrate 
bound with an analog such as adenine monophosphate would provide more structural 
information about any differences in active site regions as is currently proposed from the 
model, thus contributing new knowledge to the field of RIP research. 
A set of biological assays was conducted to explore the potential toxicity of the protein in 
living organisms. The initial biological assays focused on the model organism 
Caenorhabditis elegans and included using wild type N2 strains and also an exploration of 
the effects EHL had on genetically mutated strains. Experiments were carried out with the 
natural protein and with EHL conjugated gold nanoparticles. Winter Aconite Lectin EHL 
bound specifically to the amphid neurons of Caenorhabditis elegans when treated as an L1 
larvae, causing impairment of chemosensory function, development and fecundity, and 
disruption of the normal dauer response pathway. A different effect was observed in assays 
conducted on later life stages when the dauer decision is no longer an option. Given the 
opportunity to pursue this work further, an avenue to explore would be with worms 
expressing pan-neuronal fluorescence to identify whether the differing phenotypic effects 
already observed correlate to the outright death, or merely to the damage of particular 
sets of neurons. Mutant screens could be carried out to potentially identify lectin resistant 
strains; ultimately this would contribute to our understanding of lectin binding and the 
relationship with particular receptor groups and cell types. Also of benefit would be to 
further categorise the effects of treatment during various developmental stages. This 
would be in order to map changes as differing cell types are exposed, such as epithelial 
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cells (which are due to cuticular changes)and the onset of pharyngeal pumping (feeding), 
especially if  fluorescently labelled EHL could be used to map localisation of the toxin. 
The opportunity to conduct mammalian cancer cell investigations arose towards the 
conclusion of this study, and whilst the main scope of the experiments was to achieve a 
working protocol for a toxicity screen for future work, one of the outcomes of that work 
potentially demonstrates that EHL may have mitogenic properties in combination with p53 
mutant lines. It would be interesting to establish whether this as a result of an additional 
mechanism such as a higher binding affinity in those cells or if it is a purely tumour 
suppressor gene dependent effect. With this observation in mind using a panel of cells 
would seek to explore further and to more clearly define the relationship between EHL 
effects on a number of cell types, both healthy and cancerous.  
One of the objectives of this work was to establish the viability of a functionalised EHL 
nanoparticle conjugate and its potential effect on the cytotoxicity of EHL; and the results 
from this research can be found in Chapters Three and Five. The aim of this was first to 
provide some insights into the viability of the conjugate, and then perform some 
preliminary assays to establish if the EHL biological effect is altered, providing the ground 
for future research.  Gold nanoparticles functionalised with EHL were successfully 
synthesized by Dr Javier Lodeiro and Ms Jamila Djafari at the BIOSCOPE-PROTEOMASS 
Laboratory (FCT-UNL, Portugal), and assays using C. elegans and mammalian cancer cells 
performed. With the successful conjugation of EHL to gold nanoparticles in place, countless 
opportunities have opened up. Further work would investigate the structural impact on 
EHL from the nanoparticles and whether this consistently renders the protein less active 
overall as seen in the C. elegans experiments. The nematology experiments indicate that 
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the protein is affected, potentially due to inhibition of binding caused by the presence of 
the nanoparticle or perhaps because of an overall conformational change has rendered the 
b-chain, which is of course responsible for agglutination, inactive. The alternative 
hypothesis is that both chains are affected and that the toxic effect is also reduced. These 
questions would form the foundations of any further work with the nanoparticle 
conjugate. This has great potential in cytology applications since nanoparticles themselves 
show a greater permeability across cancer cell membranes than healthy cells, as discussed 
in Chapter Six. The idea that they can be used as delivery systems for drugs and imaging 
agents lends itself to the notion of targeting cells with the A chain of EHL.  EHL would seem 
to show lower overall toxicity as part of the native protein than its more toxic counterparts 
Ricin and Abrin, but potentially when delivered via a nanoparticle conjugate to the region 
of interest could deliver the same N-glycosidase activity. 
Throughout any discussion of lectins and RIPs, the overall function of the protein remains 
under debate and whilst many hypotheses have been tested and shown promising 
explanations, a definitive answer is still elusive. A future study on the fully refined and 
sequenced structure of EHL could be aimed towards establishing that function.  
7.2 Concluding remarks 
This study has contributed new knowledge to the field of lectin research.  Winter aconite 
is the first plant in its family to have lectin and ribosome inactivating activity described. 
This adds to our understanding of the evolutionary relationships in this important class of 
molecules. Through X-ray crystallography diffraction experiments, a new protein structure 
has been defined and whilst not yet fully complete, already contributes useful structural 
information to the field. On completion of the genome assembly and accompanying 
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structure refinement, it will ultimately result in the deposition of a new structure in the 
PDB for other researchers to use. The dauer phenotype described has not been reported 
before, and whilst C. elegans is a free living nematode, it can act as a model organism for 
understanding parasitic nematodes such as Steinernema and Heterorhabditis (which 
parasitise insects), and Strongyloides stercoralis, which is  a human parasitic species (Riddle 
and Albert, 1997). 
The development of a cellular toxicity assay with EHL is in its beginnings. However early 
indications are that there are interesting and previously unreported effects of this 
important plant toxin against mammalian cells. 
In conclusion, this work has attempted to tell a complete story on which to build further 
studies of EHL. That story was to experimentally find a way to gather enough protein to 
conduct further studies, firstly in order that crystals could be grown, to find out the 
molecular structure of the toxin. The question then to be answered was: how does it affect 
living organisms and is it a useful tool in biological research? The research conducted shows 
that EHL displays blood type specific agglutination, mitogenic activity, can be successfully 
conjugated to gold nanoparticles, displays neuron specific cytotoxic binding properties, 
and also shows an interesting divergence from ancestral RIPs.  The results from this study 
have unlocked huge potential for EHL to undergo considerable onwards investigation and 
testing in a variety of directions, and has contributed new knowledge to this expanding 
area of research.  
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Abstract 
The lectin found in the tubers of the Winter Aconite (Eranthis hyemalis) plant is an N-
acetyl-D-galactosamine specific Type II Ribosome Inactivating Protein (RIP); Type II 
RIPs have shown anti-cancer properties, and hence have potential as therapeutic agents. 
Here we present a modified protocol for the extraction and purification of the E. hyemalis 
lectin (EHL) using affinity chromatography. De novo amino acid sequencing of EHL 
confirms its classification as a Type II Ribosome Inactivating protein. The biocidal 
properties of EHL have been investigated against the nematode Caenorhabditis elegans. 
Arrested first stage larvae treated with EHL have shown some direct mortality, with 
surviving larvae subsequently showing a range of phenotypes including food avoidance, 
reduced fecundity, developmental delay and constitutive dauer larvae formation. Both 
inappropriate dauer larvae development and failure to locate to bacterial food source are 
consistent with the disruption of chemosensory function and the ablation of amphid 
neurons. Further investigation indicates that mutations that disrupt normal amphid 
formation can block the EHL-induced dauer larvae formation. In combination, these 
phenotypes indicate that EHL is cytotoxic and suggest a cell specific activity against the 
amphid neurons of C. elegans.  
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Introduction 
 
Lectins are a class of carbohydrate binding proteins ubiquitously expressed in plants, 
animals, bacteria and viruses, characterised by their ability to agglutinate erythrocytes 
(Peumans & Van Damme, 1995), a property that enabled the development of the ABO 
system of blood typing.  The second characteristic common to all lectins is the ability to 
bind carbohydrates selectively based on the individual sugar specifity of the lectin.  This 
also results in lectins binding to the carbohydrate moieties of extracellular glycoconjugates 
specifically and reversibly without introducing conformational changes to the mono- or 
oligosaccharides to which they bind (Sharon & Lis, 2004).  Plant lectins are involved in a 
wide range of processes including carbohydrate transport, cell-cell signalling, cell surface 
binding and recognition, pathogenic defence and in potentially mediating symbiotic 
relationships (Sharon & Lis, 2004).  Plant lectins play a key role in defence, with many 
specifically binding to epithelial cells of herbivore and nematode guts (Schubert et al., 
2012; Delatorre et al., 2007).  Insecticidal, antifungal and antiviral qualities have also been 
widely described (e.g. Kumar et al., 1993; Rao et al., 1998; Peumans, Hao & Van Damme, 
2001; Edwards & Gatehouse, 2007).  For example, Balsamin, from Momordica balsamina, 
demonstrates potent anti-HIV activity (Kaur et al., 2013). 
 
In recent years the potential of lectins for use in cancer therapies has become a significant 
research focus due to their ability to preferentially bind to specific carbohydrates, and 
differentiate between glycosylation patterns.  Moreover, a number of plant derived lectins 
have been shown to have potent in vitro and in vivo anti-cancer effects (e.g. Voss et al., 
2006; Otsuka et al., 2014) inducing autophagous and apoptotic pathways in tumour cells, 
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and some are already used therapeutically.  For instance, the recombinant mistletoe lectin 
rViscumin has been through phase 1 clinical trials and a number of other native mistletoe 
lectin preparations such as Lektinol and Iscador are prescribed widely throughout Europe 
as adjuvant therapies although their efficacy is not readily quantified (Horneber et al., 
2008). 
 
Using a modified extraction protocol developed from previously published studies 
(Cammue, Peeters & Peumans 1985, Kumar et al. 1993, George et al. 2011). This paper 
focuses on the lectin found in the tubers of Winter Aconite, Eranthis hyemalis, (EHL).  To 
date, EHL is the sole lectin representative described from the Ranunculaceae and has been 
identified as a Type II Ribosome Inactivating Protein (RIP) (Kumar et al., 1993).  EHL 
preferentially binds N-acetyl-galactosamine, but also binds galactose, galacto-pyransosyl-
D-glucose, and to a lesser degree D-ribose (Kumar et al., 1993).  Type II RIPs are 
classified as chimerolectins and cytotoxic N-glycosidases and consist of either one or two 
heterodimers linked by disulphide bonds.  The B chain subunit is a sugar specific lectin 
containing the highly conserved ricin B domain and will bind to extracellular 
glyconjugates. This mediates entry to the intracellular environment for the attached 
cytotoxic A chain by endocytosis (Virgilio et al., 2010).  The toxin is then subjected to 
retrograde transport via the Golgi complex; to the endoplasmic reticulum where the 
disulphide bonds are reduced and the A chain is free in the cytosol to refold into an 
enzymatically active form (Hartley & Lord, 2004).  The A chain acts as an inhibitor of 
eukaryotic protein synthesis by cleaving a single adenosine (A4234) in the 28s rRNA 
subunit preventing Elongation Factor 2 from binding and resulting in immediate and 
absolute cessation of peptide elongation (Hartley & Lord, 2004). 
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Type II RIPs are an area of increasing interest due to their antineoplastic properties, and 
their glycomic binding profile can be used to target specific glycans of biological 
molecules.  For instance, the GalNac specific RIP Ximenia americana (Riproximin) (Voss 
et al., 2006), Sambucas sp (Ferreras et al., 2011) and ML1 from Viscum album (Tonevitsky 
et al., 1996) show higher binding affinity for tumour cells than for healthy cells.  This can 
be partly attributed to the expression of particular surface saccharide groups in the 
changing glycomics of malignant cells (Peumans, Hao & Van Damme, 2001; Bayer et al., 
2012).  The use of lectins and Type II RIPs is also indicated in some studies for marking 
metastatic proliferation of tumour cells due to excessive glycosylation in metastatic cell 
lines (Zhou et al., 2015). 
 
Herein we present a modified extraction and purification protocol for EHL. Protein 
sequencing of EHL further supports the findings of earlier work that EHL is a Type II RIP. 
We also investigate the effect of EHL on the free living nematode Caenorhabditis elegans. 
C elegans is a well-established model organism for initial toxicological studies due to the 
conserved nature of its biological and biochemical processes including stress response and 
disease pathways (Boyd, Smith & Freedman, 2012).  Our research has revealed a range of 
phenotypes including direct mortality and a constitutive dauer formation phenotype that is 
consistent with neuronal ablation. 
 
Material and Methods 
Preparation of affinity chromatography column 
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An Amersham chromatography column was packed at room temperature with a final bed 
volume of 8 ml of Fetuin-Agarose in solution with 0.5 M NaCl and immobilised on cross-
linked 4 % beaded agarose (Sigma-Aldrich Company ltd, UK).  Prior to use the column 
was equilibrated with 8 column volumes of Phosphate buffered solution (PBS). 
 
Extraction of EHL 
60 g of E. hyemalis tubers supplied by Eurobulbs Ltd (UK) were prepared using a 
modified method from those described in previous studies (Cammue, Peeters & Peumans, 
1985, Kumar et al. 1993, George et al. 2011)  with adaptions as follows.  The tubers were 
finely sliced before being homogenised with 250 ml of ice cold PBS containing 5 mM 
thiourea and left to settle on ice for 30 minutes. The homogenate was removed and stored 
and the remaining slurry was mixed with a further 250 ml of PBS. The two fractions were 
then combined and stirred at 4°C for 4 hours. The homogenised mixture was then 
centrifuged (Sorvall RC6 plus HSC) at 20,000 g for 30 minutes. The supernatant was 
retained and frozen at -80°C overnight in order to induce aggregation of any remaining 
lipid content in sample. The sample was then defrosted and filtered through 3MM 
Whatman filter paper before undergoing a further centrifuge cycle of 20,000 g for 20 
minutes. The clarified supernatant then underwent ammonium sulphate precipitation.  
 
Ammonium sulphate precipitation.  
Solid ammonium sulphate was added slowly to the crude extract initially to a saturation 
point of 40%, and after one hour of stirring at 4°C was centrifuged at 10,000g for 15 
minutes.  The pellet was re-suspended in 15mls of PBS.  Ammonium sulphate was then 
added to the supernatant to a final saturation point of 80%, with a further hour of stirring at 
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4°C.  The resulting pellet was also re-suspended in PBS.  Agglutination activity was found 
to be retained in the 40% pellet and absent from the 80% pellet.  An SDS-PAGE gel 
confirmed the presence of target protein in the 40% fraction.  Samples were dialysed 
against PBS in 3 buffer changes consisting of 200 x sample volume each including a final 
overnight exchange. 
 
Purification of EHL 
The crude dialysed extract was applied to a Fetuin-agarose affinity chromatography 
column at a rate of 1 ml per minute using ÄKTA Express protein purification system (GE 
Healthcare), non-target proteins were then eluted with PBS until absorbance at λ280 was 
restored to base line value circa 40 mAU. The affinity matrix was then equilibrated with 
PBS and subsequently EHL was eluted with 40 mM 1,3 diaminopropanol (DAP) and peak 
fractions were collected in 0.5ml aliquots. The oligosaccharide structure of Fetuin has been 
well defined and shown to have Gal and GlcNAc branched residues present.  Fetuin has 
been purified using the lectin RCA I which has specificity for Galactose and N-
acetylgalactosamine (Green et al., 1988).  Its use, therefore as an affinity chromatography 
media for the lectin/type II RIP purification is based on this complementary interaction.  
The eluant was neutralised with 2-Amino-2-hydroxymethyl-propane-1,3-diol 
hydrochloride (Tris-HCl) at pH 7.0.  Peak fractions were applied to pre-equilibriated PD-
10 desalting columns (GE Healthcare) and buffer exchanged into PBS. 
 
Analysis of EHL 
Purified EHL was tested for agglutination ability using defibrinated rabbit erythrocytes 
(TCS Biosciences), with 20 µl of post column eluant, or control, added to a 20 µl sample 
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of erythrocytes in a welled microscope slide.  The purified EHL was also analysed by 
SDS-PAGE, with both reduced and non-reduced samples electrophoresed on 12 % gels 
and subsequently stained with Coomassie Brilliant Blue.  Concentration was measured 
using a Qubit flourometric protein assay.  
 
Purified EHL was commercially sequenced.  In-gel tryptic digestion was performed after 
reduction with DTE and S-carbamidomethylation with iodoacetamide. Gel pieces were 
washed two times with 50% (v:v) aqueous acetonitrile containing 25 mM ammonium 
bicarbonate, then once with acetonitrile and dried in a vacuum concentrator for 20 min.  
Sequencing-grade, modified porcine trypsin (Promega) was dissolved in the 50 mM acetic 
acid supplied by the manufacturer, then diluted 5-fold with 25 mM ammonium bicarbonate 
to give a final trypsin concentration of 0.02 g/L.  Gel pieces were rehydrated by adding 
10 L of trypsin solution, and after 10 min enough 25 mM ammonium bicarbonate solution 
was added to cover the gel pieces.  Digests were incubated overnight at 37oC. 
 
A 1 L aliquot of each peptide mixture was applied to a ground steel MALDI target plate, 
followed immediately by an equal volume of a freshly-prepared 5 mg/mL solution of 4-
hydroxy--cyano-cinnamic acid (Sigma) in 50% aqueous (v:v) acetonitrile containing 0.1% 
, trifluoroacetic acid (v:v).   
 
Positive-ion MALDI mass spectra were obtained using a Bruker ultraflex III in reflectron 
mode, equipped with a Nd:YAG smart beam laser.  MS spectra were acquired over a range 
of 800-5000 m/z.  Final mass spectra were externally calibrated against an adjacent spot 
containing 6 peptides (des-Arg1-Bradykinin, 904.681; Angiotensin I, 1296.685; Glu1-
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Fibrinopeptide B, 1750.677; ACTH (1-17 clip), 2093.086; ACTH (18-39 clip), 2465.198; 
ACTH (7-38 clip), 3657.929.). Monoisotopic masses were obtained using a SNAP averagine 
algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) and a S/N threshold of 2.  
 
For each spot the ten strongest precursors, with a S/N greater than 30, were selected for 
MS/MS fragmentation. Fragmentation was performed in LIFT mode without the 
introduction of a collision gas. The default calibration was used for MS/MS spectra, which 
were baseline-subtracted and smoothed (Savitsky-Golay, width 0.15 m/z, cycles 4); 
monoisotopic peak detection used a SNAP averagine algorithm (C 4.9384, N 1.3577, O 
1.4773, S 0.0417, H 7.7583) with a minimum S/N of 6.  Bruker flexAnalysis software 
(version 3.3) was used to perform spectral processing and peak list generation. 
 
De novo sequencing of tandem mass spectra was performed by hand, with a-, b-, b0-, y-, y0- 
and y*-ions considered as possible fragment ions.  De novo derived peptides sequences were 
matched to homologous protein sequences using the on-line MS-BLAST service provided 
by Washington University.  The results of which were consistent with the in-house 
homology search results conducted on confidently assigned sequences using the University 
of Virginia UVa FASTA Server, the FASTS and SSearch algorithms were used for 
homology searching against the SwissProt (NCBI) and PDB databases. 
 
Activity against C. elegans 
Worms were obtained from the Caenorhabditis Genetics Center and maintained using 
standard methods (Stiernagle, 2006), on nematode growth media plates (NGM) using 
Escherichia coli OP50 strain food source. N2 was used for initial testing and as a control 
187 
 
in other assays. To assess the effect of various mutations on EHL-induced dauer larvae 
formation, the following strains were used: CX2065, odr-1(n1936); CX2205 odr-
3(n2150); 
PR671, tax-2(p671); PR672, che-1(p672); PR813, osm-5(p813); SP1205, dyf-1(mn335); 
and SP1709, dyf-10(e1383). In all experiments, treatments and genotypes were blind 
coded, the position of plates within experimental blocks was randomised, and 
contaminated plates excluded from all analysis. 
 
For all assays, arrested and synchronised C. elegans first stage larvae (L1s) were obtained 
by allowing eggs, isolated from gravid hermaphrodites by hypochlorite treatment 
(Stiernagle, 2006), to hatch on NGM plates in the absence of food for 24 hours at 20°C. 
For experiment 1, arrested N2 L1s were washed from plates, resuspended in M9 with a 
series of EHL concentrations from 3.92 to 0 mg/ml, incubated at 20°C for 6 hours, and 15 
worms per treatment were picked for analysis.  For experiment 2, arrested N2 L1s treated 
as above except treatments were 2.94 mg/ml and 0 mg/ml EHL and a greater number of 
worms per treatment were analysed (n = 55 and n = 33 for the 2.94 and 0 mg/ml 
treatments, respectively).  After incubation, worms were washed 3 times in water. For the 
analysis of development and fecundity (experiments 1 and 2), worms were transferred in a 
small volume of liquid to NGM plates without food, then individually transferred from this 
plate to NGM plates with E. coli OP50 strain food source and maintained at 20°C.  
Standard methods were then used to analyse the reproductive schedule and lifetime 
fecundity (Hodgkin & Doniach, 1997).  These data were then used to assess the effect of 
EHL on reproduction as assessed by lifetime reproductive success (LRS), the total number 
of progeny produced (experiments 1 and 2), and the intrinsic rate of increase (r) 
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(experiment 2), calculated by iteration from Σe-rxlxmx = 1, where lx represents the age 
specific survivorship to day x and mx represents the fecundity on day x (Vassilieva & 
Lynch, 1999). 
 
Based on phenotypes observed in the initial screen, the ability of EHL to induce 
constitutive dauer larvae formation (a dauer-constitutive, or Daf-c, phenotype) was 
investigated in greater detail.  Here, worms were treated with 0.98, 1.96 or 2.94 mg/ml 
EHL, as described above, except that after washing, worms were transferred en masse to 
plates with food.  After four days at 20°C plates were visually scored to assess the 
proportion of worms that had developed as dauer larvae (number of dauer larvae/total 
number of worms).  After counting, worms were washed from plates and incubated in 1 % 
SDS for one hour, a treatment that kills all C. elegans stages except dauer larvae (Cassada 
& Russell, 1975), worms were washed once in M9, transferred to fresh NGM plates with 
food and the number of dauer larvae again counted.  These dauer larvae were then 
transferred individually to NGM plates with food at 20°C and monitored for the next 14 
days to determine if they were capable of resuming development.  To further analyse EHL-
induced dauer larvae formation, N2 and mutant worms were treated, as described above, 
with 0, or 1.54 mg/ml EHL, washed, and transferred en masse to plates (n = 3 per 
combination of treatment and genotype) with food.  Plates were then incubated at 20°C for 
four days at which time the proportion of worms that had developed as dauer larvae was 
scored. 
 
Dauer larvae formation in PR672, che-1(p672), was further analysed both in standard 
dauer larvae formation assays and in assays of growing populations.  For assays of dauer 
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larvae formation in response to defined amounts of pheromone, assays were performed as 
previously described (Golden & Riddle 1984; Green et al., 2014), with worms allowed to 
lay eggs on assay plates containing dauer pheromone extract and limited amounts of food, 
and progeny scored after two days at 25°C.  Dauer larvae formation in growing 
populations was assessed as previously described (Green et al., 2013), with populations 
initiated with single worms and a defined amount of food allowed to grow to food 
exhaustion, except that assays were performed at  25°C.  
 
Results 
Purification and characterisation of EHL 
Qubit fluorometric measurement showed a typical concentration of 2.5 mg/ml using our 
revised and improved purification strategy.  This shows an approximately 5 to 6-fold 
increase in recovery in comparison to the previously reported yield of 380 µg/ml in George 
et al. (2011). Non-reducing SDS-PAGE analysis produced characteristic reduced protein 
bands at circa 31 and 28 kDa as well as an unreduced band circa 50kDa (Fig. 1); these 
values are consistent with those previously reported in the literature (Kumar et al., 1993).  
An intense agglutination response of rabbit erythrocytes was exhibited and thus confirmed 
the presence of EHL (Fig. 2). 
 
De novo sequencing analysis.  
De novo sequence analysis of fragmentation spectra was carried out and suggested two 
confidently assigned peptide fragment sequences, with the following tags,  
QQWA[L/I]YSDST[L/I]R and NWNNNGNP[L/I]Q[L/I]WQCTQQQNQR (Fig. 3). 
Peptide fragment homology searches produced matches to various Type II Ribosome 
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Inactivating Proteins (RIPS) all within ricin-b domain (carbohydrate binding) regions.  
This result confirms the status of EHL as a Type II RIP, as has been reported in previously 
published sequence data (Kumar et al., 1993).  Sequence tags QQWA[L/I]YSDST[L/I]R 
and NWNNNGNP[L/I]Q[L/I]WQCTQQQNQR were matched to two regions in Nigrin-b 
(SNA-V; Sambucas nigra agglutinin-V) UniProtKB P33183.2 correlating to residues 470-
481 and 325-345 respectively using the FASTS search facility against the SwissProt 
database.  Close homology to other Type II RIPS was also matched within the ricin b 
domain of Abrin-a (P11140) and Ricin (P02879).  PDB structures were searched using 
SSearch algorithm and also showed matches to SNA-II (3C9Z) (Sambucas nigra  
agglutinin II), Abrin-a (1ABRB) and Ricin (1RZOB) in the ricin b domain as well as ML1 
from Viscum album (1QNKB).  
 
EHL affects survival, development and reproduction in C. elegans  
Acute treatment of arrested C. elegans L1s for 6 hours with EHL at different 
concentrations resulted in a subsequent range of developmental, fertility and survival 
defects  (Fig. 4), with all EHL concentrations reducing lifetime reproductive success 
(LRS) (Fig. 4A, pairwise, Bonferroni corrected, Mann–Whitney U tests against N2 
showing reduced fecundity in all EHL treatments).  Much of this decrease in fecundity is 
however a consequence of worms not reproducing in the EHL treatments (comparison of 
Fig. 4A and B), although LRS does still decrease over the range of EHL concentrations 
tested when only those worms that reproduced are considered (Fig. 4B, Pearson product-
moment correlation of LRS against EHL concentration: including the 0 mg/ml group, r = -
0.52, p < 0.001; excluding the 0 mg/ml group, r = -0.38, p = 0.013). EHL-treated worms 
that did reproduce showed a delay in development, with many treated worms starting 
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reproduction a day or more after the control worms.  Of the worms that did not reproduce, 
some showed no movement from the point at which they were placed on the plate and no 
response to stimulus after 24 hours and therefore died as a consequence of the EHL 
treatment. Other EHL-treated worms were observed to remain as arrested L1s or to 
develop as dauer larvae, a non-feeding developmentally arrested stage.  Many of the non-
reproducing worms were found not on a food source, and more than would be expected 
under these conditions were found to have climbed the sides of the plate; both behaviours 
are indicative of a disruption to chemosensory ability and an inability to detect the 
bacterial food.  
 
To investigate these reproductive effects and the survival in more detail, a larger number 
of worms were assayed (Fig. 5).  Here, EHL treatment resulted in immediate mortality of 
41% of EHL treated individuals and again EHL-treated worms were observed to remain as 
L1s and to arrest as dauer larvae.  These results suggest that EHL treatment affects the 
sensory neurons.  Overall, EHL treatment reduced subsequent LRS (Fig. 5A, control vs all 
EHL treated worms, W = 2376.0, p < 0.001), with the subset of EHL treated worms that 
did reproduce producing a greatly reduced number of progeny (control vs reproducing 
EHL treated worms, W = 792.0, p < 0.001).  A similar pattern was observed in the analysis 
of the effects of EHL treatment on the estimated rate of increase (Fig. 5B, control vs all 
EHL treated worms, W = 2376.0, p < 0.001; control vs reproducing EHL treated worms, 
W = 792.0, p < 0.001).  
 
To further characterise the development of EHL-treated worms as dauer larvae, an 
additional set of arrested L1s were analysed.  As in the assay for reproductive effects 
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(above), some of these EHL treated worms developed as dauer larvae (Fig. 6).  These 
worms were then SDS treated, with survival confirming that they were indeed dauer 
larvae.  Fifty of these dauer larvae were then transferred to plates with food and 
maintained at 20°C, with only one worm out of the fifty recovering and completing 
development as a reproductive adult after four days, and a second  recovering after a total 
of fourteen days.  Under these conditions dauer larvae normally recover rapidly and would 
be expected to have commenced reproduction approximately 2 days after transfer to food 
(Green & Harvey, 2012).   
 
Analysis of mutant strains indicates that the ability of EHL treatment to induce dauer 
larvae formation varied across the genotypes (Table 1). All genotypes were however 
observed to show a developmental delay in response to EHL treatment, with reproduction 
of most EHL-treated worms not commencing until day 5 after treatment.  Analysis of 
dauer larvae formation in PR672, che-1(p672) showed that this mutation does not block 
dauer larvae formation in response to defined amounts of pheromone and that similar 
numbers of dauer larvae are formed in N2 and PR672 in growing populations (F1,33 = 0.05, 
p = 0.82).  
 
Discussion 
We have successfully isolated the type II RIP found in the tubers of the Winter Aconite, E. 
hyemalis, by modification of a previously published protocol (Cammue, Peeters & 
Peumans, 1985; Kumar et al., 1993).  Analysis indicates EHL is a heterodimeric protein 
consisting of two chains of molecular weights of approximately 28 and 31 kDa (Fig. 1). 
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Protein sequencing confirms that EHL is a Type II RIP with the cytotoxic potential for 
depurination of eukaryotic ribosomes.  
 
EHL was used to study potential lectin-mediated toxicity against C. elegans.  The 
bioassays performed indicate that EHL has biocidal properties against C. elegans.  Four 
phenotypic effects were identified: reduced fecundity (Fig. 4 and 5), developmental delay, 
chemosensory disruption and constitutive dauer formation (Fig. 6 and Table 1).  C. elegans 
physiology is such that at the arrested L1 larval stage, the only cells which are not enclosed 
by a largely impermeable cuticle are the amphids and phasmids.  These are bilaterally 
symmetrical sensory organs that contain the sensory neurons: each amphid containing 
twelve neurons and each phasmid containing two (Ward et al., 1975).  Of the twelve 
amphid neurons, the ciliated nerve endings of eight are exposed to the external 
environment via the amphid pore (Ward et al., 1975).  These neurons control a range of 
phenotypes, including egg-laying and the decision to develop as a dauer larvae (Albert, 
Brown & Riddle, 1981). Laser ablation of the ASI, ADF and ASG cells is sufficient to 
result in constitutive dauer larvae development, with ablation of the ASJ cell resulting in 
an inability to recover from dauer arrest (Bargmann & Horvitz, 1991).  Our observations 
of inappropriate dauer larvae formation and the failure of most such dauer larvae to resume 
development indicate that EHL is interacting with these neurons and are consistent with 
EHL resulting in neuron death.  
 
In general, biocidal assays with lectins involve ingestion of the lectin by the target 
organism. For example, EHL had previously been tested against the coleopteran pest 
Diabrotica undecimpunctata howardii, resulting in a high mortality rate and an 80% 
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reduction in body size of survivors; there was however no previous data on reproductive 
effects (Kumar et al., 1993). A study of the toxic effects of the CCL2 lectin from 
Coprnopsis cinerea  (Ink Cap mushroom) on C. elegans reported a phenotype of severe 
developmental delay; the lectin was adsorbed in the epithelial cells of the intestine, 
potentially degrading the membrane and preventing growth (Schubert et al., 2012). The 
absence of a food source in our assay has therefore enabled the observation of entirely new 
lectin-mediated C. elegans phenotypes induced by EHL, including a Daf-c phenotype 
which has not been reported before.  
 
The cause of the developmental delay in EHL-treated worms is not clear. Possibilities 
would include damage to the pharynx and a subsequent reduction in pumping (feeding) 
ability, or, if some feeding is initiated, damage to the epithelial cells of the intestine as 
observed in response to the C. cinerea CCL2 lectin (Schubert et al., 2012). A further 
possibility is that differences in body size and development are also a consequence of 
damaged neurons (see Fujiwara, Sengupta & McIntire, 2002). 
 
Wild-type C. elegans take up dyes such as DiI and FITC into the amphid neurons AWB, 
ASH, ASJ, ASK, ADL and ASI (Hedgecock et al., 1985).  Given the likely mode of action 
of EHL, we reasoned that mutations that disrupt the normal formation of sensory amphids 
would block EHL-induced dauer larvae formation. Consistent with this, disruption of osm-
5, dyf-1 and dyf-10, all mutations in which the amphid neurons cannot take up dyes, result 
in no EHL-induced dauer larvae formation (Table 1). In both odr-1 and odr-3 mutants, 
where dye filling is not affected and EHL would be expected to be able to access the 
neurons normally, there is no reduction in dauer larvae formation in response to EHL 
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treatment (Table 1).  In contrast, dauer larvae formation is reduced in PR671, but some are 
still formed (Table 1), indicating that disruption of tax-2 only partially blocks the effect. 
TAX-2 forms, with TAX-4, a cyclic nucleotide-gated cation channel that is required for 
chemotaxis in response to AWC-sensed odorants (Coburn & Bargman, 1996).  Axon 
outgrowth defects have however been noted in tax-2 mutants, with c. 80% of tax-2(p671) 
animals observed to have abnormal ASJ axons (Coburn & Bargman, 1996).  It is not clear 
if the reduction in the EHL-induced dauer larvae formation observed in the tax-2 mutants 
is a consequence of the axon guidance defects or the channel disruption.   
  
That EHL-induced dauer larvae formation is also blocked in che-1 mutants further 
supports the hypothesis that EHL is disrupting neurons.   CHE-1 is a C2H2-type zinc-
finger transcription factor that is required for the identity of ASE neurons (Uchida et al., 
2003). Loss of CHE-1 expression eliminates the function of ASE neurons and che-1 
mutations have previously been shown to suppress Daf-c phenotypes (Reiner et al., 2008).  
No significant structural defects have been observed in che-1 mutants (Lewis & Hodgkin, 
1977) and our results indicate that dauer larvae formation does not appear altered in either 
standard dauer larvae assays or in growing populations.  This thereby implies that the 
mutation is specifically blocking EHL-induced constitutive dauer larvae formation.  
It is well established that lectins bind to glyconjugates on cell surfaces and that toxicity in 
RIPs is due to lectin mediated entry to the cell; this mode of action is consistent with the 
results presented here. In the case of C. elegans the only cells exposed are the amphid 
neurons.  As a Type II RIP EHL can be subject to retrograde transport from the cell 
surface along the neuronal processes, at which point the ribosomes are inactivated, causing 
translation to cease (Wiley, Blessing & Reis, 1982).  As no post-embryonic somatic 
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division occurs in mature individuals, and multiple chemoreceptors are expressed in a 
single neuron, ribosome inactivation of the neurons within the amphids would affect many 
functions derived from chemosensation (Sulston & Horvitz, 1977).  Toxicity variables can 
be attributed to differing carbohydrate specificities but there is also evidence of the role of 
individual cell types in how they interact with lectins, indicating that any effects are 
characteristic of both variables (Battelli et al., 1997).  
 
In conclusion, successful extraction using affinity chromatography has enabled assays to 
be conducted for biocidal properties against C. elegans. The results obtained demonstrate a 
significant reduction in fecundity, development, growth and a high incidence of abnormal 
dauer development when arrested L1 larvae were treated in the absence of food.  The 
occurrence of dauer formation and a failure to recover in the presence of food supports the 
hypothesis that EHL is binding specifically to amphid neurons. Mutant screening has 
demonstrated that EHL can act as a neuronally specific cytotoxin, an effect which has 
previously been described with Ricin and other RIPs on mammalian sensory neurons 
(Wiley, Blessing & Reis, 1982; Tong et al., 2012).  Further studies will aim to determine if 
those individuals that remained as arrested L1s were doing so as a consequence of an 
inability to perceive the food or if an additional mechanism is at work. 
 
Our research shows that EHL has biocidal and potential cytotoxic activity. Moreover, EHL 
shows specificity for GalNac, an overexpressed sugar in the Tn (GalNac clustered) antigen 
which characterises cancer linked O-glycans (Ju, Otto & Cummings, 2011). Other GalNac 
Type II RIPs such as Mistletoe Lectin (ML1) and Riproximin have demonstrated 
promising therapeutic relevance as anticancer agents (Voss et al., 2006; Bayer et al., 2012; 
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Adwan et al., 2014.  These factors suggest that EHL is a viable candidate for further study 
in respect of antineoplastic characteristics. 
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Appendix 1.2 Published figures and legends 
  Mean % dauer ± S.E.   
Isolate Genotype Control Lectin Phenotype 
N2 Wild-type 0 49 ± 2.5 - 
CX2065 odr-1(n1936) X 0 53 ± 6.1 Defective chemotaxis1 
CX2205 odr-3(n2150) V 0 35 ± 3.1 
 
Defective chemotaxis1  
Defective osmotic avoidance1  
PR671 tax-2(p671) I 0 8 ± 1.9* 
 
Defective chemotaxis2  
Defective thermotaxis2 
PR672 che-1(p672) I 0 0* Defective chemotaxis2 
PR813 osm-5(p813) X 0 0* 
 
Defective dye filling3 
Defective osmotic avoidance3  
SP1205 dyf-1(mn335) I 0 0* 
 
Defective dye filling4  
Defective chemotaxis4 
SP1709 dyf-10(e1383) I 0 0* 
 
Defective dye filling4  
Defective chemotaxis4 
 
 
Mutations affecting amphid structure can block EHL-induced dauer larvae 
formation. The mean dauer larvae formation found on three plates of control and 80% 
(1.548mg/ml) EHL treated worms of differing genotypes of C. elegans. *Denotes 
genotypes where the proportion of dauer larvae observed in the EHL treatment differs 
from that observed in N2 (p < 0.05, Fisher's Exact Test with Bonferroni adjustment to 
correct for multiple testing). 1Bargmann, Hartweig & Horvitz (1993). 2Dusenbery (1976). 
3Dusenbery (1980). 4Starich et al.(1995). 
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Figure 1: EHL is a heterodimeric Type II Ribosome Inactivating Protein. Coomassie 
Blue stained 12% SDS-PAGE analysis of EHL showing molecular weight marker (M), non-
reduced EHL (1) and β -mercaptoethanol reduced EHL (2). 
 
 
 
Figure 2: EHL induces agglutination of erythrocytes. (A) Control, with no clumping of 
erythrocytes observed, and (B) incubation with EHL, which results in agglutination. 
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Figure 3: De novo peptide sequencing based on the MALDI-TOF MS/MS 
fragmentation spectra of EHL in-gel tryptic digestion after reduction with DTE and S-
carbamidomethylation with iodocetamide. (A) QQWA(L/I)YSDST(L/I)R, the most 
confidently assigned peptide with a good level of overlapping y- and b- ion series. (B) 
NWNNNGNP(L/I)Q(L/I)WQCTQQQNQR, a strong y- ion series is observed throughout 
the peptide 
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Figure 4: EHL reduces fecundity in C. elegans. Box plots of Lifetime reproductive 
success (LRS) of (A) EHL treated worms and (B) the subset of EHL treated worms that 
reproduced for a range of lectin concentrations. For (A) n=15 for all treatments, for (B) 
numbers associated with the boxes denote the sample sizes 
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Figure 5: EHL reduces fecundity and slows development in C. elegans. Boxplots of 
(A) lifetime reproductive success, LRS, and (B) intrinsic rate of increase, r, of control 
worms, all EHL treated worms and of the subset of EHL treated worms that reproduced. n 
denotes the sample sizes 
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Figure 6: EHL treatment induces dauer larvae formation in C. elegans. The proportion 
of larvae that developed into dauer larvae observed in populations in three different EHL 
treatments. In the abscence of EHL treatment no dauer formation is observed under these 
experimental conditions in N2
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Appendix 2 Crystal screen chemical conditions 
 
 
Morpheus Conc1Units1Salt Conc2Units2Buffer2 pH Conc3 Units3 Precipitant3
A1 0.06 M Divalents 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
A2 0.06 M Divalents 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
A3 0.06 M Divalents 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
A4 0.06 M Divalents 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
A5 0.06 M Divalents 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
A6 0.06 M Divalents 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
A7 0.06 M Divalents 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
A8 0.06 M Divalents 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
A9 0.06 M Divalents 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
A10 0.06 M Divalents 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
A11 0.06 M Divalents 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
A12 0.06 M Divalents 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
B1 0.09 M Halogens 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
B2 0.09 M Halogens 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
B3 0.09 M Halogens 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
B4 0.09 M Halogens 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
B5 0.09 M Halogens 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
B6 0.09 M Halogens 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
B7 0.09 M Halogens 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
B8 0.09 M Halogens 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
B9 0.09 M Halogens 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
B10 0.09 M Halogens 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
B11 0.09 M Halogens 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
B12 0.09 M Halogens 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
C1 0.09 M NPS 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
C2 0.09 M NPS 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
C3 0.09 M NPS 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
C4 0.09 M NPS 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
C5 0.09 M NPS 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
C6 0.09 M NPS 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
C7 0.09 M NPS 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
C8 0.09 M NPS 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
C9 0.09 M NPS 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
C10 0.09 M NPS 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
C11 0.09 M NPS 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
C12 0.09 M NPS 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
D1 0.12 M Alcohols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
D2 0.12 M Alcohols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
D3 0.12 M Alcohols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
D4 0.12 M Alcohols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
D5 0.12 M Alcohols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
D6 0.12 M Alcohols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
D7 0.12 M Alcohols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
D8 0.12 M Alcohols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
D9 0.12 M Alcohols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
D10 0.12 M Alcohols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
D11 0.12 M Alcohols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
D12 0.12 M Alcohols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
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Morpheus continued:
E1 0.12 M Ethylene glycols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
E2 0.12 M Ethylene glycols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
E3 0.12 M Ethylene glycols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
E4 0.12 M Ethylene glycols 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
E5 0.12 M Ethylene glycols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
E6 0.12 M Ethylene glycols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
E7 0.12 M Ethylene glycols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
E8 0.12 M Ethylene glycols 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
E9 0.12 M Ethylene glycols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
E10 0.12 M Ethylene glycols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
E11 0.12 M Ethylene glycols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
E12 0.12 M Ethylene glycols 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
F1 0.12 M Monosaccharides 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
F2 0.12 M Monosaccharides 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
F3 0.12 M Monosaccharides 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
F4 0.12 M Monosaccharides 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
F5 0.12 M Monosaccharides 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
F6 0.12 M Monosaccharides 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
F7 0.12 M Monosaccharides 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
F8 0.12 M Monosaccharides 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
F9 0.12 M Monosaccharides 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
F10 0.12 M Monosaccharides 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
F11 0.12 M Monosaccharides 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
F12 0.12 M Monosaccharides 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
G1 0.1 M Carboxylic acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
G2 0.1 M Carboxylic acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
G3 0.1 M Carboxylic acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
G4 0.1 M Carboxylic acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
G5 0.1 M Carboxylic acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
G6 0.1 M Carboxylic acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
G7 0.1 M Carboxylic acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
G8 0.1 M Carboxylic acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
G9 0.1 M Carboxylic acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
G10 0.1 M Carboxylic acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
G11 0.1 M Carboxylic acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
G12 0.1 M Carboxylic acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
H1 0.1 M Amino acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 1
H2 0.1 M Amino acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 2
H3 0.1 M Amino acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 3
H4 0.1 M Amino acids 0.1 M Buffer System 1 6.5 50 % v/v Precipitant Mix 4
H5 0.1 M Amino acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1
H6 0.1 M Amino acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 2
H7 0.1 M Amino acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 3
H8 0.1 M Amino acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 4
H9 0.1 M Amino acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 1
H10 0.1 M Amino acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 2
H11 0.1 M Amino acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 3
H12 0.1 M Amino acids 0.1 M Buffer System 3 8.5 50 % v/v Precipitant Mix 4
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MIDAS Conc1 Units1Salt Conc2 Units2 Buffer2 pH Conc3 Units3 Precipitant3 Conc4 Units4 Preicpitant4 Conc5 Units5Precipitant5
1-1 0.1 M HEPES 6.0 50 % v/v Polypropylene glycol 400 5  % v/v Dimethyl sulfoxide
1-2 0.1 M MES 5.5 12 % w/v Polyvinylpyrrolidone
1-3 0.1 M HEPES 6.5 45 % w/v Poly(acrylic acid sodium salt) 2100
1-4 14 % v/v Poly(acrylic acid-co-maleic acid) solution
1-5 0.5 M Ammonium phosphate monobasic 12.5 % w/v Poly(acrylic acid sodium salt) 2100
1-6 0.1 M Tris 8.5 19 % v/v Poly(acrylic acid-co-maleic acid) solution
1-7 10 % v/v Polypropylene glycol 400
1-8 5 % w/v Poly(acrylic acid sodium salt) 2100
1-9 0.1 M MES 6.0 25 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
1-10 0.1 M Sodium sulfate 24 % w/v Polyvinylpyrrolidone
1-11 0.2 M Calcium chloride dihydrate 0.1 M HEPES 6.5 35 % v/v Pentaerythritol ethoxylate (15/4 EO/OH)
1-12 0.1 M Potassium/sodium phosphate 7.0 35 % v/v Polypropylene glycol 400
1-13 0.2 M Sodium chloride 0.1 M MES 5.5 20 % v/v Jeffamine® D-2000 10 % v/v Jeffamine® M-2005
1-14 0.2 M Sodium thiocyanate 0.1 M HEPES 7.0 15 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
1-15 0.2 M Potassium acetate 0.1 M HEPES 7.0 5 % w/v Polyvinyl alcohol 10 % v/v Jeffamine® T-403
1-16 0.2 M Sodium chloride 0.1 M MES 6.0 45 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
1-17 0.1 M HEPES 7.0 8 % w/v Polyvinyl alcohol 10 % v/v 1-Propanol
1-18 0.1 M Lithium sulfate 0.1 M HEPES 7.0 30 % w/v Polyvinylpyrrolidone
1-19 0.2 M Imidazole 7.0 40 % v/v Polypropylene glycol 400
1-20 0.06 M Lithium sulfate 0.1 M HEPES 7.5 8 % v/v Poly(acrylic acid-co-maleic acid) solution 3 % v/v Pentaerythritol ethoxylate (3/4 EO/OH)
1-21 0.1 M Sodium chloride 0.1 M Tris 8.0 35 % v/v Jeffamine® SD-2001
1-22 30 % v/v Jeffamine® M-600 10 % v/v Dimethyl sulfoxide
1-23 20 % v/v Polypropylene glycol 400 10 % v/v 1-Propanol
1-24 0.1 M HEPES 6.5 28 % v/v Poly(acrylic acid-co-maleic acid) solution
1-25 15 % v/v Jeffamine® ED-2003 10 % v/v Ethanol
1-26 0.2 M Sodium chloride 0.1 M MES 6.0 30 % v/v Jeffamine® ED-2003
1-27 0.1 M Sodium malonate dibasic monohydrate 0.1 M MES 5.5 25 % v/v Jeffamine® SD-2001
1-28 0.2 M Sodium chloride 0.1 M MES 6.0 15 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
1-29 0.2 M Magnesium chloride hexahydrate 35 % v/v Pentaerythritol ethoxylate (3/4 EO/OH)
1-30 40 % v/v Pentaerythritol propoxylate (5/4 PO/OH) 15 % v/v Ethanol
1-31 0.1 M Tris 8.0 50 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
1-32 0.2 M Sodium chloride 0.1 M Tris 8.0 12.5 % w/v Polyvinylpyrrolidone 10 % w/v PEG 4000
1-33 0.1 M Sodium chloride 25 % v/v Pentaerythritol propoxylate (5/4 PO/OH) 10 % v/v Dimethyl sulfoxide
1-34 0.2 M Ammonium sulfate 0.1 M HEPES 7.5 35 % w/v Poly(acrylic acid sodium salt) 2100
1-35 0.1 M Magnesium formate dihydrate 0.1 M Tris 8.5 30 % v/v Pentaerythritol ethoxylate (15/4 EO/OH)
1-36 0.2 M Potassium acetate 24 % v/v Poly(acrylic acid-co -maleic acid) solution
1-37 0.1 M Tris 8.0 60 % v/v Polypropylene glycol 400
1-38 0.1 M HEPES 7.5 30 % v/v Pentaerythritol ethoxylate (15/4 EO/OH) 6 % w/v Polyvinylpyrrolidone
1-39 45 % v/v Polypropylene glycol 400 10 % v/v Ethanol
1-40 10 % v/v Pentaerythritol ethoxylate (3/4 EO/OH) 10 % v/v 1-Butanol
1-41 0.1 M HEPES 7.0 12.5 % w/v Poly(acrylic acid sodium salt) 2100 6 % v/v Jeffamine® SD-2001
1-42 0.1 M HEPES 6.5 6 % w/v Polyvinylpyrrolidone
1-43 0.1 M HEPES 6.5 20 % v/v Jeffamine® ED-2003
1-44 0.1 M Tris 8.0 20 % v/v Glycerol ethoxylate 10 % v/v Tetrahydrofuran
1-45 0.2 M Imidazole 7.0 25 % v/v Jeffamine® D-2000
1-46 0.2 M Potassium chloride 0.1 M HEPES 6.5 30 % v/v Jeffamine® SD-2001
1-47 0.1 M Sodium chloride 30 % v/v Polypropylene glycol 400
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1-48 20 % v/v Jeffamine® SD-2001 15 % v/v 1-Propanol
2-1 0.2 M Lithium sulfate 0.1 M Tris 8.0 25 % v/v Jeffamine® T-403
2-2 0.2 M Potassium acetate 35 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
2-3 0.2 M Potassium chloride 0.1 M Glycine 9.5 20 % v/v Pentaerythritol ethoxylate (15/4 EO/OH)
2-4 0.2 M Sodium thiocyanate 0.1 M HEPES 7.0 40 % v/v Pentaerythritol propoxylate (5/4 PO/OH)
2-5 0.2 M Potassium chloride 0.1 M HEPES 6.5 15 % v/v Jeffamine® T-403 15 % v/v Jeffamine® ED-2003
2-6 0.2 M Potassium acetate 0.1 M MES 6.0 15 % v/v Pentaerythritol ethoxylate (15/4 EO/OH) 3 % v/v Jeffamine® T-403
2-7 0.1 M Sodium malonate dibasic monohydrate 0.1 M HEPES 7.0 30 % w/v Poly(acrylic acid sodium salt) 2100
2-8 10 % v/v Jeffamine® D-2000 10 % v/v Jeffamine® M-2005 10 % v/v Ethanol
2-9 0.1 M Lithium sulfate 0.1 M Tris 8.0 25 % v/v Jeffamine® ED-2003
2-10 0.1 M Tris 8.0 10 % v/v Jeffamine® T-403 10 % v/v Jeffamine® ED-2003
2-11 0.1 M Lithium sulfate 0.1 M HEPES 6.5 25 % w/v Poly(acrylic acid sodium salt) 2100
2-12 0.2 M Magnesium chloride hexahydrate 0.1 M HEPES 7.5 15 % w/v Poly(acrylic acid sodium salt) 2100
2-13 0.1 M HEPES 6.5 40 % v/v Jeffamine® D-2000
2-14 0.5 M Sodium chloride 0.1 M Tris 8.0 10 % w/v Poly(acrylic acid sodium salt) 2100
2-15 0.1 M Potassium/sodium phosphate 7.0 14 % v/v Jeffamine® ED-900 11 % v/v Jeffamine® SD-2001
2-16 0.2 M Sodium chloride 0.1 M BICINE 9.0 20 % w/v Poly(acrylic acid sodium salt) 2100
2-17 0.2 M Sodium malonate dibasic monohydrate 0.1 M MES 5.5 20 % v/v Jeffamine® D-2000
2-18 0.2 M Potassium chloride 0.1 M Tris 8.0 30 % v/v Jeffamine® M-2070
2-19 20 % v/v Jeffamine® M-2070 20 % v/v Dimethyl sulfoxide
2-20 0.2 M Magnesium chloride hexahydrate 0.1 M MES 5.5 40 % v/v Pentaerythritol propoxylate (17/8 PO/OH)
2-21 0.1 M Tris 8.0 20 % w/v Poly(acrylic acid sodium salt) 5100
2-22 0.1 M HEPES 7.0 28 % v/v Polyethyleneimine
2-23 0.1 M Ammonium formate 0.1 M HEPES 7.0 20 % w/v SOKALAN® CP 7
2-24 0.2 M Sodium sulfate 0.1 M Tris 8.0 20 % w/v SOKALAN® HP 56
2-25 0.1 M Potassium chloride 0.1 M HEPES 7.0 25 % w/v SOKALAN® CP 7
2-26 0.3 M Ammonium formate 0.1 M HEPES 7.0 20 % w/v SOKALAN® CP 5
2-27 40 % v/v Glycerol ethoxylate
2-28 0.1 M Tris 8.5 30 % v/v Glycerol ethoxylate
2-29 55 % v/v Polypropylene glycol 400
2-30 0.2 M Lithium citrate tribasic tetrahydrate 35 % v/v Glycerol ethoxylate
2-31 0.2 M Ammonium acetate 0.1 M MES 6.5 30 % v/v Glycerol ethoxylate
2-32 0.1 M Tris 8.0 20 % w/v SOKALAN® CP 42 5 % v/v Methanol
2-33 0.1 M Tris 7.0 25 % w/v SOKALAN® CP 42 10 % v/v Tetrahydrofuran
2-34 0.1 M Lithium acetate dihydrate 0.1 M Bis-Tris 6.0 20 % w/v SOKALAN® CP 42
2-35 0.2 M HEPES 6.5 10 % v/v Jeffamine® M-2005
2-36 0.1 M Bis-Tris 6.0 15 % w/v SOKALAN® CP 5
2-37 0.1 M Bis-Tris 6.0 25 % w/v SOKALAN® CP 42
2-38 35 % v/v Jeffamine® D-2000
2-39 0.1 M Tris 8.5 20 % v/v Glycerol ethoxylate 3 % v/v Polyethyleneimine
2-40 0.2 M Ammonium chloride 0.1 M HEPES 7.5 25 % v/v Glycerol ethoxylate
2-41 0.1 M Tris 8.5 10 % w/v SOKALAN® CP 42
2-42 0.1 M MES 6.0 30 % w/v Poly(acrylic acid sodium salt) 5100 10 % v/v Ethanol
2-43 0.2 M Potassium citrate tribasic monohydrate 15 % w/v SOKALAN® CP 42
2-44 0.1 M Tris 8.5 30 % w/v SOKALAN® CP 42
2-45 0.2 M Ammonium acetate 0.1 M HEPES 7.0 25 % w/v SOKALAN® HP 56
2-46 0.1 M Tris 8.5 25 % w/v SOKALAN® CP 5
2-47 0.2 M Ammonium formate 10 % w/v Polyvinylpyrrolidone 20 % w/v PEG 4000
2-48 0.1 M Tris 8.0 15 % w/v Polyvinylpyrrolidone 25 % w/v PEG 5000 MME
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Units1 Salt1 Conc2 Units2 Salt2 Conc5 Units5 Buffer5 pH Conc6 Units6 Precipitant6Conc7 Units7 Precipitant7
M Lithium sulfate 0.1 M Sodium acetate 4.5 50 % w/v PEG 400
None 0.1 M Sodium citrate 5.5 20 % w/v PEG 3000
M Ammonium citrate dibasic None - 20 % w/v PEG 3350
M Calcium chloride dihydrate 0.1 M Sodium acetate 4.6 30 % v/v MPD
M Magnesium formate dihydrate None - 20 % w/v PEG 3350
M Lithium sulfate 0.1 M Phosphate/citrate 4.2 20 % w/v PEG 1000
None 0.1 M CHES 9.5 20 % w/v PEG 8000
M Ammonium formate None - 20 % w/v PEG 3350
M Ammonium chloride None - 20 % w/v PEG 3350
M Potassium formate None - 20 % w/v PEG 3350
M Ammonium phosphate monobasic 0.1 M Tris 8.5 50 % v/v MPD
M Potassium nitrate None - 20 % w/v PEG 3350
M Ammonium sulfate 0.1 M Citrate 4 None
M Sodium thiocyanate None - 20 % w/v PEG 3350
None 0.1 M BICINE 9 20 % w/v PEG 6000
None 0.1 M HEPES 7.5 10 % w/v PEG 8000 8 % v/v Ethylene glycol
None 0.1 M Sodium cacodylate 6.5 40 % v/v MPD 5 % w/v PEG 8000
None 0.1 M Phosphate/citrate 4.2 40 % v/v Ethanol 5 % w/v PEG 1000
None 0.1 M Sodium acetate 4.6 8 % w/v PEG 4000
M Magnesium chloride hexahydrate 0.1 M Tris 7 10 % w/v PEG 8000
None 0.1 M Citrate 5 20 % w/v PEG 6000
M Magnesium chloride hexahydrate 0.1 M Sodium cacodylate 6.5 50 % v/v PEG 200
M Sodium citrate tribasic dihydrate None 6.5 None
M Potassium citrate tribasic monohydrate None - 20 % w/v PEG 3350
M Sodium chloride 0.1 M Phosphate/citrate 4.2 20 % w/v PEG 8000
M Lithium chloride 0.1 M Citrate 4 20 % w/v PEG 6000
M Ammonium nitrate None - 20 % w/v PEG 3350
None 0.1 M HEPES 7 10 % w/v PEG 6000
M Sodium phos 0.8 M Potassium phosphate monobasic 0.1 M Sodium HEPES 7.5 None
None 0.1 M Phosphate/citrate 4.2 40 % v/v PEG 300
M Zinc acetate dihydrate 0.1 M Sodium acetate 4.5 10 % w/v PEG 3000
None 0.1 M Tris 8.5 20 % v/v Ethanol
None 0.1 M Sodium/potassium phosphate 6.2 25 % v/v 1,2-Propaned 10 %v/v Glycerol
None 0.1 M BICINE 9 10 % w/v PEG 20,000 2 % v/v 1,4-Dioxane
M Ammonium sulfate 0.1 M Sodium acetate 4.6 None
None None - 10 % w/v PEG 1000 10 % w/v PEG 8000
None None - 24 % w/v PEG 1500 20 % v/v Glycerol
M Magnesium chloride hexahydrate 0.1 M Sodium HEPES 7.5 30 % v/v PEG 400
M Sodium chloride 0.1 M Sodium/potassium phosphate 6.2 50 % v/v PEG 200
M Lithium sulfate 0.1 M Sodium acetate 4.5 30 % w/v PEG 8000
None 0.1 M HEPES 7.5 70 % v/v MPD
M Magnesium chloride hexahydrate 0.1 M Tris 8.5 20 % w/v PEG 8000
M Lithium sulfate 0.1 M Tris 8.5 40 % v/v PEG 400
None 0.1 M Tris 8 40 % v/v MPD
M Ammonium sulfate None - 25.5 % w/v PEG 4000 15 % v/v Glycerol
M Calcium acetate hydrate 0.1 M Sodium cacodylate 6.5 40 % v/v PEG 300
M Calcium chloride dihydrate 0.07 M Sodium acetate 4.6 14 % v/v 2-Propanol 30 % v/v Glycerol
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M Potassium phosphate monobasic None - 16 % w/v PEG 8000 20 % v/v Glycerol
M Sodium citrate tribasic dihydrate 0.1 M Sodium caco 6.5 None
M Ammonium s 0.2 M Sodium chloride 0.1 M Sodium caco 6.5 None
M Sodium chloride 0.1 M HEPES 7.5 10 % v/v 2-Propanol
M Ammonium s 0.2 M Lithium sulfate 0.1 M Tris 8.5 None
None 0.1 M CAPS 10.5 40 % v/v MPD
M Zinc acetate dihydrate 0.1 M Imidazole 8 20 % w/v PEG 3000
M Zinc acetate dihydrate 0.1 M Sodium caco 6.5 10 % v/v 2-Propanol
M Ammonium phosphate dibasic 0.1 M Sodium aceta 4.5 None
M Magnesium sulfate heptahydrate 0.1 M MES 6.5 None
None 0.1 M BICINE 9 10 % w/v PEG 6000
M Calcium acetate hydrate 0.08 M Sodium caco 6.5 14.4 % w/v PEG 8000 20 % v/v Glycerol
None 0.1 M Imidazole 8 10 % w/v PEG 8000
M Cesium chloride 0.1 M MES 6.5 30 % v/v Jeffamine® M-600
M Ammonium sulfate 0.1 M Citrate 5 None
None 0.1 M Tris 8 20 % v/v MPD
None 0.1 M HEPES 7.5 20 % v/v Jeffamine® M-600
M Magnesium chloride hexahydrate 0.1 M Tris 8.5 50 % v/v Ethylene glycol
None 0.1 M BICINE 9 10 % v/v MPD
M Succinic acid None 7 None
M DL-Malic acid None 7 None
M Sodium malonate dibasic monohydrate None 7 None
M Sodium malonate dibasic monohydrate 0.1 M HEPES 7 0.5 % v/v Jeffamine® ED-2003
M Succinic acid 0.1 M HEPES 7 1 % w/v PEG 2000 MME
None 0.1 M HEPES 7 30 % v/v Jeffamine® M-600
None 0.1 M HEPES 7 30 % v/v Jeffamine® ED-2003
M Magnesium chloride hexahydrate 0.1 M HEPES 7.5 22 % w/v Poly(acrylic acid sodium salt) 5100
M Cobalt(II) chloride hexahydrate 0.1 M Tris 8.5 20 % w/v Polyvinylpyrolidone
M TMAO 0.1 M Tris 8.5 20 % w/v PEG 2000 MME
M Cobalt(II) chl 0.005 M Cadmium chloride hemi(pentahydra 0.005 M Magnesium chloride hexahydrate 0.005 M Nickel(II) chl 0.1 M HEPES 7.5 12 % w/v PEG 3350
M Sodium malonate dibasic monohydrate None - 20 % w/v PEG 3350
M Succinic acid None - 15 % w/v PEG 3350
M DL-Malic acid None - 20 % w/v PEG 3350
M Potassium thiocyanate None - 30 % w/v PEG 2000 MME
M Potassium bromide None - 30 % w/v PEG 2000 MME
M Ammonium sulfate 0.1 M Bis-Tris 5.5 None
M Sodium chloride 0.1 M Bis-Tris 5.5 None
M Magnesium formate dihydrate 0.1 M Bis-Tris 5.5 None
M Ammonium sulfate 0.1 M Bis-Tris 5.5 1 % w/v PEG 3350
None 0.1 M Bis-Tris 5.5 25 % w/v PEG 3350
M Calcium chloride dihydrate 0.1 M Bis-Tris 5.5 45 % v/v MPD
M Ammonium acetate 0.1 M Bis-Tris 5.5 45 % v/v MPD
M Ammonium acetate 0.1 M Bis-Tris 5.5 17 % w/v PEG 10,000
M Ammonium sulfate 0.1 M Bis-Tris 5.5 25 % w/v PEG 3350
M Sodium chloride 0.1 M Bis-Tris 5.5 25 % w/v PEG 3350
M Lithium sulfate 0.1 M Bis-Tris 5.5 25 % w/v PEG 3350
M Ammonium acetate 0.1 M Bis-Tris 5.5 25 % w/v PEG 3350
M Magnesium chloride hexahydrate 0.1 M Bis-Tris 5.5 25 % w/v PEG 3350
M Ammonium acetate 0.1 M HEPES 7.5 45 % v/v MPD
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PACT 
Well # Conc1 Units1 Salt 1 Conc2 Units2 Buffer2 pH Conc3 Units3 Precipitant3
A1 0.1 M SPG 4.0 25 % w/v PEG 1500
A2 0.1 M SPG 5.0 25 % w/v PEG 1500
A3 0.1 M SPG 6.0 25 % w/v PEG 1500
A4 0.1 M SPG 7.0 25 % w/v PEG 1500
A5 0.1 M SPG 8.0 25 % w/v PEG 1500
A6 0.1 M SPG 9.0 25 % w/v PEG 1500
A7 0.2 M Sodium chloride 0.1 M Sodium acetate 5.0 20 % w/v PEG 6000
A8 0.2 M Ammonium chloride 0.1 M Sodium acetate 5.0 20 % w/v PEG 6000
A9 0.2 M Lithium chloride 0.1 M Sodium acetate 5.0 20 % w/v PEG 6000
A10 0.2 M Magnesium chloride hexahydrate 0.1 M Sodium acetate 5.0 20 % w/v PEG 6000
A11 0.2 M Calcium chloride dihydrate 0.1 M Sodium acetate 5.0 20 % w/v PEG 6000
A12 0.01 M Zinc chloride 0.1 M Sodium acetate 5.0 20 % w/v PEG 6000
B1 0.1 M MIB 4.0 25 % w/v PEG 1500
B2 0.1 M MIB 5.0 25 % w/v PEG 1500
B3 0.1 M MIB 6.0 25 % w/v PEG 1500
B4 0.1 M MIB 7.0 25 % w/v PEG 1500
B5 0.1 M MIB 8.0 25 % w/v PEG 1500
B6 0.1 M MIB 9.0 25 % w/v PEG 1500
B7 0.2 M Sodium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B8 0.2 M Ammonium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B9 0.2 M Lithium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B10 0.2 M Magnesium chloride hexahydrate 0.1 M MES 6.0 20 % w/v PEG 6000
B11 0.2 M Calcium chloride dihydrate 0.1 M MES 6.0 20 % w/v PEG 6000
B12 0.01 M Zinc chloride 0.1 M MES 6.0 20 % w/v PEG 6000
C1 0.1 M PCTP 4.0 25 % w/v PEG 1500
C2 0.1 M PCTP 5.0 25 % w/v PEG 1500
C3 0.1 M PCTP 6.0 25 % w/v PEG 1500
C4 0.1 M PCTP 7.0 25 % w/v PEG 1500
C5 0.1 M PCTP 8.0 25 % w/v PEG 1500
C6 0.1 M PCTP 9.0 25 % w/v PEG 1500
C7 0.2 M Sodium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C8 0.2 M Ammonium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C9 0.2 M Lithium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C10 0.2 M Magnesium chloride hexahydrate 0.1 M HEPES 7.0 20 % w/v PEG 6000
C11 0.2 M Calcium chloride hexahydrate 0.1 M HEPES 7.0 20 % w/v PEG 6000
C12 0.01 M Zinc chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
D1 0.1 M MMT 4.0 25 % w/v PEG 1500
D2 0.1 M MMT 5.0 25 % w/v PEG 1500
D3 0.1 M MMT 6.0 25 % w/v PEG 1500
D4 0.1 M MMT 7.0 25 % w/v PEG 1500
D5 0.1 M MMT 8.0 25 % w/v PEG 1500
D6 0.1 M MMT 9.0 25 % w/v PEG 1500
D7 0.2 M Sodium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000
D8 0.2 M Ammonium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000
D9 0.2 M Lithium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000
D10 0.2 M Magnesium chloride hexahydrate 0.1 M Tris 8.0 20 % w/v PEG 6000
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D11 0.2 M Calcium chloride dihydrate 0.1 M Tris 8.0 20 % w/v PEG 6000
D12 0.002 M Zinc chloride 0.1 M Tris 8.0 20 % w/v PEG 6000
E1 0.2 M Sodium fluoride 20 % w/v PEG 3350
E2 0.2 M Sodium bromide 20 % w/v PEG 3350
E3 0.2 M Sodium iodide 20 % w/v PEG 3350
E4 0.2 M Potassium thiocyanate 20 % w/v PEG 3350
E5 0.2 M Sodium nitrate 20 % w/v PEG 3350
E6 0.2 M Sodium formate 20 % w/v PEG 3350
E7 0.2 M Sodium acetate trihydrate 20 % w/v PEG 3350
E8 0.2 M Sodium sulfate 20 % w/v PEG 3350
E9 0.2 M Potassium sodium tartrate tetrahydrate 20 % w/v PEG 3350
E10 0.02 M Sodium/potassium phosphate 20 % w/v PEG 3350
E11 0.2 M Sodium citrate tribasic dihydrate 20 % w/v PEG 3350
E12 0.2 M Sodium malonate dibasic monohydrate 20 % w/v PEG 3350
F1 0.2 M Sodium fluoride 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F2 0.2 M Sodium bromide 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F3 0.2 M Sodium iodide 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F4 0.2 M Potassium thiocyanate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F5 0.2 M Sodium nitrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F6 0.2 M Sodium formate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F7 0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F8 0.2 M Sodium sulfate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F9 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F10 0.02 M Sodium/potassium phosphate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F11 0.2 M Sodium citrate tribasic dihydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
F12 0.2 M Sodium malonate dibasic monohydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
G1 0.2 M Sodium fluoride 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G2 0.2 M Sodium bromide 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G3 0.2 M Sodium iodide 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G4 0.2 M Potassium thiocyanate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G5 0.2 M Sodium nitrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G6 0.2 M Sodium formate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G7 0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G8 0.2 M Sodium sulfate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G9 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G10 0.02 M Sodium/potassium phosphate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G11 0.2 M Sodium citrate tribasic dihydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
G12 0.2 M Sodium malonate dibasic monohydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
H1 0.2 M Sodium fluoride 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H2 0.2 M Sodium bromide 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H3 0.2 M Sodium iodide 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H4 0.2 M Potassium thiocyanate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H5 0.2 M Sodium nitrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H6 0.2 M Sodium formate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H7 0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H8 0.2 M Sodium sulfate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H9 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H10 0.02 M Sodium/potassium phosphate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H11 0.2 M Sodium citrate tribasic dihydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
H12 0.2 M Sodium malonate dibasic monohydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
